<!DOCTYPE html><html lang="en" class="bg-surface-base antialiased"><head><meta charSet="utf-8"/><meta name="viewport" content="width=device-width, initial-scale=1, interactive-widget=resizes-content"/><link rel="stylesheet" href="/_next/static/css/62c4caba71dfda84.css" nonce="YzBlMjE1NjMtYjg2MC00MmIzLWJmMzktNTk1ZDcyYjYzMzVi" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/eb3d87f98fe1565f.css" nonce="YzBlMjE1NjMtYjg2MC00MmIzLWJmMzktNTk1ZDcyYjYzMzVi" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/1b5e561215938d4d.css" nonce="YzBlMjE1NjMtYjg2MC00MmIzLWJmMzktNTk1ZDcyYjYzMzVi" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/0227d069a630d414.css" nonce="YzBlMjE1NjMtYjg2MC00MmIzLWJmMzktNTk1ZDcyYjYzMzVi" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/f87fff2ab93d05a7.css" nonce="YzBlMjE1NjMtYjg2MC00MmIzLWJmMzktNTk1ZDcyYjYzMzVi" data-precedence="next"/><link rel="preload" as="script" fetchPriority="low" nonce="YzBlMjE1NjMtYjg2MC00MmIzLWJmMzktNTk1ZDcyYjYzMzVi" href="/_next/static/chunks/webpack-e121ed42680f327e.js"/><script src="/_next/static/chunks/78a669d9-e7993486b22c4915.js" async="" nonce="YzBlMjE1NjMtYjg2MC00MmIzLWJmMzktNTk1ZDcyYjYzMzVi"></script><script src="/_next/static/chunks/40c4a5a7-abdabb07419d1cfc.js" async="" nonce="YzBlMjE1NjMtYjg2MC00MmIzLWJmMzktNTk1ZDcyYjYzMzVi"></script><script src="/_next/static/chunks/2230-f7c87dc9fa57c408.js" async="" nonce="YzBlMjE1NjMtYjg2MC00MmIzLWJmMzktNTk1ZDcyYjYzMzVi"></script><script src="/_next/static/chunks/main-app-536d4b8fca62396a.js" async="" nonce="YzBlMjE1NjMtYjg2MC00MmIzLWJmMzktNTk1ZDcyYjYzMzVi"></script><script src="/_next/static/chunks/63f0ec43-8ee6a76d70472249.js" async="" nonce="YzBlMjE1NjMtYjg2MC00MmIzLWJmMzktNTk1ZDcyYjYzMzVi"></script><script src="/_next/static/chunks/7670-7326298c9856172b.js" async="" nonce="YzBlMjE1NjMtYjg2MC00MmIzLWJmMzktNTk1ZDcyYjYzMzVi"></script><script src="/_next/static/chunks/282-691fffb366e24ca5.js" async="" nonce="YzBlMjE1NjMtYjg2MC00MmIzLWJmMzktNTk1ZDcyYjYzMzVi"></script><script src="/_next/static/chunks/7515-336759ef5dad2b52.js" async="" nonce="YzBlMjE1NjMtYjg2MC00MmIzLWJmMzktNTk1ZDcyYjYzMzVi"></script><script src="/_next/static/chunks/927-34e2a6da3e15e26b.js" async="" nonce="YzBlMjE1NjMtYjg2MC00MmIzLWJmMzktNTk1ZDcyYjYzMzVi"></script><script src="/_next/static/chunks/5855-243eeca8f0e4cabd.js" async="" nonce="YzBlMjE1NjMtYjg2MC00MmIzLWJmMzktNTk1ZDcyYjYzMzVi"></script><script src="/_next/static/chunks/4393-1c8dff25ec904469.js" async="" nonce="YzBlMjE1NjMtYjg2MC00MmIzLWJmMzktNTk1ZDcyYjYzMzVi"></script><script src="/_next/static/chunks/2225-454cf9f44775e7ce.js" async="" nonce="YzBlMjE1NjMtYjg2MC00MmIzLWJmMzktNTk1ZDcyYjYzMzVi"></script><script src="/_next/static/chunks/7618-43536a8fb0dd3bfe.js" async="" nonce="YzBlMjE1NjMtYjg2MC00MmIzLWJmMzktNTk1ZDcyYjYzMzVi"></script><script src="/_next/static/chunks/app/page/%5Bslug%5D/layout-55a344716dd57c44.js" async="" nonce="YzBlMjE1NjMtYjg2MC00MmIzLWJmMzktNTk1ZDcyYjYzMzVi"></script><script src="/_next/static/chunks/7720-3a1e7e411adba2d3.js" async="" nonce="YzBlMjE1NjMtYjg2MC00MmIzLWJmMzktNTk1ZDcyYjYzMzVi"></script><script src="/_next/static/chunks/7086-1f1c4891d766e04f.js" async="" nonce="YzBlMjE1NjMtYjg2MC00MmIzLWJmMzktNTk1ZDcyYjYzMzVi"></script><script src="/_next/static/chunks/app/page/%5Bslug%5D/not-found-69a3edc7db5749d6.js" async="" nonce="YzBlMjE1NjMtYjg2MC00MmIzLWJmMzktNTk1ZDcyYjYzMzVi"></script><script src="/_next/static/chunks/app/global-error-4d07d20223cd4b4c.js" async="" nonce="YzBlMjE1NjMtYjg2MC00MmIzLWJmMzktNTk1ZDcyYjYzMzVi"></script><script src="/_next/static/chunks/8208b75a-a48e5a4507a0de91.js" async="" nonce="YzBlMjE1NjMtYjg2MC00MmIzLWJmMzktNTk1ZDcyYjYzMzVi"></script><script src="/_next/static/chunks/5497-ab85ef3ea59dd353.js" async="" nonce="YzBlMjE1NjMtYjg2MC00MmIzLWJmMzktNTk1ZDcyYjYzMzVi"></script><script src="/_next/static/chunks/6281-c6e84786dade3614.js" async="" nonce="YzBlMjE1NjMtYjg2MC00MmIzLWJmMzktNTk1ZDcyYjYzMzVi"></script><script src="/_next/static/chunks/2660-d983a7f287e89f18.js" async="" nonce="YzBlMjE1NjMtYjg2MC00MmIzLWJmMzktNTk1ZDcyYjYzMzVi"></script><script src="/_next/static/chunks/5002-9735c25beda556ba.js" async="" nonce="YzBlMjE1NjMtYjg2MC00MmIzLWJmMzktNTk1ZDcyYjYzMzVi"></script><script src="/_next/static/chunks/3655-6717081f7512305a.js" async="" nonce="YzBlMjE1NjMtYjg2MC00MmIzLWJmMzktNTk1ZDcyYjYzMzVi"></script><script src="/_next/static/chunks/8945-e4e3cf487f5e27c7.js" async="" nonce="YzBlMjE1NjMtYjg2MC00MmIzLWJmMzktNTk1ZDcyYjYzMzVi"></script><script src="/_next/static/chunks/9214-a10614844a67ba31.js" async="" nonce="YzBlMjE1NjMtYjg2MC00MmIzLWJmMzktNTk1ZDcyYjYzMzVi"></script><script src="/_next/static/chunks/4789-2080f6497f78b5b6.js" async="" nonce="YzBlMjE1NjMtYjg2MC00MmIzLWJmMzktNTk1ZDcyYjYzMzVi"></script><script src="/_next/static/chunks/app/layout-226f2bd71acf9f9e.js" async="" nonce="YzBlMjE1NjMtYjg2MC00MmIzLWJmMzktNTk1ZDcyYjYzMzVi"></script><script src="/_next/static/chunks/24cf1b50-159cca90b09285e0.js" async="" nonce="YzBlMjE1NjMtYjg2MC00MmIzLWJmMzktNTk1ZDcyYjYzMzVi"></script><script src="/_next/static/chunks/9ffa21ba-c069766d809bd4c7.js" async="" nonce="YzBlMjE1NjMtYjg2MC00MmIzLWJmMzktNTk1ZDcyYjYzMzVi"></script><script src="/_next/static/chunks/600-9a9fcafaaa6c1c4c.js" async="" nonce="YzBlMjE1NjMtYjg2MC00MmIzLWJmMzktNTk1ZDcyYjYzMzVi"></script><script src="/_next/static/chunks/5448-2a3cfd853d899c9a.js" async="" nonce="YzBlMjE1NjMtYjg2MC00MmIzLWJmMzktNTk1ZDcyYjYzMzVi"></script><script src="/_next/static/chunks/8-8ca70ca619d8e099.js" async="" nonce="YzBlMjE1NjMtYjg2MC00MmIzLWJmMzktNTk1ZDcyYjYzMzVi"></script><script src="/_next/static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js" async="" nonce="YzBlMjE1NjMtYjg2MC00MmIzLWJmMzktNTk1ZDcyYjYzMzVi"></script><script src="/_next/static/chunks/app/error-4a29e9399afba038.js" async="" nonce="YzBlMjE1NjMtYjg2MC00MmIzLWJmMzktNTk1ZDcyYjYzMzVi"></script><script src="/_next/static/chunks/app/not-found-dd95690acf732f18.js" async="" nonce="YzBlMjE1NjMtYjg2MC00MmIzLWJmMzktNTk1ZDcyYjYzMzVi"></script><meta name="next-size-adjust" content=""/><title>Grokipedia</title><meta name="description" content="Grokipedia is an open source, comprehensive collection of all knowledge."/><link rel="icon" type="image/x-icon" href="/favicon.ico" sizes="48x48"/><link rel="icon" href="/images/icon-dark.png" media="(prefers-color-scheme: light)" type="image/png"/><link rel="icon" href="/images/icon-light.png" media="(prefers-color-scheme: dark)" type="image/png"/><link rel="apple-touch-icon" href="/icon-192x192.png"/><link rel="manifest" href="/manifest.webmanifest"/><meta name="robots" content="index, follow"/><meta name="googlebot" content="index, follow, max-snippet:-1"/><meta property="og:title" content="Grokipedia"/><meta property="og:description" content="Grokipedia is an open source, comprehensive collection of all knowledge."/><meta property="og:url" content="https://grokipedia.com"/><meta property="og:site_name" content="Grokipedia"/><meta property="og:locale" content="en_US"/><meta property="og:type" content="website"/><meta property="og:image" content="https://grokipedia.com/icon-512x512.png"/><meta property="og:image:width" content="512"/><meta property="og:image:height" content="512"/><meta property="og:image:alt" content="Grokipedia"/><meta name="twitter:card" content="summary"/><meta name="twitter:creator" content="@Grokipedia"/><meta name="twitter:title" content="Grokipedia"/><meta name="twitter:description" content="Grokipedia is an open source, comprehensive collection of all knowledge."/><meta name="twitter:image" content="https://grokipedia.com/icon-512x512.png"/><title>Kidney disease</title><meta name="description" content="Kidney disease comprises a range of disorders that impair the kidneys&#x27; capacity to filter blood, remove waste products, and regulate electrolytes and fluid balance, often resulting from damage to the nephrons, the functional units of the kidney. It includes acute kidney injury (AKI), characterized by a sudden decline in renal function that may be reversible if addressed promptly, and chronic kidney disease (CKD), defined as structural or functional abnormalities persisting for more than three..."/><meta name="author" content="system"/><link rel="manifest" href="/manifest.webmanifest"/><meta name="keywords" content="renal disease, nephropathy"/><meta name="robots" content="index, follow"/><meta name="googlebot" content="index, follow, max-snippet:-1"/><link rel="canonical" href="https://grokipedia.com/page/Kidney_disease"/><meta property="og:title" content="Kidney disease"/><meta property="og:description" content="Kidney disease comprises a range of disorders that impair the kidneys&#x27; capacity to filter blood, remove waste products, and regulate electrolytes and fluid balance, often resulting from damage to the nephrons, the functional units of the kidney. It includes acute kidney injury (AKI), characterized by a sudden decline in renal function that may be reversible if addressed promptly, and chronic kidney disease (CKD), defined as structural or functional abnormalities persisting for more than three..."/><meta property="og:url" content="https://grokipedia.com/page/Kidney_disease"/><meta property="og:site_name" content="Grokipedia"/><meta property="og:locale" content="en"/><meta property="og:image" content="https://grokipedia.com/icon-512x512.png"/><meta property="og:image:width" content="512"/><meta property="og:image:height" content="512"/><meta property="og:image:alt" content="Kidney disease"/><meta property="og:type" content="article"/><meta property="article:modified_time" content="1970-01-21T09:19:42.918Z"/><meta name="twitter:card" content="summary"/><meta name="twitter:creator" content="@Grokipedia"/><meta name="twitter:title" content="Kidney disease"/><meta name="twitter:description" content="Kidney disease comprises a range of disorders that impair the kidneys&#x27; capacity to filter blood, remove waste products, and regulate electrolytes and fluid balance, often resulting from damage to the nephrons, the functional units of the kidney. It includes acute kidney injury (AKI), characterized by a sudden decline in renal function that may be reversible if addressed promptly, and chronic kidney disease (CKD), defined as structural or functional abnormalities persisting for more than three..."/><meta name="twitter:image" content="https://grokipedia.com/icon-512x512.png"/><link rel="icon" href="/favicon.ico" type="image/x-icon" sizes="16x16"/><meta name="sentry-trace" content="08dca610e83ed36aadf3869a65c26840-ce66a617177b58a6-1"/><meta name="baggage" content="sentry-environment=production,sentry-public_key=5f2258f71198ee26a355127af230c3a6,sentry-trace_id=08dca610e83ed36aadf3869a65c26840,sentry-org_id=4508179396558848,sentry-transaction=GET%20%2Fpage%2F%5Bslug%5D,sentry-sampled=true,sentry-sample_rand=0.23342787657821318,sentry-sample_rate=1"/><script src="/_next/static/chunks/polyfills-42372ed130431b0a.js" noModule="" nonce="YzBlMjE1NjMtYjg2MC00MmIzLWJmMzktNTk1ZDcyYjYzMzVi"></script></head><body class="flex h-[100svh] w-full flex-col __variable_13c637 __variable_8a0ba0 __variable_779740 __variable_2484fd __variable_525cc3 __variable_13486b"><div hidden=""><!--$--><!--/$--></div><script nonce="YzBlMjE1NjMtYjg2MC00MmIzLWJmMzktNTk1ZDcyYjYzMzVi">((a,b,c,d,e,f,g,h)=>{let i=document.documentElement,j=["light","dark"];function k(b){var c;(Array.isArray(a)?a:[a]).forEach(a=>{let c="class"===a,d=c&&f?e.map(a=>f[a]||a):e;c?(i.classList.remove(...d),i.classList.add(f&&f[b]?f[b]:b)):i.setAttribute(a,b)}),c=b,h&&j.includes(c)&&(i.style.colorScheme=c)}if(d)k(d);else try{let a=localStorage.getItem(b)||c,d=g&&"system"===a?window.matchMedia("(prefers-color-scheme: dark)").matches?"dark":"light":a;k(d)}catch(a){}})("class","theme","dark",null,["light","dark"],null,true,true)</script><header class="h-16 bg-surface-base fixed top-0 z-50 w-full"><div class="hidden h-full grid-cols-[1fr_3fr_1fr] items-center gap-4 !py-0 md:grid max-w-full py-6 px-4 w-full mx-auto"><div class="-ml-2 justify-self-start"><a class="cursor-pointer" href="/"><svg width="200" height="auto" viewBox="0 0 955 225" fill="none" xmlns="http://www.w3.org/2000/svg"><path d="M99.6937 159.214C90.008 159.214 81.5652 157.414 74.3652 153.814C67.1652 150.214 61.5509 144.986 57.5223 138.129C53.5794 131.271 51.608 123.043 51.608 113.443C51.608 103.843 53.5794 95.4857 57.5223 88.3714C61.5509 81.2572 67.1652 75.7286 74.3652 71.7857C81.6509 67.8429 90.1794 65.8714 99.9509 65.8714C103.208 65.8714 106.679 66.1286 110.365 66.6429C114.051 67.0714 117.222 67.6714 119.879 68.4429C121.508 68.8714 123.008 69.2572 124.379 69.6C125.751 69.9429 127.122 70.1143 128.494 70.1143C129.522 70.1143 130.551 69.9857 131.579 69.7286C131.751 73.5 131.922 77.4 132.094 81.4286C132.265 85.4572 132.522 89.6572 132.865 94.0286C131.065 94.2857 129.565 94.3714 128.365 94.2857C126.651 86.4 123.522 80.5714 118.979 76.8C114.437 72.9429 108.394 71.0143 100.851 71.0143C94.8509 71.0143 89.708 72.1286 85.4223 74.3572C81.2223 76.5 77.7937 79.4572 75.1366 83.2286C72.5652 87 70.6794 91.3714 69.4794 96.3429C68.2794 101.229 67.6794 106.457 67.6794 112.029C67.6794 120.171 68.9223 127.371 71.408 133.629C73.8937 139.886 77.6652 144.814 82.7223 148.414C87.8652 151.929 94.2937 153.686 102.008 153.686C104.408 153.686 107.065 153.471 109.979 153.043C112.894 152.529 115.679 151.757 118.337 150.729V134.529C118.337 131.871 118.208 129.814 117.951 128.357C117.779 126.814 117.222 125.7 116.279 125.014C115.422 124.329 114.008 123.857 112.037 123.6C110.151 123.257 107.537 122.957 104.194 122.7C103.937 121.329 103.937 119.957 104.194 118.586C105.994 118.586 108.179 118.629 110.751 118.714C113.322 118.714 115.894 118.757 118.465 118.843C121.122 118.843 123.308 118.843 125.022 118.843C127.679 118.843 130.722 118.8 134.151 118.714C137.665 118.629 140.665 118.586 143.151 118.586C143.322 119.871 143.322 121.2 143.151 122.571C139.637 123 137.108 123.429 135.565 123.857C134.022 124.286 133.079 125.143 132.737 126.429C132.394 127.714 132.222 129.9 132.222 132.986V137.1C132.222 141.129 132.308 144.514 132.479 147.257C132.737 150 132.951 151.971 133.122 153.171C121.208 157.2 110.065 159.214 99.6937 159.214ZM148.19 157.414C147.933 156.043 147.933 154.714 148.19 153.429C151.105 153.257 153.248 153 154.619 152.657C155.99 152.229 156.89 151.371 157.319 150.086C157.748 148.8 157.962 146.743 157.962 143.914V115.114C157.962 111.771 157.79 109.286 157.448 107.657C157.19 106.029 156.376 104.914 155.005 104.314C153.719 103.629 151.49 103.071 148.319 102.643C148.062 101.443 148.062 100.329 148.319 99.3C151.748 98.6143 155.09 97.8429 158.348 96.9857C161.605 96.0429 165.033 94.8429 168.633 93.3857L170.819 94.1572V105.471C176.819 97.8429 182.948 94.0286 189.205 94.0286C192.205 94.0286 194.433 94.8429 195.89 96.4714C197.348 98.0143 198.076 99.7714 198.076 101.743C198.076 104.057 197.305 105.857 195.762 107.143C194.219 108.343 192.462 108.943 190.49 108.943C188.862 108.943 187.233 108.514 185.605 107.657C184.062 106.8 182.905 105.471 182.133 103.671C179.219 103.671 176.605 104.829 174.29 107.143C172.062 109.371 170.948 111.986 170.948 114.986V142.629C170.948 145.971 171.119 148.371 171.462 149.829C171.89 151.286 172.919 152.229 174.548 152.657C176.262 153 179.005 153.257 182.776 153.429C182.948 154.629 182.948 155.957 182.776 157.414C179.862 157.414 176.862 157.371 173.776 157.286C170.69 157.2 167.519 157.157 164.262 157.157C161.09 157.157 158.262 157.2 155.776 157.286C153.376 157.371 150.848 157.414 148.19 157.414ZM229.285 158.829C223.028 158.829 217.542 157.5 212.828 154.843C208.199 152.1 204.599 148.371 202.028 143.657C199.457 138.857 198.171 133.371 198.171 127.2C198.171 120.514 199.499 114.686 202.157 109.714C204.899 104.743 208.714 100.886 213.599 98.1429C218.485 95.4 224.099 94.0286 230.442 94.0286C236.699 94.0286 242.142 95.4 246.771 98.1429C251.399 100.886 254.999 104.657 257.571 109.457C260.142 114.257 261.428 119.7 261.428 125.786C261.428 132.043 260.057 137.7 257.314 142.757C254.657 147.729 250.928 151.671 246.128 154.586C241.328 157.414 235.714 158.829 229.285 158.829ZM212.699 125.657C212.699 134.4 214.114 141.343 216.942 146.486C219.857 151.543 224.185 154.071 229.928 154.071C235.414 154.071 239.614 151.671 242.528 146.871C245.442 141.986 246.899 135.471 246.899 127.329C246.899 118.671 245.442 111.771 242.528 106.629C239.614 101.486 235.371 98.9143 229.799 98.9143C224.314 98.9143 220.071 101.271 217.071 105.986C214.157 110.7 212.699 117.257 212.699 125.657ZM267.394 157.414C267.308 157.071 267.265 156.729 267.265 156.386C267.265 156.043 267.265 155.7 267.265 155.357C267.265 155.014 267.265 154.714 267.265 154.457C267.265 154.114 267.308 153.771 267.394 153.429C270.308 153.257 272.451 153 273.822 152.657C275.194 152.229 276.094 151.371 276.522 150.086C276.951 148.8 277.165 146.743 277.165 143.914V79.5C277.165 76.8429 276.908 74.8714 276.394 73.5857C275.965 72.2143 274.979 71.2714 273.437 70.7572C271.979 70.1572 269.751 69.7286 266.751 69.4714C266.665 69.1286 266.622 68.8286 266.622 68.5714C266.622 68.3143 266.622 68.0572 266.622 67.8C266.622 67.4572 266.622 67.1572 266.622 66.9C266.622 66.6429 266.665 66.3429 266.751 66C270.179 65.5714 273.694 64.9286 277.294 64.0714C280.894 63.1286 284.579 61.8429 288.351 60.2143L290.537 60.9857C290.451 62.8714 290.365 65.0143 290.279 67.4143C290.279 69.8143 290.279 72.4286 290.279 75.2572V122.957C291.308 122.957 292.165 122.786 292.851 122.443C293.537 122.1 294.094 121.757 294.522 121.414C294.694 121.243 295.037 120.943 295.551 120.514C296.065 120 296.965 119.1 298.251 117.814C299.537 116.529 301.379 114.6 303.779 112.029C306.008 109.543 307.765 107.614 309.051 106.243C310.422 104.786 311.108 103.586 311.108 102.643C311.108 101.957 310.508 101.4 309.308 100.971C308.194 100.457 306.651 100.157 304.679 100.071C304.594 99.7286 304.551 99.3857 304.551 99.0429C304.551 98.7 304.551 98.3572 304.551 98.0143C304.551 97.6714 304.551 97.3286 304.551 96.9857C304.551 96.6429 304.594 96.3 304.679 95.9572C306.394 95.9572 308.537 96 311.108 96.0857C313.765 96.1714 316.122 96.2143 318.179 96.2143C319.208 96.2143 320.665 96.2143 322.551 96.2143C324.522 96.1286 326.494 96.0857 328.465 96.0857C330.437 96.0857 331.894 96.0857 332.837 96.0857C332.922 96.4286 332.965 96.7714 332.965 97.1143C333.051 97.4572 333.094 97.8 333.094 98.1429C333.094 98.4857 333.051 98.8286 332.965 99.1714C332.965 99.4286 332.922 99.7286 332.837 100.071C328.379 100.157 324.608 101.271 321.522 103.414C318.437 105.471 315.479 107.914 312.651 110.743L303.394 120L321.137 143.4C323.022 145.886 324.565 147.857 325.765 149.314C327.051 150.686 328.422 151.671 329.879 152.271C331.337 152.871 333.351 153.257 335.922 153.429C336.094 154.629 336.094 155.957 335.922 157.414C334.808 157.414 333.137 157.371 330.908 157.286C328.765 157.2 325.379 157.157 320.751 157.157C320.065 157.157 319.037 157.157 317.665 157.157C316.294 157.157 315.008 157.243 313.808 157.414C313.808 156.471 313.294 155.186 312.265 153.557C311.237 151.843 310.422 150.6 309.822 149.829C309.565 149.4 308.922 148.5 307.894 147.129C306.865 145.671 305.622 144 304.165 142.114C302.794 140.143 301.379 138.171 299.922 136.2C298.465 134.143 297.137 132.343 295.937 130.8C294.994 129.514 294.094 128.529 293.237 127.843C292.465 127.071 291.479 126.686 290.279 126.686V142.629C290.279 145.971 290.408 148.371 290.665 149.829C291.008 151.286 291.737 152.229 292.851 152.657C294.051 153 295.851 153.257 298.251 153.429C298.422 154.714 298.422 156.043 298.251 157.414C296.022 157.414 293.665 157.371 291.179 157.286C288.779 157.2 286.165 157.157 283.337 157.157C280.594 157.157 277.894 157.2 275.237 157.286C272.579 157.371 269.965 157.414 267.394 157.414ZM369.34 157.414C366.94 157.414 364.454 157.371 361.883 157.286C359.311 157.2 356.526 157.157 353.526 157.157C350.783 157.157 347.997 157.2 345.169 157.286C342.426 157.371 339.769 157.414 337.197 157.414C336.94 156.043 336.94 154.714 337.197 153.429C340.111 153.257 342.254 153 343.626 152.657C344.997 152.229 345.897 151.371 346.326 150.086C346.754 148.8 346.969 146.743 346.969 143.914V115.114C346.969 111.771 346.84 109.286 346.583 107.657C346.326 106.029 345.511 104.914 344.14 104.314C342.854 103.629 340.583 103.071 337.326 102.643C337.069 101.443 337.069 100.329 337.326 99.3C341.097 98.6143 344.697 97.7572 348.126 96.7286C351.554 95.7 354.854 94.5857 358.026 93.3857L360.211 94.1572C360.126 96.8143 360.04 99.3 359.954 101.614C359.954 103.929 359.954 106.114 359.954 108.171V142.629C359.954 145.971 360.126 148.371 360.469 149.829C360.897 151.286 361.754 152.229 363.04 152.657C364.411 153 366.511 153.257 369.34 153.429C369.597 154.714 369.597 156.043 369.34 157.414ZM343.626 71.5286C343.626 69.0429 344.483 66.9429 346.197 65.2286C347.997 63.5143 350.14 62.6572 352.626 62.6572C355.026 62.6572 357.083 63.5143 358.797 65.2286C360.597 66.9429 361.497 69 361.497 71.4C361.497 73.6286 360.64 75.6857 358.926 77.5715C357.211 79.3714 355.026 80.2714 352.369 80.2714C349.969 80.2714 347.911 79.4143 346.197 77.7C344.483 75.9857 343.626 73.9286 343.626 71.5286ZM372.678 188.914C372.592 187.543 372.592 186.214 372.678 184.929C375.678 184.757 377.864 184.457 379.235 184.029C380.607 183.6 381.464 182.743 381.807 181.457C382.235 180.257 382.45 178.286 382.45 175.543V115.114C382.45 111.771 382.278 109.286 381.935 107.657C381.678 106.029 380.864 104.914 379.492 104.314C378.207 103.629 375.978 103.071 372.807 102.643C372.635 101.443 372.635 100.329 372.807 99.3C376.321 98.6143 379.75 97.8 383.092 96.8572C386.435 95.9143 389.907 94.7572 393.507 93.3857L395.307 94.2857C395.221 96.4286 395.178 98.2714 395.178 99.8143C395.178 101.271 395.178 102.686 395.178 104.057C398.521 100.543 401.821 98.0143 405.078 96.4714C408.335 94.8429 411.807 94.0286 415.492 94.0286C420.892 94.0286 425.435 95.4429 429.121 98.2714C432.892 101.1 435.764 104.786 437.735 109.329C439.707 113.871 440.692 118.8 440.692 124.114C440.692 130.371 439.321 136.157 436.578 141.471C433.921 146.7 430.192 150.9 425.392 154.071C420.592 157.243 415.021 158.829 408.678 158.829C406.192 158.829 403.835 158.614 401.607 158.186C399.378 157.843 397.278 157.329 395.307 156.643V174C395.307 177.343 395.564 179.743 396.078 181.2C396.592 182.657 397.707 183.557 399.421 183.9C401.135 184.329 403.835 184.629 407.521 184.8C407.607 186.171 407.607 187.543 407.521 188.914C404.607 188.914 401.65 188.871 398.65 188.786C395.735 188.7 392.521 188.657 389.007 188.657C385.664 188.657 382.792 188.7 380.392 188.786C377.992 188.871 375.421 188.914 372.678 188.914ZM395.178 146.1C398.864 151.414 403.75 154.071 409.835 154.071C414.121 154.071 417.507 152.871 419.992 150.471C422.564 148.071 424.407 144.943 425.521 141.086C426.721 137.229 427.321 133.157 427.321 128.871C427.321 124.586 426.764 120.386 425.65 116.271C424.535 112.157 422.692 108.771 420.121 106.114C417.635 103.371 414.207 102 409.835 102C404.607 102 399.721 104.529 395.178 109.586V146.1ZM477.335 158.829C471.25 158.829 466.107 157.414 461.907 154.586C457.707 151.757 454.493 147.986 452.264 143.271C450.121 138.471 449.05 133.2 449.05 127.457C449.05 121.543 450.164 116.057 452.393 111C454.707 105.943 458.05 101.871 462.421 98.7857C466.793 95.6143 472.107 94.0286 478.364 94.0286C485.907 94.0286 491.778 96.3 495.978 100.843C500.264 105.3 502.407 111.086 502.407 118.2C502.407 119.057 502.364 119.829 502.278 120.514C502.278 121.114 502.235 121.629 502.15 122.057L461.65 121.671C461.65 122.014 461.65 122.314 461.65 122.571C461.65 130.971 463.578 137.571 467.435 142.371C471.293 147.171 476.693 149.571 483.635 149.571C489.464 149.571 495.207 147.686 500.864 143.914C501.721 144.943 502.364 145.929 502.793 146.871C495.507 154.843 487.021 158.829 477.335 158.829ZM462.035 116.914L488.65 116.4C488.735 116.229 488.778 116.014 488.778 115.757C488.778 115.414 488.778 115.2 488.778 115.114C488.778 110.486 487.75 106.629 485.693 103.543C483.721 100.457 480.764 98.9143 476.821 98.9143C473.135 98.9143 469.921 100.414 467.178 103.414C464.435 106.414 462.721 110.914 462.035 116.914ZM559.644 158.957L557.587 158.057L557.073 149.186C554.073 152.443 550.987 154.886 547.816 156.514C544.73 158.057 541.302 158.829 537.53 158.829C532.216 158.829 527.544 157.414 523.516 154.586C519.573 151.671 516.53 147.9 514.387 143.271C512.244 138.643 511.173 133.629 511.173 128.229C511.173 121.971 512.502 116.271 515.159 111.129C517.902 105.986 521.716 101.871 526.602 98.7857C531.573 95.6143 537.359 94.0286 543.959 94.0286C545.93 94.0286 547.987 94.2 550.13 94.5429C552.273 94.8 554.502 95.2714 556.816 95.9572V79.5C556.816 76.8429 556.559 74.8714 556.044 73.5857C555.53 72.2143 554.502 71.2714 552.959 70.7572C551.502 70.1572 549.273 69.7286 546.273 69.4714C546.016 68.3572 546.016 67.2 546.273 66C549.702 65.5714 553.216 64.9286 556.816 64.0714C560.416 63.1286 564.102 61.8429 567.873 60.2143L570.059 60.9857C569.973 62.8714 569.887 65.0143 569.802 67.4143C569.802 69.8143 569.802 72.4286 569.802 75.2572V139.029C569.802 142.286 569.93 144.729 570.187 146.357C570.445 147.986 571.216 149.143 572.502 149.829C573.787 150.429 575.973 150.986 579.059 151.5C579.316 152.614 579.316 153.771 579.059 154.971C575.63 155.486 572.287 156.043 569.03 156.643C565.773 157.243 562.644 158.014 559.644 158.957ZM556.944 106.886C553.259 101.829 548.416 99.3 542.416 99.3C536.502 99.3 532.044 101.486 529.044 105.857C526.044 110.143 524.544 116.1 524.544 123.729C524.544 128.186 525.144 132.471 526.344 136.586C527.544 140.7 529.516 144.086 532.259 146.743C535.002 149.4 538.644 150.729 543.187 150.729C548.93 150.729 553.516 148.243 556.944 143.271V106.886ZM615.699 157.414C613.299 157.414 610.813 157.371 608.242 157.286C605.67 157.2 602.885 157.157 599.885 157.157C597.142 157.157 594.356 157.2 591.527 157.286C588.785 157.371 586.127 157.414 583.556 157.414C583.299 156.043 583.299 154.714 583.556 153.429C586.47 153.257 588.613 153 589.985 152.657C591.356 152.229 592.256 151.371 592.685 150.086C593.113 148.8 593.327 146.743 593.327 143.914V115.114C593.327 111.771 593.199 109.286 592.942 107.657C592.685 106.029 591.87 104.914 590.499 104.314C589.213 103.629 586.942 103.071 583.685 102.643C583.427 101.443 583.427 100.329 583.685 99.3C587.456 98.6143 591.056 97.7572 594.485 96.7286C597.913 95.7 601.213 94.5857 604.385 93.3857L606.57 94.1572C606.485 96.8143 606.399 99.3 606.313 101.614C606.313 103.929 606.313 106.114 606.313 108.171V142.629C606.313 145.971 606.485 148.371 606.827 149.829C607.256 151.286 608.113 152.229 609.399 152.657C610.77 153 612.87 153.257 615.699 153.429C615.956 154.714 615.956 156.043 615.699 157.414ZM589.985 71.5286C589.985 69.0429 590.842 66.9429 592.556 65.2286C594.356 63.5143 596.499 62.6572 598.985 62.6572C601.385 62.6572 603.442 63.5143 605.156 65.2286C606.956 66.9429 607.856 69 607.856 71.4C607.856 73.6286 606.999 75.6857 605.285 77.5715C603.57 79.3714 601.385 80.2714 598.727 80.2714C596.327 80.2714 594.27 79.4143 592.556 77.7C590.842 75.9857 589.985 73.9286 589.985 71.5286ZM665.837 158.571C660.18 158.571 656.623 155.743 655.165 150.086C649.08 155.914 642.865 158.829 636.523 158.829C632.151 158.829 628.423 157.543 625.337 154.971C622.337 152.314 620.837 148.671 620.837 144.043C620.837 132.729 632.365 125.614 655.423 122.7C655.423 120.643 655.423 118.543 655.423 116.4C655.508 114.257 655.551 111.986 655.551 109.586C655.551 106.586 654.437 104.271 652.208 102.643C650.065 100.929 647.451 100.071 644.365 100.071C642.137 100.071 640.251 100.414 638.708 101.1C638.708 103.071 638.28 105.086 637.423 107.143C636.565 109.2 635.365 110.957 633.823 112.414C632.365 113.786 630.565 114.471 628.423 114.471C626.537 114.471 625.037 113.957 623.923 112.929C622.894 111.814 622.38 110.486 622.38 108.943C622.38 106.886 623.323 104.957 625.208 103.157C627.18 101.271 629.665 99.6857 632.665 98.4C635.665 97.0286 638.794 95.9572 642.051 95.1857C645.308 94.4143 648.223 94.0286 650.794 94.0286C653.965 94.0286 656.88 94.6286 659.537 95.8286C662.28 96.9429 664.465 98.6572 666.094 100.971C667.808 103.2 668.665 105.986 668.665 109.329C668.665 111.386 668.623 114.086 668.537 117.429C668.451 120.686 668.365 124.2 668.28 127.971C668.28 131.657 668.237 135.171 668.151 138.514C668.065 141.857 668.023 144.557 668.023 146.614C668.023 149.357 669.223 150.729 671.623 150.729C673.165 150.729 675.523 150.214 678.694 149.186C679.037 149.614 679.251 150.086 679.337 150.6C679.508 151.114 679.637 151.586 679.723 152.014C677.58 154.329 675.308 156 672.908 157.029C670.594 158.057 668.237 158.571 665.837 158.571ZM655.165 146.614L655.423 127.329C647.537 128.357 642.094 130.029 639.094 132.343C636.18 134.657 634.723 137.614 634.723 141.214C634.723 144.214 635.494 146.529 637.037 148.157C638.665 149.7 640.68 150.471 643.08 150.471C644.623 150.471 646.337 150.129 648.223 149.443C650.194 148.757 652.508 147.814 655.165 146.614Z" fill="currentColor"></path><rect x="715" y="65" width="195" height="105" rx="52.5" fill="currentColor" fill-opacity="0.05"></rect><path d="M767.529 142.875L754.049 107.938H762.552L769.309 127.582C769.705 128.812 770.078 130.032 770.43 131.24C770.781 132.449 771.078 133.559 771.32 134.569H771.616C771.858 133.559 772.144 132.449 772.473 131.24C772.825 130.032 773.198 128.812 773.594 127.582L780.186 107.938H788.689L775.472 142.875H767.529ZM810.856 143.633C806.901 143.633 803.528 142.71 800.737 140.865C797.969 138.997 795.871 136.305 794.442 132.79C793.014 129.252 792.3 124.989 792.3 120.001V118.255C792.3 113.245 793.014 108.982 794.442 105.467C795.871 101.929 797.969 99.2373 800.737 97.3916C803.528 95.5239 806.901 94.5901 810.856 94.5901C814.789 94.5901 818.129 95.5129 820.875 97.3586C823.644 99.2043 825.731 101.907 827.138 105.467C828.566 109.004 829.28 113.267 829.28 118.255V120.001C829.28 124.989 828.577 129.252 827.171 132.79C825.764 136.327 823.677 139.019 820.908 140.865C818.162 142.71 814.811 143.633 810.856 143.633ZM810.889 136.382C813.064 136.382 814.877 135.789 816.327 134.602C817.799 133.416 818.898 131.658 819.623 129.329C820.348 126.978 820.711 124.066 820.711 120.595V117.694C820.711 114.223 820.337 111.311 819.59 108.96C818.865 106.609 817.777 104.84 816.327 103.654C814.877 102.445 813.064 101.841 810.889 101.841C808.714 101.841 806.879 102.434 805.385 103.621C803.912 104.785 802.792 106.554 802.023 108.927C801.276 111.278 800.902 114.201 800.902 117.694V120.595C800.902 124.044 801.287 126.945 802.056 129.296C802.825 131.647 803.945 133.416 805.418 134.602C806.89 135.789 808.714 136.382 810.889 136.382ZM838.988 143.205C838 143.205 837.099 142.985 836.286 142.545C835.495 142.106 834.879 141.491 834.44 140.7C834.001 139.909 833.781 139.019 833.781 138.03C833.781 137.019 834.001 136.118 834.44 135.327C834.879 134.536 835.495 133.921 836.286 133.482C837.099 133.042 838 132.823 838.988 132.823C839.977 132.823 840.867 133.042 841.658 133.482C842.449 133.921 843.064 134.536 843.504 135.327C843.943 136.118 844.163 137.019 844.163 138.03C844.163 139.019 843.943 139.909 843.504 140.7C843.064 141.491 842.449 142.106 841.658 142.545C840.867 142.985 839.977 143.205 838.988 143.205ZM857.365 142.875V104.511L846.39 111.663V103.357L858.453 95.3481H865.802V142.875H857.365Z" fill="currentColor"></path></svg></a></div><div class="mx-auto flex w-full"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 border-input text-primary hover:border-primary/15 border hover:bg-overlay-hover py-2 max-w-full px-3 shadow-none sm:w-80 focus-visible:z-1 mx-auto h-full w-full rounded-full bg-surface-l1" type="button"><div class="flex items-center justify-between sm:w-full gap-4"><div class="flex items-center justify-start gap-2"><span class="inline-flex items-center justify-center p-0 m-0 w-4 h-4 text-muted" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-4 h-4" focusable="false" style="fill:currentColor"><path d="m18.031 16.617 4.283 4.282-1.415 1.415-4.282-4.283A8.96 8.96 0 0 1 11 20c-4.968 0-9-4.032-9-9s4.032-9 9-9 9 4.032 9 9a8.96 8.96 0 0 1-1.969 5.617m-2.006-.742A6.98 6.98 0 0 0 18 11c0-3.867-3.133-7-7-7s-7 3.133-7 7 3.133 7 7 7a6.98 6.98 0 0 0 4.875-1.975z"></path></svg></span><p class="text-sm text-muted hidden sm:block">Search</p></div><span class="hidden sm:block"><div class="bg-foreground/10 text-muted inline-flex items-center rounded-md px-1 py-0.5 text-center font-sans text-xs font-normal tracking-widest rtl:space-x-reverse"><span>âŒ˜</span><span class="text-xs">K</span></div></span></div></button></div><div class="flex items-center gap-2 justify-self-end"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover px-4 py-2 w-9 h-9 flex-shrink-0" type="button" id="radix-_R_7apfiumdb_" aria-haspopup="menu" aria-expanded="false" data-state="closed"><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 rotate-0 scale-100 transition-all dark:-rotate-90 dark:scale-0" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M12 18a6 6 0 1 1 0-12 6 6 0 0 1 0 12m0-2a4 4 0 1 0 0-8 4 4 0 0 0 0 8M11 1h2v3h-2zm0 19h2v3h-2zM3.515 4.929l1.414-1.414L7.05 5.636 5.636 7.05zM16.95 18.364l1.414-1.414 2.121 2.121-1.414 1.414zm2.121-14.85 1.414 1.415-2.121 2.121-1.414-1.414zM5.636 16.95l1.414 1.414-2.121 2.121-1.414-1.414zM23 11v2h-3v-2zM4 11v2H1v-2z"></path></svg></span><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 absolute rotate-90 scale-0 transition-all dark:rotate-0 dark:scale-100" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M10 7a7 7 0 0 0 12 4.9v.1c0 5.523-4.477 10-10 10S2 17.523 2 12 6.477 2 12 2h.1A6.98 6.98 0 0 0 10 7m-6 5a8 8 0 0 0 15.062 3.762A9 9 0 0 1 8.238 4.938 8 8 0 0 0 4 12"></path></svg></span><span class="sr-only">Toggle theme</span></button></div></div><div class="flex h-full items-center md:hidden justify-between max-w-full py-6 px-4 w-full mx-auto pt-8"><div class="flex items-center"><div class="-ml-2"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover h-9 w-9" type="button" aria-label="Toggle table of contents"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-list h-6 w-6"><path d="M3 12h.01"></path><path d="M3 18h.01"></path><path d="M3 6h.01"></path><path d="M8 12h13"></path><path d="M8 18h13"></path><path d="M8 6h13"></path></svg></button></div><a class="cursor-pointer" href="/"><svg width="160" height="auto" viewBox="0 0 955 225" fill="none" xmlns="http://www.w3.org/2000/svg"><path d="M99.6937 159.214C90.008 159.214 81.5652 157.414 74.3652 153.814C67.1652 150.214 61.5509 144.986 57.5223 138.129C53.5794 131.271 51.608 123.043 51.608 113.443C51.608 103.843 53.5794 95.4857 57.5223 88.3714C61.5509 81.2572 67.1652 75.7286 74.3652 71.7857C81.6509 67.8429 90.1794 65.8714 99.9509 65.8714C103.208 65.8714 106.679 66.1286 110.365 66.6429C114.051 67.0714 117.222 67.6714 119.879 68.4429C121.508 68.8714 123.008 69.2572 124.379 69.6C125.751 69.9429 127.122 70.1143 128.494 70.1143C129.522 70.1143 130.551 69.9857 131.579 69.7286C131.751 73.5 131.922 77.4 132.094 81.4286C132.265 85.4572 132.522 89.6572 132.865 94.0286C131.065 94.2857 129.565 94.3714 128.365 94.2857C126.651 86.4 123.522 80.5714 118.979 76.8C114.437 72.9429 108.394 71.0143 100.851 71.0143C94.8509 71.0143 89.708 72.1286 85.4223 74.3572C81.2223 76.5 77.7937 79.4572 75.1366 83.2286C72.5652 87 70.6794 91.3714 69.4794 96.3429C68.2794 101.229 67.6794 106.457 67.6794 112.029C67.6794 120.171 68.9223 127.371 71.408 133.629C73.8937 139.886 77.6652 144.814 82.7223 148.414C87.8652 151.929 94.2937 153.686 102.008 153.686C104.408 153.686 107.065 153.471 109.979 153.043C112.894 152.529 115.679 151.757 118.337 150.729V134.529C118.337 131.871 118.208 129.814 117.951 128.357C117.779 126.814 117.222 125.7 116.279 125.014C115.422 124.329 114.008 123.857 112.037 123.6C110.151 123.257 107.537 122.957 104.194 122.7C103.937 121.329 103.937 119.957 104.194 118.586C105.994 118.586 108.179 118.629 110.751 118.714C113.322 118.714 115.894 118.757 118.465 118.843C121.122 118.843 123.308 118.843 125.022 118.843C127.679 118.843 130.722 118.8 134.151 118.714C137.665 118.629 140.665 118.586 143.151 118.586C143.322 119.871 143.322 121.2 143.151 122.571C139.637 123 137.108 123.429 135.565 123.857C134.022 124.286 133.079 125.143 132.737 126.429C132.394 127.714 132.222 129.9 132.222 132.986V137.1C132.222 141.129 132.308 144.514 132.479 147.257C132.737 150 132.951 151.971 133.122 153.171C121.208 157.2 110.065 159.214 99.6937 159.214ZM148.19 157.414C147.933 156.043 147.933 154.714 148.19 153.429C151.105 153.257 153.248 153 154.619 152.657C155.99 152.229 156.89 151.371 157.319 150.086C157.748 148.8 157.962 146.743 157.962 143.914V115.114C157.962 111.771 157.79 109.286 157.448 107.657C157.19 106.029 156.376 104.914 155.005 104.314C153.719 103.629 151.49 103.071 148.319 102.643C148.062 101.443 148.062 100.329 148.319 99.3C151.748 98.6143 155.09 97.8429 158.348 96.9857C161.605 96.0429 165.033 94.8429 168.633 93.3857L170.819 94.1572V105.471C176.819 97.8429 182.948 94.0286 189.205 94.0286C192.205 94.0286 194.433 94.8429 195.89 96.4714C197.348 98.0143 198.076 99.7714 198.076 101.743C198.076 104.057 197.305 105.857 195.762 107.143C194.219 108.343 192.462 108.943 190.49 108.943C188.862 108.943 187.233 108.514 185.605 107.657C184.062 106.8 182.905 105.471 182.133 103.671C179.219 103.671 176.605 104.829 174.29 107.143C172.062 109.371 170.948 111.986 170.948 114.986V142.629C170.948 145.971 171.119 148.371 171.462 149.829C171.89 151.286 172.919 152.229 174.548 152.657C176.262 153 179.005 153.257 182.776 153.429C182.948 154.629 182.948 155.957 182.776 157.414C179.862 157.414 176.862 157.371 173.776 157.286C170.69 157.2 167.519 157.157 164.262 157.157C161.09 157.157 158.262 157.2 155.776 157.286C153.376 157.371 150.848 157.414 148.19 157.414ZM229.285 158.829C223.028 158.829 217.542 157.5 212.828 154.843C208.199 152.1 204.599 148.371 202.028 143.657C199.457 138.857 198.171 133.371 198.171 127.2C198.171 120.514 199.499 114.686 202.157 109.714C204.899 104.743 208.714 100.886 213.599 98.1429C218.485 95.4 224.099 94.0286 230.442 94.0286C236.699 94.0286 242.142 95.4 246.771 98.1429C251.399 100.886 254.999 104.657 257.571 109.457C260.142 114.257 261.428 119.7 261.428 125.786C261.428 132.043 260.057 137.7 257.314 142.757C254.657 147.729 250.928 151.671 246.128 154.586C241.328 157.414 235.714 158.829 229.285 158.829ZM212.699 125.657C212.699 134.4 214.114 141.343 216.942 146.486C219.857 151.543 224.185 154.071 229.928 154.071C235.414 154.071 239.614 151.671 242.528 146.871C245.442 141.986 246.899 135.471 246.899 127.329C246.899 118.671 245.442 111.771 242.528 106.629C239.614 101.486 235.371 98.9143 229.799 98.9143C224.314 98.9143 220.071 101.271 217.071 105.986C214.157 110.7 212.699 117.257 212.699 125.657ZM267.394 157.414C267.308 157.071 267.265 156.729 267.265 156.386C267.265 156.043 267.265 155.7 267.265 155.357C267.265 155.014 267.265 154.714 267.265 154.457C267.265 154.114 267.308 153.771 267.394 153.429C270.308 153.257 272.451 153 273.822 152.657C275.194 152.229 276.094 151.371 276.522 150.086C276.951 148.8 277.165 146.743 277.165 143.914V79.5C277.165 76.8429 276.908 74.8714 276.394 73.5857C275.965 72.2143 274.979 71.2714 273.437 70.7572C271.979 70.1572 269.751 69.7286 266.751 69.4714C266.665 69.1286 266.622 68.8286 266.622 68.5714C266.622 68.3143 266.622 68.0572 266.622 67.8C266.622 67.4572 266.622 67.1572 266.622 66.9C266.622 66.6429 266.665 66.3429 266.751 66C270.179 65.5714 273.694 64.9286 277.294 64.0714C280.894 63.1286 284.579 61.8429 288.351 60.2143L290.537 60.9857C290.451 62.8714 290.365 65.0143 290.279 67.4143C290.279 69.8143 290.279 72.4286 290.279 75.2572V122.957C291.308 122.957 292.165 122.786 292.851 122.443C293.537 122.1 294.094 121.757 294.522 121.414C294.694 121.243 295.037 120.943 295.551 120.514C296.065 120 296.965 119.1 298.251 117.814C299.537 116.529 301.379 114.6 303.779 112.029C306.008 109.543 307.765 107.614 309.051 106.243C310.422 104.786 311.108 103.586 311.108 102.643C311.108 101.957 310.508 101.4 309.308 100.971C308.194 100.457 306.651 100.157 304.679 100.071C304.594 99.7286 304.551 99.3857 304.551 99.0429C304.551 98.7 304.551 98.3572 304.551 98.0143C304.551 97.6714 304.551 97.3286 304.551 96.9857C304.551 96.6429 304.594 96.3 304.679 95.9572C306.394 95.9572 308.537 96 311.108 96.0857C313.765 96.1714 316.122 96.2143 318.179 96.2143C319.208 96.2143 320.665 96.2143 322.551 96.2143C324.522 96.1286 326.494 96.0857 328.465 96.0857C330.437 96.0857 331.894 96.0857 332.837 96.0857C332.922 96.4286 332.965 96.7714 332.965 97.1143C333.051 97.4572 333.094 97.8 333.094 98.1429C333.094 98.4857 333.051 98.8286 332.965 99.1714C332.965 99.4286 332.922 99.7286 332.837 100.071C328.379 100.157 324.608 101.271 321.522 103.414C318.437 105.471 315.479 107.914 312.651 110.743L303.394 120L321.137 143.4C323.022 145.886 324.565 147.857 325.765 149.314C327.051 150.686 328.422 151.671 329.879 152.271C331.337 152.871 333.351 153.257 335.922 153.429C336.094 154.629 336.094 155.957 335.922 157.414C334.808 157.414 333.137 157.371 330.908 157.286C328.765 157.2 325.379 157.157 320.751 157.157C320.065 157.157 319.037 157.157 317.665 157.157C316.294 157.157 315.008 157.243 313.808 157.414C313.808 156.471 313.294 155.186 312.265 153.557C311.237 151.843 310.422 150.6 309.822 149.829C309.565 149.4 308.922 148.5 307.894 147.129C306.865 145.671 305.622 144 304.165 142.114C302.794 140.143 301.379 138.171 299.922 136.2C298.465 134.143 297.137 132.343 295.937 130.8C294.994 129.514 294.094 128.529 293.237 127.843C292.465 127.071 291.479 126.686 290.279 126.686V142.629C290.279 145.971 290.408 148.371 290.665 149.829C291.008 151.286 291.737 152.229 292.851 152.657C294.051 153 295.851 153.257 298.251 153.429C298.422 154.714 298.422 156.043 298.251 157.414C296.022 157.414 293.665 157.371 291.179 157.286C288.779 157.2 286.165 157.157 283.337 157.157C280.594 157.157 277.894 157.2 275.237 157.286C272.579 157.371 269.965 157.414 267.394 157.414ZM369.34 157.414C366.94 157.414 364.454 157.371 361.883 157.286C359.311 157.2 356.526 157.157 353.526 157.157C350.783 157.157 347.997 157.2 345.169 157.286C342.426 157.371 339.769 157.414 337.197 157.414C336.94 156.043 336.94 154.714 337.197 153.429C340.111 153.257 342.254 153 343.626 152.657C344.997 152.229 345.897 151.371 346.326 150.086C346.754 148.8 346.969 146.743 346.969 143.914V115.114C346.969 111.771 346.84 109.286 346.583 107.657C346.326 106.029 345.511 104.914 344.14 104.314C342.854 103.629 340.583 103.071 337.326 102.643C337.069 101.443 337.069 100.329 337.326 99.3C341.097 98.6143 344.697 97.7572 348.126 96.7286C351.554 95.7 354.854 94.5857 358.026 93.3857L360.211 94.1572C360.126 96.8143 360.04 99.3 359.954 101.614C359.954 103.929 359.954 106.114 359.954 108.171V142.629C359.954 145.971 360.126 148.371 360.469 149.829C360.897 151.286 361.754 152.229 363.04 152.657C364.411 153 366.511 153.257 369.34 153.429C369.597 154.714 369.597 156.043 369.34 157.414ZM343.626 71.5286C343.626 69.0429 344.483 66.9429 346.197 65.2286C347.997 63.5143 350.14 62.6572 352.626 62.6572C355.026 62.6572 357.083 63.5143 358.797 65.2286C360.597 66.9429 361.497 69 361.497 71.4C361.497 73.6286 360.64 75.6857 358.926 77.5715C357.211 79.3714 355.026 80.2714 352.369 80.2714C349.969 80.2714 347.911 79.4143 346.197 77.7C344.483 75.9857 343.626 73.9286 343.626 71.5286ZM372.678 188.914C372.592 187.543 372.592 186.214 372.678 184.929C375.678 184.757 377.864 184.457 379.235 184.029C380.607 183.6 381.464 182.743 381.807 181.457C382.235 180.257 382.45 178.286 382.45 175.543V115.114C382.45 111.771 382.278 109.286 381.935 107.657C381.678 106.029 380.864 104.914 379.492 104.314C378.207 103.629 375.978 103.071 372.807 102.643C372.635 101.443 372.635 100.329 372.807 99.3C376.321 98.6143 379.75 97.8 383.092 96.8572C386.435 95.9143 389.907 94.7572 393.507 93.3857L395.307 94.2857C395.221 96.4286 395.178 98.2714 395.178 99.8143C395.178 101.271 395.178 102.686 395.178 104.057C398.521 100.543 401.821 98.0143 405.078 96.4714C408.335 94.8429 411.807 94.0286 415.492 94.0286C420.892 94.0286 425.435 95.4429 429.121 98.2714C432.892 101.1 435.764 104.786 437.735 109.329C439.707 113.871 440.692 118.8 440.692 124.114C440.692 130.371 439.321 136.157 436.578 141.471C433.921 146.7 430.192 150.9 425.392 154.071C420.592 157.243 415.021 158.829 408.678 158.829C406.192 158.829 403.835 158.614 401.607 158.186C399.378 157.843 397.278 157.329 395.307 156.643V174C395.307 177.343 395.564 179.743 396.078 181.2C396.592 182.657 397.707 183.557 399.421 183.9C401.135 184.329 403.835 184.629 407.521 184.8C407.607 186.171 407.607 187.543 407.521 188.914C404.607 188.914 401.65 188.871 398.65 188.786C395.735 188.7 392.521 188.657 389.007 188.657C385.664 188.657 382.792 188.7 380.392 188.786C377.992 188.871 375.421 188.914 372.678 188.914ZM395.178 146.1C398.864 151.414 403.75 154.071 409.835 154.071C414.121 154.071 417.507 152.871 419.992 150.471C422.564 148.071 424.407 144.943 425.521 141.086C426.721 137.229 427.321 133.157 427.321 128.871C427.321 124.586 426.764 120.386 425.65 116.271C424.535 112.157 422.692 108.771 420.121 106.114C417.635 103.371 414.207 102 409.835 102C404.607 102 399.721 104.529 395.178 109.586V146.1ZM477.335 158.829C471.25 158.829 466.107 157.414 461.907 154.586C457.707 151.757 454.493 147.986 452.264 143.271C450.121 138.471 449.05 133.2 449.05 127.457C449.05 121.543 450.164 116.057 452.393 111C454.707 105.943 458.05 101.871 462.421 98.7857C466.793 95.6143 472.107 94.0286 478.364 94.0286C485.907 94.0286 491.778 96.3 495.978 100.843C500.264 105.3 502.407 111.086 502.407 118.2C502.407 119.057 502.364 119.829 502.278 120.514C502.278 121.114 502.235 121.629 502.15 122.057L461.65 121.671C461.65 122.014 461.65 122.314 461.65 122.571C461.65 130.971 463.578 137.571 467.435 142.371C471.293 147.171 476.693 149.571 483.635 149.571C489.464 149.571 495.207 147.686 500.864 143.914C501.721 144.943 502.364 145.929 502.793 146.871C495.507 154.843 487.021 158.829 477.335 158.829ZM462.035 116.914L488.65 116.4C488.735 116.229 488.778 116.014 488.778 115.757C488.778 115.414 488.778 115.2 488.778 115.114C488.778 110.486 487.75 106.629 485.693 103.543C483.721 100.457 480.764 98.9143 476.821 98.9143C473.135 98.9143 469.921 100.414 467.178 103.414C464.435 106.414 462.721 110.914 462.035 116.914ZM559.644 158.957L557.587 158.057L557.073 149.186C554.073 152.443 550.987 154.886 547.816 156.514C544.73 158.057 541.302 158.829 537.53 158.829C532.216 158.829 527.544 157.414 523.516 154.586C519.573 151.671 516.53 147.9 514.387 143.271C512.244 138.643 511.173 133.629 511.173 128.229C511.173 121.971 512.502 116.271 515.159 111.129C517.902 105.986 521.716 101.871 526.602 98.7857C531.573 95.6143 537.359 94.0286 543.959 94.0286C545.93 94.0286 547.987 94.2 550.13 94.5429C552.273 94.8 554.502 95.2714 556.816 95.9572V79.5C556.816 76.8429 556.559 74.8714 556.044 73.5857C555.53 72.2143 554.502 71.2714 552.959 70.7572C551.502 70.1572 549.273 69.7286 546.273 69.4714C546.016 68.3572 546.016 67.2 546.273 66C549.702 65.5714 553.216 64.9286 556.816 64.0714C560.416 63.1286 564.102 61.8429 567.873 60.2143L570.059 60.9857C569.973 62.8714 569.887 65.0143 569.802 67.4143C569.802 69.8143 569.802 72.4286 569.802 75.2572V139.029C569.802 142.286 569.93 144.729 570.187 146.357C570.445 147.986 571.216 149.143 572.502 149.829C573.787 150.429 575.973 150.986 579.059 151.5C579.316 152.614 579.316 153.771 579.059 154.971C575.63 155.486 572.287 156.043 569.03 156.643C565.773 157.243 562.644 158.014 559.644 158.957ZM556.944 106.886C553.259 101.829 548.416 99.3 542.416 99.3C536.502 99.3 532.044 101.486 529.044 105.857C526.044 110.143 524.544 116.1 524.544 123.729C524.544 128.186 525.144 132.471 526.344 136.586C527.544 140.7 529.516 144.086 532.259 146.743C535.002 149.4 538.644 150.729 543.187 150.729C548.93 150.729 553.516 148.243 556.944 143.271V106.886ZM615.699 157.414C613.299 157.414 610.813 157.371 608.242 157.286C605.67 157.2 602.885 157.157 599.885 157.157C597.142 157.157 594.356 157.2 591.527 157.286C588.785 157.371 586.127 157.414 583.556 157.414C583.299 156.043 583.299 154.714 583.556 153.429C586.47 153.257 588.613 153 589.985 152.657C591.356 152.229 592.256 151.371 592.685 150.086C593.113 148.8 593.327 146.743 593.327 143.914V115.114C593.327 111.771 593.199 109.286 592.942 107.657C592.685 106.029 591.87 104.914 590.499 104.314C589.213 103.629 586.942 103.071 583.685 102.643C583.427 101.443 583.427 100.329 583.685 99.3C587.456 98.6143 591.056 97.7572 594.485 96.7286C597.913 95.7 601.213 94.5857 604.385 93.3857L606.57 94.1572C606.485 96.8143 606.399 99.3 606.313 101.614C606.313 103.929 606.313 106.114 606.313 108.171V142.629C606.313 145.971 606.485 148.371 606.827 149.829C607.256 151.286 608.113 152.229 609.399 152.657C610.77 153 612.87 153.257 615.699 153.429C615.956 154.714 615.956 156.043 615.699 157.414ZM589.985 71.5286C589.985 69.0429 590.842 66.9429 592.556 65.2286C594.356 63.5143 596.499 62.6572 598.985 62.6572C601.385 62.6572 603.442 63.5143 605.156 65.2286C606.956 66.9429 607.856 69 607.856 71.4C607.856 73.6286 606.999 75.6857 605.285 77.5715C603.57 79.3714 601.385 80.2714 598.727 80.2714C596.327 80.2714 594.27 79.4143 592.556 77.7C590.842 75.9857 589.985 73.9286 589.985 71.5286ZM665.837 158.571C660.18 158.571 656.623 155.743 655.165 150.086C649.08 155.914 642.865 158.829 636.523 158.829C632.151 158.829 628.423 157.543 625.337 154.971C622.337 152.314 620.837 148.671 620.837 144.043C620.837 132.729 632.365 125.614 655.423 122.7C655.423 120.643 655.423 118.543 655.423 116.4C655.508 114.257 655.551 111.986 655.551 109.586C655.551 106.586 654.437 104.271 652.208 102.643C650.065 100.929 647.451 100.071 644.365 100.071C642.137 100.071 640.251 100.414 638.708 101.1C638.708 103.071 638.28 105.086 637.423 107.143C636.565 109.2 635.365 110.957 633.823 112.414C632.365 113.786 630.565 114.471 628.423 114.471C626.537 114.471 625.037 113.957 623.923 112.929C622.894 111.814 622.38 110.486 622.38 108.943C622.38 106.886 623.323 104.957 625.208 103.157C627.18 101.271 629.665 99.6857 632.665 98.4C635.665 97.0286 638.794 95.9572 642.051 95.1857C645.308 94.4143 648.223 94.0286 650.794 94.0286C653.965 94.0286 656.88 94.6286 659.537 95.8286C662.28 96.9429 664.465 98.6572 666.094 100.971C667.808 103.2 668.665 105.986 668.665 109.329C668.665 111.386 668.623 114.086 668.537 117.429C668.451 120.686 668.365 124.2 668.28 127.971C668.28 131.657 668.237 135.171 668.151 138.514C668.065 141.857 668.023 144.557 668.023 146.614C668.023 149.357 669.223 150.729 671.623 150.729C673.165 150.729 675.523 150.214 678.694 149.186C679.037 149.614 679.251 150.086 679.337 150.6C679.508 151.114 679.637 151.586 679.723 152.014C677.58 154.329 675.308 156 672.908 157.029C670.594 158.057 668.237 158.571 665.837 158.571ZM655.165 146.614L655.423 127.329C647.537 128.357 642.094 130.029 639.094 132.343C636.18 134.657 634.723 137.614 634.723 141.214C634.723 144.214 635.494 146.529 637.037 148.157C638.665 149.7 640.68 150.471 643.08 150.471C644.623 150.471 646.337 150.129 648.223 149.443C650.194 148.757 652.508 147.814 655.165 146.614Z" fill="currentColor"></path><rect x="715" y="65" width="195" height="105" rx="52.5" fill="currentColor" fill-opacity="0.05"></rect><path d="M767.529 142.875L754.049 107.938H762.552L769.309 127.582C769.705 128.812 770.078 130.032 770.43 131.24C770.781 132.449 771.078 133.559 771.32 134.569H771.616C771.858 133.559 772.144 132.449 772.473 131.24C772.825 130.032 773.198 128.812 773.594 127.582L780.186 107.938H788.689L775.472 142.875H767.529ZM810.856 143.633C806.901 143.633 803.528 142.71 800.737 140.865C797.969 138.997 795.871 136.305 794.442 132.79C793.014 129.252 792.3 124.989 792.3 120.001V118.255C792.3 113.245 793.014 108.982 794.442 105.467C795.871 101.929 797.969 99.2373 800.737 97.3916C803.528 95.5239 806.901 94.5901 810.856 94.5901C814.789 94.5901 818.129 95.5129 820.875 97.3586C823.644 99.2043 825.731 101.907 827.138 105.467C828.566 109.004 829.28 113.267 829.28 118.255V120.001C829.28 124.989 828.577 129.252 827.171 132.79C825.764 136.327 823.677 139.019 820.908 140.865C818.162 142.71 814.811 143.633 810.856 143.633ZM810.889 136.382C813.064 136.382 814.877 135.789 816.327 134.602C817.799 133.416 818.898 131.658 819.623 129.329C820.348 126.978 820.711 124.066 820.711 120.595V117.694C820.711 114.223 820.337 111.311 819.59 108.96C818.865 106.609 817.777 104.84 816.327 103.654C814.877 102.445 813.064 101.841 810.889 101.841C808.714 101.841 806.879 102.434 805.385 103.621C803.912 104.785 802.792 106.554 802.023 108.927C801.276 111.278 800.902 114.201 800.902 117.694V120.595C800.902 124.044 801.287 126.945 802.056 129.296C802.825 131.647 803.945 133.416 805.418 134.602C806.89 135.789 808.714 136.382 810.889 136.382ZM838.988 143.205C838 143.205 837.099 142.985 836.286 142.545C835.495 142.106 834.879 141.491 834.44 140.7C834.001 139.909 833.781 139.019 833.781 138.03C833.781 137.019 834.001 136.118 834.44 135.327C834.879 134.536 835.495 133.921 836.286 133.482C837.099 133.042 838 132.823 838.988 132.823C839.977 132.823 840.867 133.042 841.658 133.482C842.449 133.921 843.064 134.536 843.504 135.327C843.943 136.118 844.163 137.019 844.163 138.03C844.163 139.019 843.943 139.909 843.504 140.7C843.064 141.491 842.449 142.106 841.658 142.545C840.867 142.985 839.977 143.205 838.988 143.205ZM857.365 142.875V104.511L846.39 111.663V103.357L858.453 95.3481H865.802V142.875H857.365Z" fill="currentColor"></path></svg></a></div><div class="flex items-center gap-1"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover px-4 py-2 w-9 h-9 flex-shrink-0 [&amp;_svg]:!w-5" type="button" id="radix-_R_aipfiumdb_" aria-haspopup="menu" aria-expanded="false" data-state="closed"><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 rotate-0 scale-100 transition-all dark:-rotate-90 dark:scale-0" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M12 18a6 6 0 1 1 0-12 6 6 0 0 1 0 12m0-2a4 4 0 1 0 0-8 4 4 0 0 0 0 8M11 1h2v3h-2zm0 19h2v3h-2zM3.515 4.929l1.414-1.414L7.05 5.636 5.636 7.05zM16.95 18.364l1.414-1.414 2.121 2.121-1.414 1.414zm2.121-14.85 1.414 1.415-2.121 2.121-1.414-1.414zM5.636 16.95l1.414 1.414-2.121 2.121-1.414-1.414zM23 11v2h-3v-2zM4 11v2H1v-2z"></path></svg></span><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 absolute rotate-90 scale-0 transition-all dark:rotate-0 dark:scale-100" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M10 7a7 7 0 0 0 12 4.9v.1c0 5.523-4.477 10-10 10S2 17.523 2 12 6.477 2 12 2h.1A6.98 6.98 0 0 0 10 7m-6 5a8 8 0 0 0 15.062 3.762A9 9 0 0 1 8.238 4.938 8 8 0 0 0 4 12"></path></svg></span><span class="sr-only">Toggle theme</span></button><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover h-9 w-9" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-search h-5 w-5"><circle cx="11" cy="11" r="8"></circle><path d="m21 21-4.3-4.3"></path></svg></button></div></div></header><div class="bg-surface-base fixed right-0 top-16 z-50 h-[calc(100vh-4rem)] w-full transform border-l transition-transform duration-300 ease-in-out sm:w-1/2 md:hidden translate-x-full"><div class="flex flex-col gap-4 p-4"><div class="flex flex-row gap-2"><button class="focus-visible:ring-ring inline-flex items-center gap-x-2 whitespace-nowrap text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 border-input text-primary hover:border-primary/15 border hover:bg-overlay-hover py-2 max-w-full shadow-none sm:w-80 h-10 w-full justify-start rounded-full bg-surface-l1 px-4" type="button"><div class="flex items-center justify-between sm:w-full gap-4"><div class="flex items-center justify-start gap-2"><span class="inline-flex items-center justify-center p-0 m-0 w-4 h-4 text-muted" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-4 h-4" focusable="false" style="fill:currentColor"><path d="m18.031 16.617 4.283 4.282-1.415 1.415-4.282-4.283A8.96 8.96 0 0 1 11 20c-4.968 0-9-4.032-9-9s4.032-9 9-9 9 4.032 9 9a8.96 8.96 0 0 1-1.969 5.617m-2.006-.742A6.98 6.98 0 0 0 18 11c0-3.867-3.133-7-7-7s-7 3.133-7 7 3.133 7 7 7a6.98 6.98 0 0 0 4.875-1.975z"></path></svg></span><p class="text-sm text-muted hidden sm:block">Search</p></div><span class="hidden sm:block"><div class="bg-foreground/10 text-muted inline-flex items-center rounded-md px-1 py-0.5 text-center font-sans text-xs font-normal tracking-widest rtl:space-x-reverse"><span>âŒ˜</span><span class="text-xs">K</span></div></span></div></button></div></div></div><div><div class="min-[1350px]:grid min-[1350px]:grid-cols-[1fr_3fr_1fr]"><nav class="bg-surface-base hidden h-[calc(100vh-4rem)] overflow-y-auto px-6 pb-32 min-[1350px]:sticky min-[1350px]:top-16 min-[1350px]:block scrollbar-none [-ms-overflow-style:none] [scrollbar-width:none] [&amp;::-webkit-scrollbar]:hidden [overscroll-behavior:contain] pt-8"><ul class="space-y-2 text-sm"><li style="padding-left:0rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#kidney-disease" class="transition-opacity hover:opacity-100 opacity-50">Kidney disease</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#overview-and-classification" class="transition-opacity hover:opacity-100 opacity-50">Overview and Classification</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#definition-and-types" class="transition-opacity hover:opacity-100 opacity-50">Definition and Types</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#acute-kidney-injury" class="transition-opacity hover:opacity-100 opacity-50">Acute Kidney Injury</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#chronic-kidney-disease-stages" class="transition-opacity hover:opacity-100 opacity-50">Chronic Kidney Disease Stages</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#epidemiology" class="transition-opacity hover:opacity-100 opacity-50">Epidemiology</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#global-prevalence-and-incidence" class="transition-opacity hover:opacity-100 opacity-50">Global Prevalence and Incidence</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#demographic-risk-patterns" class="transition-opacity hover:opacity-100 opacity-50">Demographic Risk Patterns</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#pathophysiology" class="transition-opacity hover:opacity-100 opacity-50">Pathophysiology</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#core-mechanisms-of-renal-damage" class="transition-opacity hover:opacity-100 opacity-50">Core Mechanisms of Renal Damage</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#progression-from-acute-to-chronic" class="transition-opacity hover:opacity-100 opacity-50">Progression from Acute to Chronic</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#causes-and-risk-factors" class="transition-opacity hover:opacity-100 opacity-50">Causes and Risk Factors</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#metabolic-and-vascular-contributors" class="transition-opacity hover:opacity-100 opacity-50">Metabolic and Vascular Contributors</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#genetic-and-congenital-factors" class="transition-opacity hover:opacity-100 opacity-50">Genetic and Congenital Factors</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#toxic-infectious-and-lifestyle-triggers" class="transition-opacity hover:opacity-100 opacity-50">Toxic, Infectious, and Lifestyle Triggers</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#diagnosis" class="transition-opacity hover:opacity-100 opacity-50">Diagnosis</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#symptoms-and-clinical-signs" class="transition-opacity hover:opacity-100 opacity-50">Symptoms and Clinical Signs</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#diagnostic-tests-and-biomarkers" class="transition-opacity hover:opacity-100 opacity-50">Diagnostic Tests and Biomarkers</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#treatment-and-management" class="transition-opacity hover:opacity-100 opacity-50">Treatment and Management</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#supportive-care-for-acute-cases" class="transition-opacity hover:opacity-100 opacity-50">Supportive Care for Acute Cases</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#progression-control-in-chronic-cases" class="transition-opacity hover:opacity-100 opacity-50">Progression Control in Chronic Cases</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#renal-replacement-therapies" class="transition-opacity hover:opacity-100 opacity-50">Renal Replacement Therapies</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#prognosis-and-complications" class="transition-opacity hover:opacity-100 opacity-50">Prognosis and Complications</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#short-term-outcomes" class="transition-opacity hover:opacity-100 opacity-50">Short-Term Outcomes</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#long-term-risks-and-mortality" class="transition-opacity hover:opacity-100 opacity-50">Long-Term Risks and Mortality</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#prevention-strategies" class="transition-opacity hover:opacity-100 opacity-50">Prevention Strategies</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#lifestyle-and-behavioral-interventions" class="transition-opacity hover:opacity-100 opacity-50">Lifestyle and Behavioral Interventions</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#medical-screening-and-risk-mitigation" class="transition-opacity hover:opacity-100 opacity-50">Medical Screening and Risk Mitigation</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#controversies-and-research-frontiers" class="transition-opacity hover:opacity-100 opacity-50">Controversies and Research Frontiers</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#debated-risk-attributions" class="transition-opacity hover:opacity-100 opacity-50">Debated Risk Attributions</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#emerging-therapies-and-evidence-gaps" class="transition-opacity hover:opacity-100 opacity-50">Emerging Therapies and Evidence Gaps</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#references" class="transition-opacity hover:opacity-100 opacity-50">References</a></li></ul></nav><div class="relative top-16 pb-32 pt-8 px-4 md:px-8"><div class="mx-auto max-w-[850px]"><button data-state="closed" type="button" class="flex items-center"><div class="text-fg-tertiary mb-2 flex cursor-help items-center gap-2 text-sm"><span class="inline-flex items-center justify-center p-0 m-0" data-namespace="@xai/icons" data-slot="icon" style="height:16px;width:16px"><svg xmlns="http://www.w3.org/2000/svg" fill="none" viewBox="0 0 33 33" aria-hidden="true" class="" focusable="false" style="fill:currentColor;height:16px;width:16px"><path fill="currentColor" d="m13.237 21.04 11.082-8.19c.543-.4 1.32-.244 1.578.38 1.363 3.288.754 7.241-1.957 9.955-2.71 2.714-6.482 3.31-9.93 1.954l-3.765 1.745c5.401 3.697 11.96 2.782 16.059-1.324 3.251-3.255 4.258-7.692 3.317-11.693l.008.009c-1.365-5.878.336-8.227 3.82-13.031q.123-.17.247-.345l-4.585 4.59v-.014L13.234 21.044M10.95 23.031c-3.877-3.707-3.208-9.446.1-12.755 2.446-2.449 6.454-3.448 9.952-1.979L24.76 6.56c-.677-.49-1.545-1.017-2.54-1.387A12.465 12.465 0 0 0 8.675 7.901c-3.519 3.523-4.625 8.94-2.725 13.561 1.42 3.454-.907 5.898-3.251 8.364-.83.874-1.664 1.749-2.335 2.674l10.583-9.466"></path></svg></span><span>Fact-checked by Grok<!-- --> <!-- -->4 days ago</span></div></button><article class="text-[16px]"><h1 id="kidney-disease" class="group relative mb-2 scroll-mt-24 font-serif text-[2.125em] font-semibold tracking-[-1px] [&amp;:not(:first-child)]:mt-14" node="[object Object]">Kidney disease<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h1>
<span class="mb-4 block break-words text-[1em] leading-7">Kidney disease comprises a range of disorders that impair the kidneys&#x27; capacity to filter blood, remove waste products, and regulate electrolytes and fluid balance, often resulting from damage to the nephrons, the functional units of the kidney. It includes <strong>acute kidney injury (AKI)</strong>, characterized by a sudden decline in renal function that may be reversible if addressed promptly, and <strong>chronic kidney disease (CKD)</strong>, defined as structural or functional abnormalities persisting for more than three months, leading to progressive loss of kidney function and potential end-stage renal disease necessitating dialysis or transplantation.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c0qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_e0qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_g0qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In the United States, CKD affects more than 1 in 7 adults, or approximately 37 million people, with prevalence increasing with ageâ€”reaching 34% among those 65 and olderâ€”and disproportionately impacting certain demographics, though diabetes and hypertension remain the predominant causes across most adult populations.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_41abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[4]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_61abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup> Globally, kidney disease contributes substantially to mortality from noncommunicable diseases, ranking as a leading cause of death in many regions, though data on precise burden highlight variations influenced by underdiagnosis and access to care.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a1abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[6]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c1abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[7]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7"></span>
<span class="mb-4 block break-words text-[1em] leading-7">Untreated progression elevates risks of cardiovascular complications, anemia, and bone disorders due to disrupted hormone production and mineral metabolism, underscoring the causal links between sustained glomerular filtration rate decline and systemic health deterioration.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_42abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_62abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[9]</sup> Early detection via estimated glomerular filtration rate and albuminuria screening is critical, as interventions targeting modifiable risks like glycemic and blood pressure control can slow advancement, though irreversible scarring often limits full recovery in advanced CKD.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a2abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[10]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c2abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup></span>
<h2 id="overview-and-classification" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Overview and Classification<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="definition-and-types" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Definition and Types<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Kidney disease, also termed renal disease, encompasses pathological conditions that damage kidney structure or impair function, hindering the organs&#x27; capacity to filter blood, excrete wastes such as urea and creatinine, regulate electrolytes, and maintain acid-base and fluid balance.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_43qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> Healthy kidneys process approximately 180 liters of blood daily through roughly 1 million nephrons per kidney, removing excess fluids and toxins while reabsorbing essential nutrients; disease disrupts these processes, potentially leading to azotemia, electrolyte derangements, or uremia if untreated.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_83qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup> Most kidney diseases target the nephrons, causing irreversible scarring or functional decline, with causes ranging from genetic defects to acquired insults like toxins or ischemia.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c3qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[11]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Kidney diseases are broadly classified by onset and duration into acute kidney injury (AKI) and chronic kidney disease (CKD), with AKI reflecting sudden dysfunction and CKD indicating persistent impairment.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_44abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[12]</sup> AKI, formerly known as acute renal failure, involves a rapid decline in glomerular filtration rate (GFR) over hours to days, often defined by criteria such as a serum creatinine increase of â‰¥0.3 mg/dL within 48 hours or â‰¥1.5 times baseline within 7 days, or urine output &lt;0.5 mL/kg/hour for 6 hours.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_84abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[12]</sup> It frequently results from prerenal factors (e.g., hypovolemia), intrinsic renal damage (e.g., acute tubular necrosis or glomerulonephritis), or postrenal obstruction, and is potentially reversible if the underlying cause is addressed promptly, though severe cases can progress to CKD.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c4abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[13]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7"></span>
<span class="mb-4 block break-words text-[1em] leading-7">CKD is characterized by abnormalities in kidney structure or function persisting for more than 3 months, with GFR &lt;60 mL/min/1.73 mÂ² or markers of kidney damage such as albuminuria, leading to progressive fibrosis and eventual end-stage renal disease requiring dialysis or transplantation in advanced stages.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_45abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup> Unlike AKI, CKD develops insidiously over months to years, often asymptomatic until late stages, and is classified etiologically into types like diabetic nephropathy (the leading cause, affecting 30-40% of diabetes patients), hypertensive nephrosclerosis, primary glomerulopathies, and inherited disorders such as polycystic kidney disease.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_85abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[14]</sup> AKI episodes superimposed on CKD (&quot;acute-on-chronic&quot;) exacerbate progression, with bidirectional risks wherein CKD predisposes to AKI and unresolved AKI fosters CKD development.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c5abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[15]</sup> Other less common types include tubulointerstitial nephritis, obstructive uropathy, and vascular diseases like renal artery stenosis, each contributing variably to overall renal pathology based on histopathological patterns.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_g5abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup></span>
<h3 id="acute-kidney-injury" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Acute Kidney Injury<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">
Acute kidney injury (AKI) is characterized by a rapid decline in kidney function over hours to days, leading to the accumulation of nitrogenous waste products such as urea and creatinine in the blood, known as azotemia.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_66abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[16]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a6abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[12]</sup> This condition, formerly termed acute renal failure, often results in dysregulation of electrolytes, acid-base balance, and fluid homeostasis.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_e6abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[17]</sup> AKI is typically reversible if the underlying cause is promptly addressed, distinguishing it from chronic kidney disease.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_i6abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[12]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">The Kidney Disease: Improving Global Outcomes (KDIGO) criteria define AKI as an increase in serum creatinine by â‰¥0.3 mg/dL within 48 hours, or â‰¥1.5 times baseline within 7 days, or urine volume &lt;0.5 mL/kg/hour for 6 hours.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_46qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[18]</sup> Staging classifies severity: stage 1 involves a creatinine rise of 1.5â€“1.9 times baseline or â‰¥0.3 mg/dL with oliguria for 6â€“12 hours; stage 2 a 2.0â€“2.9 times increase or oliguria â‰¥12 hours; stage 3 a â‰¥3 times rise, creatinine â‰¥4.0 mg/dL, oliguria â‰¥24 hours, anuria â‰¥12 hours, or need for renal replacement therapy (RRT).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_86qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[19]</sup> Higher stages correlate with worse outcomes, including in-hospital mortality rates escalating from approximately 5% in stage 1 to 25% in stage 3.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c6qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[20]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Etiologically, AKI is categorized into prerenal (reduced renal perfusion, e.g., hypovolemia, heart failure), intrinsic renal (direct parenchymal damage from ischemia, toxins, glomerulonephritis, or acute tubular necrosis), and postrenal (urinary tract obstruction, e.g., stones, tumors).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_47abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[21]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_87abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[12]</sup> Common precipitants include sepsis, nephrotoxic medications like NSAIDs or aminoglycosides, and contrast agents.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c7abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[17]</sup> In hospitalized patients, incidence varies but community-based estimates range from 134â€“162 events per 10,000 person-years, with hospital mortality around 20â€“50%, exceeding 50% in intensive care settings.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_g7abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[22]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_k7abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[12]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Clinically, AKI manifests with oliguria or anuria, fluid retention causing edema, hypertension or hypotension, fatigue, nausea, and in severe cases, uremic symptoms like confusion, seizures, or pericarditis.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_47qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[23]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_87qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[16]</sup> Diagnosis relies on history, physical exam, serum creatinine trends, blood urea nitrogen elevation, and urinalysis to differentiate causes (e.g., muddy brown casts in acute tubular necrosis).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c7qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[21]</sup> Imaging like ultrasound assesses obstruction, while biomarkers such as NGAL or cystatin C may aid early detection, though not routinely used.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_g7qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[17]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Management prioritizes treating the underlying cause: volume resuscitation for prerenal AKI, discontinuation of nephrotoxins, and relief of obstruction.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_48abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[24]</sup> Supportive care includes fluid and electrolyte correction, nutritional support, and avoidance of further insults.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_88abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[21]</sup> Indications for RRT, such as dialysis, include refractory hyperkalemia, acidosis, uremia, or volume overload.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c8abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[18]</sup> Prognosis varies by etiology and comorbidities; prerenal causes often resolve fully, while intrinsic damage like cortical necrosis carries high morbidity and may progress to chronic kidney disease in 20â€“50% of survivors.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_g8abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[12]</sup> Overall, AKI independently predicts long-term cardiovascular events and mortality.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_k8abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[17]</sup></span>
<h3 id="chronic-kidney-disease-stages" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Chronic Kidney Disease Stages<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Chronic kidney disease (CKD) staging relies on estimated glomerular filtration rate (eGFR), calculated from serum creatinine levels adjusted for age, sex, and race, to quantify the degree of kidney function loss.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_49abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[25]</sup> The system, refined in guidelines from the Kidney Disease: Improving Global Outcomes (KDIGO) organization and the National Kidney Foundation (NKF), divides CKD into five stages (G1â€“G5) based on eGFR thresholds, with stage 3 subdivided into 3a and 3b for finer prognostic assessment; staging requires confirmation over at least three months to distinguish from acute changes.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_89abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[26]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c9abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[27]</sup> This GFR-based classification predicts risks of progression to end-stage kidney disease (ESKD), cardiovascular events, and mortality, with lower eGFR correlating to exponentially higher hazardsâ€”e.g., eGFR below 60 mL/min/1.73 mÂ² doubles five-year ESKD risk compared to higher levels in population studies.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_g9abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup> Albuminuria categories (A1: &lt;30 mg/g; A2: 30â€“300 mg/g; A3: &gt;300 mg/g, measured via urine albumin-to-creatinine ratio) overlay GFR stages to refine risk, as higher albuminuria accelerates progression independently of GFR in longitudinal cohorts.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_k9abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[27]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_o9abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[28]</sup></span>








































<div class="border-border-l1 overflow-x-auto rounded-lg border my-6 w-full"><table node="[object Object]" class="w-full border-collapse text-sm"><thead node="[object Object]" class="border-border-l1 border-b bg-surface-l1"><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">GFR Category</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">eGFR (mL/min/1.73 mÂ²)</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Description</span></th></tr></thead><tbody node="[object Object]" class="divide-border-l1 divide-y"><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">G1</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">â‰¥90</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Normal or high kidney function with markers of damage (e.g., persistent albuminuria â‰¥30 mg/g or structural abnormalities like cysts).</span><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_mc9qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[29]</sup></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">G2</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">60â€“89</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Mildly decreased function, often asymptomatic but with damage indicators; progression risk low unless albuminuria present.</span><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_mk9qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[29]</sup></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">G3a</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">45â€“59</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Mild to moderate decrease; subtle symptoms like fatigue may emerge, with elevated cardiovascular risk (hazard ratio ~1.4 for events vs. G1).</span><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ms9qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[29]</sup><span class="text-[1em] leading-7"> </span><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_16s9qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">G3b</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">30â€“44</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Moderate to severe decrease; anemia, bone mineral changes, and hypertension complications more common, prompting specialist referral.</span><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_n49qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[29]</sup></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">G4</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">15â€“29</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Severe decrease; uremic symptoms (e.g., nausea, pruritus) intensify, with preparation for dialysis or transplant advised as ESKD nears within 1â€“2 years absent intervention.</span><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_nc9qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[29]</sup><span class="text-[1em] leading-7"> </span><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_17c9qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">G5</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">&lt;15</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Kidney failure (ESKD); requires dialysis or transplantation for survival, with untreated mortality exceeding 50% within months from uremia and fluid overload.</span><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_nk9qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[29]</sup><span class="text-[1em] leading-7"> </span><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_17k9qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup></td></tr></tbody></table></div>
<span class="mb-4 block break-words text-[1em] leading-7">Management escalates by stage: early stages (G1â€“G2) emphasize risk factor control (e.g., blood pressure &lt;130/80 mmHg via ACE inhibitors) to slow progression, evidenced by trials showing 20â€“30% GFR decline reduction with renin-angiotensin blockade in proteinuric patients.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4aabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[26]</sup> Later stages (G4â€“G5) involve multidisciplinary care, including erythropoietin for anemia (hemoglobin target 10â€“11.5 g/dL to avoid transfusion risks) and phosphate binders to mitigate vascular calcification, as hyperphosphatemia in G3bâ€“G5 associates with 1.5â€“2-fold higher mortality in registries.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8aabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup> Staging informs personalized prognostication tools like the Kidney Failure Risk Equation, which integrates age, sex, eGFR, and albuminuria to predict two-year ESKD probability with &gt;90% accuracy in validation studies.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_caabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[28]</sup> Limitations include eGFR overestimation in muscular individuals or underestimation in elderly due to creatinine variability, prompting KDIGO 2024 recommendations for cystatin C confirmation in ambiguous cases.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gaabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[26]</sup></span>
<h2 id="epidemiology" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Epidemiology<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="global-prevalence-and-incidence" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Global Prevalence and Incidence<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Approximately 10% of the global adult population is affected by chronic kidney disease (CKD), corresponding to an estimated 697.5 million cases as of 2017, with the age-standardized prevalence at 9.1%.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4bqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[30]</sup> More recent estimates place the total burden at 674 million individuals, or about 9% of the world population, though figures up to 850 million have been reported, reflecting variations in diagnostic criteria and underreporting in low-resource settings.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8bqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[31]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_abqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[32]</sup> The global median prevalence of CKD stands at 9.5% (interquartile range 5.9â€“11.7%), with higher rates observed in regions like Central and Eastern Europe due to aging populations and comorbidities such as diabetes and hypertension.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ebqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[33]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">The prevalence of CKD has risen substantially over time, increasing by 33% globally between 1990 and 2017, driven by epidemiological transitions including rising obesity, diabetes, and hypertension in low- and middle-income countries.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4cabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[32]</sup> Age-standardized prevalence for CKD stages 3â€“5 among adults aged 20 years and older is approximately 4.7% in men and 5.8% in women.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8cabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[34]</sup> Incidence rates for advanced CKD, particularly kidney failure requiring replacement therapy, reached 4.59 million cases globally in 2023, with an age-standardized prevalence of treated kidney failure at varying levels across regions.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ccabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[35]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Acute kidney injury (AKI), distinct from CKD but often a precursor, affects an estimated 13.3 million people annually worldwide, with incidence rates in hospitalized patients ranging from 3.2% to 20% and up to 45% in intensive care units.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4cqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[36]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6cqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[37]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8cqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[38]</sup> AKI incidence is notably higher in low- and middle-income countries, where factors like infections, dehydration, and limited access to care predominate, compared to high-income settings where iatrogenic causes such as surgery and nephrotoxins are more common.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ccqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[39]</sup> Age- and sex-standardized incidence rates for AKI hover around 134â€“162 events per 10,000 person-years across regions.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gcqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[22]</sup> Underascertainment remains a challenge, particularly in community settings outside hospitals, potentially underestimating the true global burden.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_kcqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[40]</sup></span>
<h3 id="demographic-risk-patterns" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Demographic Risk Patterns<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">CKD prevalence escalates with advancing age, reflecting cumulative exposure to risk factors such as hypertension and diabetes, as well as age-related declines in renal function. In the United States, data from 2023 indicate that 34% of adults aged 65 or older have CKD, compared to 12% of those aged 45-64 and 6% of individuals aged 18-44.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4dqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup> Globally, population aging has driven a sustained increase in CKD burden since 1990, with older age groups bearing the majority of disability-adjusted life years (DALYs) lost to the disease.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8dqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[41]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7"></span>
<span class="mb-4 block break-words text-[1em] leading-7">Sex-based patterns show higher CKD prevalence among women than men, attributed in part to women&#x27;s longer life expectancy and higher rates of autoimmune conditions affecting the kidneys, though men experience faster progression to end-stage kidney disease (ESKD) once diagnosed. U.S. estimates from 2017-2020 report 15.4% prevalence in women versus 12.6% in men.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4eqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[42]</sup> Similar disparities appear in European cohorts, where age-adjusted prevalence ranges from 3.3% to 9.5% across groups but remains elevated in women overall.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8eqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[43]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Racial and ethnic variations in CKD risk are pronounced, linked to genetic predispositions like APOL1 variants in individuals of African ancestry, alongside socioeconomic factors influencing access to care and exposure to comorbidities. In the U.S., non-Hispanic Black adults face the highest prevalence at 18.9%, followed by American Indian/Alaska Native populations; Hispanic adults have rates around 14%, while non-Hispanic White rates are lower at approximately 13%.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4fabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[44]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8fabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[45]</sup> These patterns persist across age and sex subgroups, with Black individuals showing elevated risks even after adjusting for hypertension and diabetes.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cfabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[46]</sup></span>

































<div class="border-border-l1 overflow-x-auto rounded-lg border my-6 w-full"><table node="[object Object]" class="w-full border-collapse text-sm"><thead node="[object Object]" class="border-border-l1 border-b bg-surface-l1"><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Demographic Group (U.S. Adults, 2023)</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">CKD Prevalence (%)</span></th></tr></thead><tbody node="[object Object]" class="divide-border-l1 divide-y"><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Non-Hispanic Black</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">~19</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Hispanic</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">14</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Non-Hispanic White</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">~13</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Overall Women</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">15.4</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Overall Men</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">12.6</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Aged â‰¥65 years</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">34</span></td></tr></tbody></table></div>
<span class="mb-4 block break-words text-[1em] leading-7">Geographically, CKD risk clusters in regions with high metabolic syndrome prevalence, such as the U.S. &quot;diabetes belt,&quot; and in low socio-demographic index (SDI) areas where infectious and environmental toxins predominate. Globally, the age-standardized incidence of kidney failure rose from 2019-2023, with disproportionate impacts in aging populations of East Asia and low-income countries.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4gabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[47]</sup> In high-income settings, incidence rates for kidney replacement therapy range from 89-378 per million, versus 22-222 per million in Central/Eastern Europe and lower in developing regions, underscoring causal roles of both affluence-driven comorbidities and resource-limited prevention.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8gabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[48]</sup></span>
<h2 id="pathophysiology" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Pathophysiology<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="core-mechanisms-of-renal-damage" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Core Mechanisms of Renal Damage<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Renal damage fundamentally arises from disruptions in the kidney&#x27;s microvasculature, tubular epithelium, glomeruli, and interstitium, leading to impaired filtration, reabsorption, and secretion. Primary initiating mechanisms include ischemia-reperfusion injury, nephrotoxic insults, and inflammatory cascades, which converge on cellular pathways of necrosis, apoptosis, and necroptosis in proximal tubular cells.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4hqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[49]</sup> These processes cause ATP depletion, mitochondrial dysfunction, and reactive oxygen species (ROS) accumulation, exacerbating endothelial permeability and vascular rarefaction.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8hqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[50]</sup> Oxidative stress amplifies damage by oxidizing lipids, proteins, and DNA, while inflammation recruits macrophages and T-cells that release cytokines like TNF-Î± and IL-1Î², perpetuating a cycle of epithelial injury and maladaptive repair.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_chqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[51]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ehqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[52]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Ischemic injury, common in hypoperfusion states, triggers endothelial cell activation and vasoconstriction via endothelin and thromboxane, reducing glomerular filtration rate (GFR) through afferent arteriolar narrowing.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4iabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[49]</sup> Tubular epithelial cells respond with endoplasmic reticulum stress and unfolded protein response, leading to blebbing, brush border loss, and cast formation that obstructs tubular flow.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8iabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[53]</sup> Reperfusion paradoxically worsens outcomes by generating ROS bursts and complement activation, promoting leukocyte infiltration and further parenchymal necrosis.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ciabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[54]</sup> In severe cases, such as acute cortical necrosis, widespread vascular thrombosis and fibrinoid changes result in irreversible glomerular and tubular infarction.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_giabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[55]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Nephrotoxic mechanisms involve direct cellular uptake of agents like aminoglycosides or cisplatin, which impair mitochondrial respiration and induce lysosomal rupture in proximal tubules.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4iqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[49]</sup> Heavy metals and contrast media provoke similar ATP-independent toxicity via calcium overload and phospholipase activation, culminating in tubular dilation and proteinaceous casts.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8iqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[56]</sup> These insults often synergize with ischemia, as seen in sepsis-induced AKI, where bacterial endotoxins heighten vulnerability through Toll-like receptor signaling.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ciqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[57]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Progression to chronic damage hinges on fibrogenic responses, where surviving epithelial cells undergo epithelial-mesenchymal transition (EMT), secreting transforming growth factor-Î² (TGF-Î²) to activate interstitial myofibroblasts.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4jabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[58]</sup> This drives extracellular matrix (ECM) deposition of collagen types I and III, interstitial expansion, and glomerulosclerosis, with peritubular capillary rarefaction impairing oxygen delivery and fueling hypoxia-inducible factor (HIF) pathways.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8jabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[59]</sup> Inflammatory persistence, via NF-ÎºB activation, sustains chemokine production (e.g., MCP-1), recruiting fibrocytes that amplify scarring independent of initial insults.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cjabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[60]</sup> Maladaptive repair post-AKI, rather than regeneration, underlies transition to CKD, with incomplete tubular dedifferentiation preventing full nephron recovery.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gjabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[61]</sup></span>
<h3 id="progression-from-acute-to-chronic" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Progression from Acute to Chronic<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Acute kidney injury (AKI) transitions to chronic kidney disease (CKD) when initial tubular epithelial cell damage fails to resolve fully, leading to maladaptive repair characterized by persistent inflammation, epithelial-mesenchymal transition, and progressive fibrosis.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4kabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[62]</sup> This process involves incomplete regeneration of nephrons, where surviving cells undergo maladaptive changes such as G2/M cell-cycle arrest, cellular senescence, and epigenetic reprogramming, which perpetuate tissue remodeling and extracellular matrix deposition.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8kabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[61]</sup> Mitochondrial dysfunction and metabolic shifts, including altered lipid metabolism and oxidative stress, further exacerbate endothelial and podocyte injury, impairing vascular integrity and glomerular filtration over time.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ckabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[52]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">The incidence of CKD following AKI varies by severity and context; systematic reviews report pooled rates of incident CKD at approximately 25.8 per 100 person-years and end-stage renal disease at 8.6 per 100 person-years among survivors.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4kqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[63]</sup> For milder AKI, incident CKD occurs at 6.6 per 100 person-years, rising with prolonged recovery; over 20-year follow-up, CKD risk reaches 26.3% even in cases of rapid AKI reversal.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8kqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[64]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ckqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[65]</sup> Cumulative CKD incidence at 5 years post-AKI can approach 30%, particularly in trajectories showing linear eGFR decline.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gkqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[66]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Key risk factors accelerating this progression include advanced age, pre-existing comorbidities such as diabetes and hypertension, repeated AKI episodes, and genetic predispositions influencing repair pathways.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4labav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[66]</sup> Patients with baseline CKD face heightened susceptibility due to suppressed reparative signaling in tubular cells, compounded by factors like metabolic syndrome and sustained uremic toxin exposure, which promote inflammation and ferroptosis.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8labav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[67]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_clabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[68]</sup> Early post-AKI eGFR loss and persistent azotemia signal higher transition risk, underscoring the need for vigilant monitoring to interrupt fibrotic cascades.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_glabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[69]</sup></span>
<h2 id="causes-and-risk-factors" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Causes and Risk Factors<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="metabolic-and-vascular-contributors" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Metabolic and Vascular Contributors<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Diabetes mellitus is the leading cause of chronic kidney disease (CKD) globally, with diabetic kidney disease developing in approximately 40% of diabetic patients through mechanisms involving hyperglycemia-induced glomerular hyperfiltration, oxidative stress, and podocyte injury.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4mqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[70]</sup> Hyperglycemia promotes advanced glycation end-products that damage renal vasculature and interstitium, accelerating progression to end-stage renal disease (ESRD).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8mqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[71]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Hypertension independently contributes to CKD by inducing afferent arteriolar sclerosis and glomerular ischemia, with sustained elevations in blood pressure directly correlating with renal function decline; studies show it increases ESRD risk by impairing autoregulation in renal arterioles.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4nabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[72]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8nabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[73]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Metabolic syndrome, encompassing central obesity, dyslipidemia, insulin resistance, and hypertension, synergistically elevates CKD incidence, with affected individuals facing up to twofold higher risk due to combined endothelial dysfunction and inflammatory pathways.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4nqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[74]</sup> Obesity exacerbates this via adipokine dysregulation and intrarenal fat deposition, where a body mass index increase exceeding 10% from baseline heightens CKD onset by approximately 30% in longitudinal cohorts.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8nqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[75]</sup> Dyslipidemia, particularly hypertriglyceridemia and low HDL, fosters renal lipid accumulation and foam cell formation, further promoting tubulointerstitial fibrosis independent of diabetes.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cnqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[76]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Vascular factors such as atherosclerosis underlie renovascular disease, where plaque buildup narrows renal arteries, reducing perfusion and triggering ischemic nephropathy; atherosclerotic renal artery stenosis accounts for over 90% of cases and frequently culminates in CKD among those with bilateral involvement.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4oabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[77]</sup> Renal artery stenosis impairs pressure-flow dynamics, leading to renin-mediated hypertension that perpetuates a vicious cycle of vascular remodeling and parenchymal atrophy.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8oabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[78]</sup> Endothelial dysfunction from systemic atherosclerosis also manifests intrarenally, with reduced nitric oxide bioavailability contributing to microvascular rarefaction observed in advanced CKD.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_coabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[79]</sup></span>
<h3 id="genetic-and-congenital-factors" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Genetic and Congenital Factors<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Inherited kidney diseases account for approximately 10-15% of cases of early-onset chronic kidney disease, with genetic variants identifiable in about 10% of adults and up to 20-50% of pediatric cohorts requiring dialysis or transplantation.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4pabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[80]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6pabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[81]</sup> Over 625 genes have been linked to chronic kidney disease development, often through monogenic mutations disrupting renal structure, filtration, or tubular function.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_apabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[82]</sup> These conditions frequently manifest as progressive glomerular or tubulointerstitial damage, independent of common acquired risks like diabetes or hypertension.</span>
<span class="mb-4 block break-words text-[1em] leading-7">Autosomal dominant polycystic kidney disease (ADPKD), the most prevalent monogenic kidney disorder, arises from heterozygous mutations in <em>PKD1</em> (encoding polycystin-1) in 85% of cases or <em>PKD2</em> (polycystin-2) in 15%, leading to cyst formation, renal enlargement, and end-stage renal disease by age 60 in many patients.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cpqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[83]</sup> Less commonly, mutations in genes like <em>GANAB</em> contribute, with disease penetrance nearing 100% by age 80 due to disrupted ciliary signaling and fluid secretion in tubular epithelia.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_kpqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[83]</sup> Alport syndrome, another hereditary nephropathy, results from mutations in type IV collagen genes (<em>COL4A3</em>, <em>COL4A4</em>, or <em>COL4A5</em>), causing basement membrane defects that provoke hematuria, proteinuria, and progression to end-stage kidney disease, often by the third decade in males with X-linked forms.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_14pqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[84]</sup> These genetic etiologies underscore disrupted extracellular matrix integrity and podocyte function as core pathogenic mechanisms.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_18pqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[84]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Congenital anomalies of the kidney and urinary tract (CAKUT) represent structural malformations present at birth, occurring in 0.3-1.6 per 1,000 live births and comprising 20-30% of all pediatric renal disorders, with many linked to genetic factors like <em>PAX2</em> or <em>HNF1B</em> mutations.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cqabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[85]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_eqabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[86]</sup> CAKUT accounts for 40-50% of chronic kidney failure cases in children, encompassing conditions such as renal agenesis (unilateral in 1:1,000-2,000 births), dysplasia, and obstructive uropathies like posterior urethral valves, which impair nephrogenesis or urine flow and precipitate hydronephrosis or vesicoureteral reflux.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_iqabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[86]</sup> While some cases stem from multifactorial inheritance or de novo variants, early detection via prenatal ultrasound enables intervention to mitigate progression to chronic kidney disease.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_mqabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[87]</sup></span>
<h3 id="toxic-infectious-and-lifestyle-triggers" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Toxic, Infectious, and Lifestyle Triggers<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Nephrotoxic agents, including certain medications and environmental toxins, contribute to both acute kidney injury (AKI) and progression of chronic kidney disease (CKD) through mechanisms such as tubular damage, interstitial nephritis, and glomerular injury.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4rabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[88]</sup> Common pharmaceuticals implicated include nonsteroidal anti-inflammatory drugs (NSAIDs), which inhibit renal prostaglandins and reduce glomerular filtration rate, particularly in volume-depleted patients; aminoglycoside antibiotics, which accumulate in proximal tubules causing necrosis; and iodinated contrast media used in imaging, leading to vasoconstriction and direct cytotoxicity in up to 17% of AKI cases attributed to drugs.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8rabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[89]</sup> Heavy metals like arsenic, cadmium, and lead, often from occupational or environmental exposure, induce oxidative stress and fibrosis, with systematic reviews linking chronic low-level exposure to elevated CKD risk and end-stage renal disease incidence.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_crabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[90]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Infectious agents provoke kidney disease via direct invasion, immune-mediated damage, or systemic effects like sepsis. Bacterial infections, such as <em>Escherichia coli</em> causing pyelonephritis, ascend from the urinary tract and inflame renal parenchyma, potentially leading to abscesses or scarring if untreated; sepsis from gram-negative bacteria accounts for a significant portion of AKI in hospitalized patients.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8rqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[91]</sup> Viral pathogens including HIV, hepatitis B, and hepatitis C viruses establish chronic infections that accelerate glomerular sclerosis and proteinuria, with HIV-associated nephropathy featuring collapsing focal segmental glomerulosclerosis in up to 10% of untreated cases.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_crqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[92]</sup> Parasitic infections like schistosomiasis (<em>Schistosoma haematobium</em>) and malaria (<em>Plasmodium</em> spp.) cause obstructive uropathy or hemolytic-uremic syndromes, respectively, with evidence from endemic regions showing associations with CKD in 20 parasite species affecting humans.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_orqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[93]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Lifestyle factors independently elevate kidney disease risk through vascular, metabolic, and inflammatory pathways. Smoking accelerates CKD progression by promoting endothelial dysfunction and proteinuria, with cohort studies indicating a dose-dependent increase in incidence among current smokers compared to never-smokers.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4sabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[94]</sup> Obesity, defined by BMI â‰¥30 kg/mÂ², correlates with hyperfiltration and glomerular hypertension, contributing to CKD onset in morbidly obese individuals via adipokine dysregulation and insulin resistance.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8sabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[95]</sup> Physical inactivity and diets high in processed foods exacerbate risks, while excessive alcohol consumption shows inconsistent links, with no broad association except for high-proof distilled spirits like moonshine potentially causing lead contamination-related damage.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_csabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[96]</sup> Modifiable behaviors such as tobacco cessation and weight management can mitigate progression, as evidenced by longitudinal data linking healthier profiles to slower eGFR decline.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gsabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[97]</sup></span>
<h2 id="diagnosis" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Diagnosis<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="symptoms-and-clinical-signs" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Symptoms and Clinical Signs<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Kidney disease manifests through a spectrum of symptoms and clinical signs that vary by acuity and stage, with acute kidney injury (AKI) often presenting abruptly and chronic kidney disease (CKD) progressing insidiously, frequently remaining asymptomatic in early phases.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4tqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[12]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6tqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[98]</sup> In AKI, patients commonly report decreased urine output (oliguria) or anuria, alongside fluid retention leading to edema in the legs, ankles, or feet and shortness of breath from pulmonary congestion.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_atqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[23]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ctqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[99]</sup> Fatigue, nausea, and confusion may arise due to uremic toxin accumulation, with severe cases progressing to seizures, coma, or chest pain from pericardial effusion.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gtqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[100]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">For CKD, symptoms typically emerge in stages 3â€“5 (glomerular filtration rate &lt;60 mL/min/1.73 mÂ²), including fatigue and weakness from anemia or electrolyte imbalances, loss of appetite, nausea, and unintentional weight loss.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4uabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[98]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6uabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup> Changes in urination such as nocturia, polyuria, or foamy urine (indicating proteinuria) are frequent, accompanied by pruritus and dry skin from phosphate retention.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_auabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[101]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cuabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[102]</sup> Cognitive effects like decreased mental sharpness, sleep disturbances, and muscle cramps further contribute to reduced quality of life.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_guabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[103]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Clinical signs in both conditions include hypertension, often exacerbated by sodium retention and renin-angiotensin activation, and peripheral edema reflecting impaired sodium excretion.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4uqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup> In advanced CKD, observable features encompass pallor from anemia, uremic frost (rare crystalline urea deposits on skin), and scratch marks from pruritus-induced excoriations.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8uqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup> Cardiac signs such as left ventricular hypertrophy or fluid overload-related dyspnea indicate systemic involvement, while AKI may show rapid rises in serum creatinine alongside these.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cuqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[12]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_euqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[104]</sup> Early detection relies on recognizing nonspecific signs like persistent fatigue or edema, as overt symptoms correlate with poorer prognosis.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_iuqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[105]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_kuqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[103]</sup></span>
<h3 id="diagnostic-tests-and-biomarkers" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Diagnostic Tests and Biomarkers<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Diagnosis of kidney disease relies primarily on laboratory assessments of glomerular filtration rate (GFR) and markers of kidney damage. Estimated GFR (eGFR) is calculated from serum creatinine levels using equations such as the CKD-EPI formula, which incorporates age, sex, and race; values below 60 mL/min/1.73 mÂ² for three months or more indicate chronic kidney disease (CKD).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4vqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[26]</sup> Blood urea nitrogen (BUN) levels provide supportive evidence of reduced kidney function, though they are influenced by factors like dehydration and diet.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8vqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[106]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Urine tests detect proteinuria or albuminuria, key indicators of glomerular damage. The urine albumin-to-creatinine ratio (uACR) is preferred over total proteinuria, with levels above 30 mg/g signaling early CKD; spot urine samples suffice for screening, while 24-hour collections offer precision in ambiguous cases.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_50abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[26]</sup> Urinalysis identifies hematuria, casts, or crystals, aiding differentiation of causes like glomerulonephritis or infection.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_90abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[107]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Imaging modalities assess structural abnormalities. Renal ultrasound, the initial choice due to its non-invasiveness and low cost, evaluates kidney size, echogenicity, and obstruction; small kidneys (&lt;9-10 cm) suggest chronicity.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_50qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[28]</sup> Computed tomography (CT) or magnetic resonance imaging (MRI) is reserved for suspected stones, cysts, or tumors, though contrast agents pose risks in impaired renal function.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_90qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[106]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Renal biopsy provides histopathological confirmation when etiology remains unclear, such as in nephrotic syndrome, rapidly progressive glomerulonephritis, or unexplained acute kidney injury (AKI) with persistent dysfunction.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_51abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[108]</sup> Performed percutaneously under ultrasound guidance, it involves risks including macroscopic hematuria (5-10% incidence), perinephric hematoma (up to 90% subclinical), and rare arteriovenous fistula formation; contraindications include uncontrolled hypertension or bleeding diathesis.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_91abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[109]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_d1abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[110]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Emerging biomarkers enhance early detection beyond traditional markers. For AKI, neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury molecule-1 (KIM-1) in urine predict tubular injury hours before creatinine rises, with NGAL showing sensitivity in cardiac surgery cohorts.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_51qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[111]</sup> The product of urinary tissue inhibitor of metalloproteinases-2 (TIMP-2) and insulin-like growth factor-binding protein 7 (IGFBP7) outperforms other panels for risk stratification in critically ill patients, as validated in the Sapphire trial.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_91qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[112]</sup> In CKD, cystatin C offers a more accurate eGFR estimate independent of muscle mass, while soluble urokinase plasminogen activator receptor (suPAR) correlates with progression risk, though routine clinical adoption awaits larger validation studies.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_d1qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[113]</sup> These biomarkers, derived from peer-reviewed cohorts, promise refined prognostication but require integration with standard tests for causal attribution.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_h1qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[114]</sup></span>
<h2 id="treatment-and-management" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Treatment and Management<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="supportive-care-for-acute-cases" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Supportive Care for Acute Cases<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Supportive care in acute kidney injury (AKI) focuses on stabilizing hemodynamics, correcting metabolic derangements, and preventing additional renal insult pending resolution of the precipitating cause, such as hypovolemia, sepsis, or obstruction.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_53abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[115]</sup> This approach emphasizes individualized management to maintain renal perfusion without exacerbating injury from overload or under-resuscitation.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_93abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[115]</sup> Evidence from randomized controlled trials, including the SMART and CLASSIC studies, supports tailored interventions over liberal fluid strategies, as excessive volumes associate with worsened outcomes like prolonged ventilation and higher mortality.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_d3abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[115]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Hemodynamic optimization targets a mean arterial pressure of 65-85 mmHg, adjusted for patient comorbidities, using volume assessment via physical exam, point-of-care ultrasound (e.g., inferior vena cava collapsibility or VExUS scoring), or dynamic maneuvers like passive leg raising.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_53qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[115]</sup> In hypovolemic states, initial resuscitation employs balanced crystalloids (e.g., Plasma-Lyte or lactated Ringer&#x27;s) at doses guided by response rather than fixed boluses like 30 mL/kg, as hyperchloremic acidosis from normal saline can impair renal function.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_93qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[115]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_b3qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[21]</sup> If fluids alone fail, vasopressorsâ€”norepinephrine as first-line, with vasopressin as an adjunct in septic shockâ€”preserve perfusion; vasopressin may confer renal benefits by reducing norepinephrine requirements and mitigating vasoconstriction.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_f3qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[115]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Fluid balance monitoring is critical, aiming for neutral or negative balance in oliguric AKI to avert pulmonary edema and intra-abdominal hypertension, which independently predict non-recovery; conservative strategies in perioperative settings have reduced AKI duration compared to liberal ones in meta-analyses.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_54abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[115]</sup> Diuretics like furosemide are reserved for volume overload unresponsive to fluids, not for converting oliguric to non-oliguric AKI, as routine use lacks efficacy and risks worsening depletion.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_94abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[21]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Electrolyte and acid-base management addresses common imbalances: hyperkalemia (&gt;6.5 mEq/L or with ECG changes) warrants stabilization with calcium gluconate, followed by shifting agents (insulin-glucose, beta-agonists, or sodium bicarbonate) and, if refractory, dialysis; hyponatremia correction avoids rapid shifts to prevent osmotic demyelination.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_54qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[115]</sup> Hyperphosphatemia and metabolic acidosis are monitored, with phosphate binders or bicarbonate considered based on severity, though evidence for routine buffering in non-severe cases is limited.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_94qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[115]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Minimizing nephrotoxins involves immediate discontinuation of agents like NSAIDs, aminoglycosides, and contrast media, alongside dose adjustments for renally cleared drugs using estimated glomerular filtration rate or pharmacokinetic monitoring to prevent accumulation (e.g., reduced cefepime dosing in stage 3 AKI).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_55abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[115]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_75abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[21]</sup> Pharmacist-led protocols have demonstrated up to 64% reductions in nephrotoxic exposures.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_b5abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[21]</sup> Nutritional support prioritizes enteral over parenteral routes, limiting protein to 0.8-1.0 g/kg/day in azotemia to curb uremia while ensuring caloric needs (25-30 kcal/kg/day) to support recovery, with evidence from cohort studies linking early nutrition to shorter AKI duration.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_f5abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[115]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Close monitoring includes serial serum creatinine, urine output (target &gt;0.5 mL/kg/h), and biomarkers like cystatin C for early trends, with nephrology consultation recommended for persistent stage 2-3 AKI to guide escalation to renal replacement therapy if indications (e.g., refractory hyperkalemia, uremia, or overload) arise.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_55qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[21]</sup> Glycemic control targeting 140-180 mg/dL reduces infection risk without proven direct renal benefit in AKI.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_95qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[21]</sup></span>
<h3 id="progression-control-in-chronic-cases" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Progression Control in Chronic Cases<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Control of chronic kidney disease (CKD) progression involves targeted interventions to mitigate glomerular filtration rate (GFR) decline, reduce proteinuria, and avert end-stage kidney disease (ESKD), with evidence from randomized trials and meta-analyses supporting multifaceted approaches. The Kidney Disease: Improving Global Outcomes (KDIGO) 2024 guidelines emphasize early risk assessment and multimodal strategies, including blood pressure management below 130/80 mmHg, particularly in proteinuric cases, to yield long-term benefits in delaying kidney failure.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_56qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[26]</sup> These measures, when implemented comprehensively, have demonstrated up to 30-50% reductions in progression rates in high-risk cohorts, though individual responses vary based on baseline GFR and comorbidities.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_96qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[116]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Renin-angiotensin system (RAS) blockade with angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) constitutes foundational pharmacotherapy, especially for patients with hypertension, diabetes, or albuminuria exceeding 30 mg/day, as these agents confer renoprotective effects independent of blood pressure reduction by decreasing intraglomerular pressure and proteinuria. Meta-analyses of trials involving over 10,000 CKD patients show RAS inhibitors slow GFR decline by 2-4 mL/min/1.73 mÂ² per year compared to placebo or other antihypertensives, with benefits persisting in advanced stages (GFR &lt;30 mL/min/1.73 mÂ²) absent severe hyperkalemia.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_57abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[117]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_97abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[118]</sup> Continuation of RAS therapy in stage 4-5 CKD, versus discontinuation, correlates with lower ESKD incidence in observational data adjusted for confounders, though monitoring for acute GFR drops (up to 30% initially) and potassium elevation is essential.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_d7abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[119]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Sodium-glucose cotransporter-2 (SGLT2) inhibitors, such as dapagliflozin and empagliflozin, have emerged as disease-modifying agents across CKD etiologies, reducing progression risk by 30-40% in trials like DAPA-CKD and EMPA-KIDNEY, through mechanisms including afferent arteriolar vasodilation, reduced tubular hypoxia, and inflammation suppression, even in non-diabetic patients.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_57qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[120]</sup> These benefits accrue irrespective of baseline albuminuria or diabetes status, with number-needed-to-treat values of 12-20 over 2-4 years to prevent ESKD events.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_97qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[116]</sup> Adjunctive therapies like mineralocorticoid receptor antagonists (e.g., finerenone) show promise in diabetic CKD by further curbing albuminuria and fibrosis, per phase 3 data, but require caution for hyperkalemia risk.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_d7qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[121]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Non-pharmacological measures complement drugs, with moderate protein intake capped at 0.8 g/kg/day in non-dialysis CKD to lessen uremic toxin load and GFR stress, supported by meta-analyses indicating 1-2 mL/min/1.73 mÂ² annual preservation versus unrestricted diets.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_58abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[122]</sup> Bicarbonate supplementation for metabolic acidosis (serum bicarbonate &lt;22 mEq/L) slows progression by 1-2 mL/min/1.73 mÂ² yearly in randomized studies, countering tubulointerstitial damage from chronic acidemia.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_98abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[123]</sup> Lifestyle factors, including smoking cessation (reducing progression odds by 20-30% per cohort studies) and weight management via calorie-restricted diets, address obesity-driven hyperfiltration, while avoiding nephrotoxins like NSAIDs preserves function.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_d8abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[124]</sup> Integrated care models, incorporating patient education and multidisciplinary follow-up, enhance adherence and outcomes, as evidenced by programs halving ESRD transitions in value-based settings.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_h8abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[125]</sup> Regular monitoring of GFR, electrolytes, and albuminuria guides adjustments, prioritizing empirical response over rigid protocols.</span>
<h3 id="renal-replacement-therapies" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Renal Replacement Therapies<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Renal replacement therapy (RRT) encompasses modalities that substitute for lost kidney function in patients with acute kidney injury (AKI) or end-stage renal disease (ESRD), primarily by removing waste products, excess fluid, and correcting electrolyte imbalances when conservative management fails. Indications include severe uremia (e.g., blood urea nitrogen &gt;100 mg/dL), refractory hyperkalemia (&gt;6.5 mEq/L), metabolic acidosis (pH &lt;7.15), or volume overload unresponsive to diuretics.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_59abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[126]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_99abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[127]</sup> In ESRD, RRT is initiated when estimated glomerular filtration rate falls below 10-15 mL/min/1.73 mÂ² with symptoms, though timing debates persist without clear survival benefits from early versus delayed start in AKI.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_d9abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[26]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Dialysis, the most common RRT form, includes hemodialysis (HD) and peritoneal dialysis (PD). HD involves extracorporeal blood filtration via a dialyzer, typically performed thrice weekly for 3-5 hours per session using arteriovenous fistulas or grafts for access; it excels in rapid solute clearance but risks intradialytic hypotension from ultrafiltration and solute shifts.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_59qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[127]</sup> PD employs the peritoneal membrane as a natural filter by infusing dialysate into the abdomen, allowing continuous ambulatory or automated cycles; it offers home-based flexibility and better hemodynamic stability but carries peritonitis risk from bacterial contamination.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_99qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[128]</sup> Continuous RRT (CRRT), used mainly in critically ill AKI patients, provides slow, steady clearance to minimize instability, though circuit clotting affects up to 30% of sessions due to inadequate anticoagulation or catheter issues.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_d9qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[129]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_h9qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[130]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Kidney transplantation represents the optimal long-term RRT, restoring near-normal function via donor organ implantation, with living donors yielding superior graft survival (median 15-20 years) over deceased donors (10-15 years).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5aabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[131]</sup> One-year patient survival post-transplant exceeds 94%, surpassing dialysis rates, while five-year survival reaches 80-90% versus under 50% on dialysis; however, allograft rejection (acute in 10-15%, chronic in 30-50% by five years) necessitates lifelong immunosuppression, elevating infection and malignancy risks.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9aabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[132]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_daabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[133]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Survival comparisons favor transplantation over dialysis, where HD and PD yield similar adjusted mortality (hazard ratio ~1.0-1.2), though PD associates with higher early mortality in elderly patients (hazard ratio 1.17) due to technique failure and comorbidities.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5aqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[128]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9aqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[134]</sup> RRT complications include vascular access thrombosis (20-30% annually in HD), infections (peritonitis in 0.2-0.5 episodes/patient-year for PD), and cardiovascular events, which account for 40-50% of dialysis deaths; no modality universally dominates, with choice guided by patient factors like age, vascular status, and lifestyle.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_daqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[129]</sup> Evidence from registries like USRDS underscores dialysis as a bridge to transplant, where pre-transplant PD may confer slight graft advantage over HD in select cohorts.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_haqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[135]</sup></span>
<h2 id="prognosis-and-complications" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Prognosis and Complications<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="short-term-outcomes" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Short-Term Outcomes<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Short-term outcomes in kidney disease predominantly pertain to acute kidney injury (AKI), where in-hospital mortality rates typically range from 10% to 30%, varying by severity, comorbidities, and care setting.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5cabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[136]</sup> 00021-9/fulltext) In critically ill patients, AKI elevates 30-day mortality to 17.5% versus 5.8% in non-AKI cohorts, driven by factors such as multi-organ failure and prolonged hospital stays.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9cabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[136]</sup> Severe AKI (stage 3) in contexts like myocardial infarction yields in-hospital mortality up to 31.8%, compared to 2.1% without AKI.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_dcabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[137]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Renal recovery post-AKI occurs in 40-70% of survivors within days to weeks, with complete recovery in about 44% of moderate-to-severe cases; however, partial recovery predominates, and failure to recover within 1-4 days correlates with higher short-term kidney failure risk.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5cqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[138]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9cqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[139]</sup> Duration and severity of AKI, alongside hyperkalemia and short hospital stays, independently predict 30-day in-hospital mortality.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_dcqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[140]</sup> Acute complications include fluid overload, electrolyte derangements, and sepsis exacerbation, often necessitating temporary renal replacement therapy, which further increases mortality odds by 2-3 fold in dialysis-requiring cases.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hcqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[136]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In chronic kidney disease (CKD), short-term outcomes manifest during acute deteriorations or hospitalizations, where CKD patients exhibit 1.5-2 times higher admission rates and in-hospital mortality than non-CKD peers, particularly with infections or heart failure.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5dabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[141]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9dabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[142]</sup> For instance, CKD stage 4-5 elevates hospitalization risks and short-term death in heart failure by 20-40%, underscoring vulnerability to decompensation.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ddabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[143]</sup> Rapid eGFR decline in CKD predicts prolonged stays and readmissions, with one-year post-hospitalization mortality reaching 16-44% across stages.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hdabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[144]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ldabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[145]</sup></span>
<h3 id="long-term-risks-and-mortality" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Long-Term Risks and Mortality<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7"></span>
<span class="mb-4 block break-words text-[1em] leading-7">Chronic kidney disease (CKD) substantially elevates the risk of cardiovascular disease, which manifests as accelerated atherosclerosis, left ventricular hypertrophy, and increased incidence of myocardial infarction and stroke due to uremic toxins, hypertension, and dyslipidemia.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5eqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[146]</sup> Anemia arises from reduced erythropoietin production and contributes to fatigue, cardiovascular strain, and shortened erythrocyte lifespan.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9eqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[146]</sup> Mineral and bone disorders, including hyperphosphatemia and secondary hyperparathyroidism, lead to vascular calcification and fragile bones prone to fractures.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_deqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[147]</sup> Hyperkalemia and fluid retention heighten risks of arrhythmias and pulmonary edema, respectively.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_heqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[148]</sup> Infections occur more frequently owing to uremia-induced immune dysfunction, while gout stems from uric acid accumulation.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_leqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[147]</sup> Neurological complications, such as peripheral neuropathy and encephalopathy, emerge in advanced stages from toxin buildup.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_peqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[149]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In end-stage renal disease (ESRD), progression to dialysis or transplantation amplifies these risks, with cardiovascular events predominating despite renal replacement therapy.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5fabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[150]</sup> Mortality in CKD patients exceeds that of the general population, with 5-year survival rates around 55% for those with CKD compared to 77% without, based on large cohort analyses.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9fabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[151]</sup> For patients on long-term dialysis, the 5-year survival rate is approximately 35%, declining further with age and comorbidities.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_dfabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[152]</sup> In stage 3 CKD, all-cause mortality ranges from 6% over 3 years to 51% over 10 years across surveyed studies.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hfabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[153]</sup> Cardiovascular disease accounts for 40-50% of deaths in CKD, surpassing infection and withdrawal from dialysis as subsequent causes.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_lfabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[154]</sup> In the United States, nephritis, nephrotic syndrome, and nephrosis caused 55,253 deaths in recent data, ranking as the 8th leading cause at 16.5 per 100,000 population.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_pfabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[155]</sup> Globally, age-adjusted CKD mortality rose from 15.95 to 18.35 per 100,000 between specified periods, projecting continued increases.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_tfabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[156]</sup> Among Medicare beneficiaries aged 66 and older with CKD, unadjusted mortality fell over 20% in a decade to below 145 per 1,000 person-years, reflecting improvements in management yet persistent high burden.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_11fabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[157]</sup></span>
<h2 id="prevention-strategies" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Prevention Strategies<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="lifestyle-and-behavioral-interventions" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Lifestyle and Behavioral Interventions<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Lifestyle interventions targeting modifiable risk factors, including diet, physical activity, smoking, and weight management, form the cornerstone of chronic kidney disease (CKD) prevention, with evidence from cohort studies and guidelines demonstrating reductions in incidence and progression through improved blood pressure control, glycemic regulation, and vascular health. A 2021 systematic review of randomized trials found that multifaceted lifestyle programs, emphasizing dietary changes and exercise, lowered CKD risk markers such as albuminuria and estimated glomerular filtration rate decline in high-risk groups, including those with prediabetes or hypertension.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5gqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[158]</sup> The KDIGO 2024 guideline endorses these approaches, recommending physical activity compatible with cardiovascular tolerance and achievement of optimal body mass index to mitigate obesity-related renal strain, supported by observational data linking adiposity to glomerular hyperfiltration.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9gqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[159]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Dietary modifications prioritize sodium restriction to less than 2 g per day and adoption of patterns like the Dietary Approaches to Stop Hypertension (DASH) diet, which emphasizes fruits, vegetables, whole grains, and low-fat dairy while limiting processed meats and sweets; such regimens have been associated with 20-30% reductions in hypertension incidence, a primary CKD driver, in meta-analyses of over 10,000 participants.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5habav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[160]</sup> Potassium-rich salt substitutes may aid blood pressure control but require caution in advanced CKD stages due to hyperkalemia risk. Regular physical activity, targeting 150 minutes of moderate aerobic exercise weekly (e.g., brisk walking), enhances endothelial function and insulin sensitivity, with trials showing 10-15% improvements in renal blood flow and reduced proteinuria in prediabetic adults.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9habav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[161]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Smoking cessation is critical, as tobacco exposure promotes oxidative stress and endothelial dysfunction, accelerating CKD progression by up to 50% in smokers per pack-year; longitudinal studies report glomerular filtration rate stabilization post-quitting, with benefits evident within 1-2 years.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5hqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[97]</sup> Moderation of alcohol to less than 14 units weekly prevents dehydration and hepatic-renal interactions, while avoiding overuse of nonsteroidal anti-inflammatory drugs preserves tubular integrity, as overuse doubles acute kidney injury risk in susceptible individuals.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9hqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[162]</sup> Comprehensive programs combining self-monitoring, goal-setting, and counseling yield adherence rates of 60-70% at 12 months, underscoring behavioral support&#x27;s role in sustaining these interventions.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_dhqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[163]</sup></span>
<h3 id="medical-screening-and-risk-mitigation" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Medical Screening and Risk Mitigation<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Screening for chronic kidney disease (CKD) targets individuals at elevated risk, including those with diabetes, hypertension, cardiovascular disease, family history of CKD, age over 60 years, obesity, or exposure to nephrotoxins, using estimated glomerular filtration rate (eGFR) calculated from serum creatinine and urine albumin-to-creatinine ratio (uACR) to detect albuminuria.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5iqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[26]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_7iqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[164]</sup> These tests enable early identification, as CKD often progresses asymptomatically until advanced stages, with eGFR below 60 mL/min/1.73 mÂ² or uACR above 30 mg/g indicating potential disease.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_biqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[165]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_diqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[166]</sup> Screening is recommended annually for high-risk groups, with confirmatory testing if initial results are abnormal, though universal population screening lacks strong evidence due to low prevalence in low-risk individuals.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hiqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[167]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_jiqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[168]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Risk mitigation focuses on modifiable factors to prevent CKD onset or slow progression in at-risk populations. Primary strategies include tight control of blood pressure to below 140/90 mm Hg in hypertensive individuals, as sustained hypertension accelerates glomerular damage through vascular stiffness and endothelial dysfunction.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5jabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[169]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_7jabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[170]</sup> In diabetic patients, glycemic management targeting HbA1c below 7% reduces hyperfiltration and mesangial expansion, key causal mechanisms in diabetic kidney disease.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_bjabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[171]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_djabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[172]</sup> Lifestyle interventions such as weight loss in obesity (aiming for BMI reduction via diet and exercise), smoking cessation to preserve vascular integrity, and avoidance of nonsteroidal anti-inflammatory drugs limit podocyte injury and interstitial fibrosis.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hjabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[173]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_jjabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[174]</sup></span>
<ul class="marker:text-primary my-4 ml-6 list-disc space-y-2 text-[1em]">
<li class="text-[1em]"><strong>Hypertension management</strong>: Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers are preferred for their renoprotective effects beyond BP lowering, reducing proteinuria by 30-50% in proteinuric states.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_1ljqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[175]</sup></li>
<li class="text-[1em]"><strong>Diabetes control</strong>: SGLT2 inhibitors and GLP-1 receptor agonists provide additive kidney protection by mitigating glomerular hyperfiltration and inflammation, independent of glucose effects.</li>
<li class="text-[1em]"><strong>Other measures</strong>: Addressing dyslipidemia with statins in high-risk adults over 40 reduces cardiovascular-renal interplay, while population-level policies targeting environmental toxins like heavy metals further mitigate non-genetic risks.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_1tjqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[171]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2djqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[173]</sup></li>
</ul>
<span class="mb-4 block break-words text-[1em] leading-7">Empirical data from cohort studies show that combined risk factor control can delay CKD progression by 20-30%, emphasizing causal pathways like oxidative stress and hemodynamic overload over correlative associations.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5kabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[176]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_7kabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[177]</sup></span>
<h2 id="controversies-and-research-frontiers" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Controversies and Research Frontiers<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="debated-risk-attributions" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Debated Risk Attributions<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">The bidirectional relationship between hypertension and chronic kidney disease (CKD) remains a subject of ongoing debate, with evidence indicating that while severe or malignant hypertension can directly damage renal vasculature leading to nephrosclerosis, milder essential hypertension may not independently cause significant glomerular injury or progression to end-stage renal disease (ESRD). Physiological models, such as those emphasizing renal sodium handling and pressure-natriuresis mechanisms, suggest that much of population-level hypertension arises as a consequence of subtle, undetected renal dysfunction rather than as a primary driver, challenging the traditional attribution of &quot;hypertensive kidney disease&quot; without histopathological confirmation.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5lqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[178]</sup> Longitudinal studies using Mendelian randomization have found no causal effect of moderately elevated blood pressure on CKD progression, supporting the view that reduced nephron mass or function often precedes and perpetuates hypertension through mechanisms like salt retention and renin-angiotensin activation.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9lqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[179]</sup> This perspective implies overestimation of hypertension&#x27;s causal role in biopsy-unproven cases, potentially leading to misattribution in up to 20-30% of ESRD listings where renal parenchymal disease is the underlying initiator.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_dlqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[180]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Racial and ethnic disparities in CKD incidence and progression, particularly the four- to fivefold higher ESRD rates among individuals of African ancestry compared to Europeans, have sparked debate over genetic versus socioeconomic and environmental attributions. High-risk variants in the APOL1 gene (G1 and G2 alleles), prevalent in 13-15% of African Americans, confer a 7- to 30-fold increased risk for nondiabetic CKD forms like focal segmental glomerulosclerosis (FSGS) and hypertension-attributed ESRD, accounting for a substantial portion of excess burden through podocyte injury and endothelial dysfunction.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5mabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[181]</sup> However, critics argue that social determinantsâ€”such as disparities in access to care, higher prevalence of uncontrolled comorbidities, and historical inequitiesâ€”amplify these genetic risks, with some analyses attributing up to 70% of variance to modifiable factors rather than biology alone, though empirical data show APOL1&#x27;s effect persists even after adjusting for socioeconomic status.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9mabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[182]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_bmabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[183]</sup> This tension highlights potential biases in source interpretations, where institutional emphases on structural inequities may underplay genetic causality supported by genome-wide association studies.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_fmabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[184]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Non-traditional environmental exposures, including heat stress and agrochemicals, are increasingly debated as attributable risks in clusters of CKD of unknown etiology (CKDu), such as Mesoamerican nephropathy affecting agricultural workers since the early 2000s, with incidence rates exceeding 15% in some Nicaraguan and Salvadoran communities. Proponents cite epidemiological links to repetitive dehydration and toxin-induced tubular injury (e.g., paraquat exposure with hazard ratio 2.23), yet causal attribution remains contested due to confounding by poverty, limited diagnostic access, and inconsistent biopsy findings, contrasting with traditional risks like diabetes (attributable to 40-50% of global CKD).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5mqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[185]</sup> Similarly, the role of certain medications, such as nonsteroidal anti-inflammatory drugs (NSAIDs), in accelerating progression (odds ratio up to 2.54 for ketorolac) is debated, with acute kidney injury risks well-documented but chronic attribution questioned in observational data prone to reverse causation. These debates underscore gaps in randomized evidence, urging caution against over-relying on associative studies from potentially biased registries.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9mqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[185]</sup></span>
<h3 id="emerging-therapies-and-evidence-gaps" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Emerging Therapies and Evidence Gaps<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Recent pharmacological advancements include the approval of semaglutide, a GLP-1 receptor agonist, by the FDA on January 28, 2025, for reducing the risk of kidney disease progression in patients with type 2 diabetes and chronic kidney disease (CKD), building on evidence from cardiovascular outcome trials demonstrating renal protective effects independent of glycemic control.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5nqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[186]</sup> Non-steroidal mineralocorticoid receptor antagonists like finerenone, combined with SGLT2 inhibitors and renin-angiotensin system blockers, represent a multifaceted approach targeting inflammation and fibrosis, with ongoing trials evaluating additive benefits in non-diabetic CKD.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9nqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[187]</sup> Emerging non-pharmacological therapies encompass gene therapies using adeno-associated viruses to target genetic causes of CKD, such as polycystic kidney disease, with preclinical models showing promise in halting cyst growth as of December 2024.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_dnqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[188]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Regenerative strategies, including mesenchymal stem cell therapies, entered phase II trials in April 2025 for preserving kidney function in diabetic CKD, aiming to modulate immune responses and reduce tubular injury through paracrine effects rather than direct engraftment.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5oabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[189]</sup> In renal replacement therapy, xenotransplantation advanced with gene-edited porcine kidneys transplanted into humans in 2024, addressing organ shortages but facing immunological and ethical hurdles, with short-term graft survival reported up to 60 days in brain-dead recipients.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9oabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[190]</sup> Bioengineered kidneys and implantable devices remain in early preclinical stages, with innovations in continuous kidney replacement therapies focusing on improved biocompatibility and reduced anticoagulation needs in intensive care settings.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_doabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[191]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Despite these developments, significant evidence gaps persist, including underrepresentation of advanced CKD stages (eGFR &lt;30 mL/min/1.73 mÂ²) and comorbid populations in cardiovascular-renal-metabolic trials, leading to extrapolated rather than direct efficacy data for high-risk groups.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5oqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[192]</sup> The evidence-practice gap is pronounced, with only a fraction of eligible patients receiving guideline-recommended therapies like SGLT2 inhibitors due to barriers in prescribing, adherence, and continuity of care, as evidenced by US cohort studies from 2001â€“2020 showing suboptimal uptake.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9oqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[193]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_boqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[194]</sup> Long-term outcomes for novel agents, such as gene therapies, lack robust human data, while inequities in trial enrollment exacerbate disparities, with Black and Hispanic patients less likely to benefit from early detection and interventions.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_foqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[195]</sup> Head-to-head comparisons of emerging drugs and personalized biomarkers for therapy response remain underdeveloped, hindering causal attribution of benefits amid heterogeneous CKD etiologies.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_joqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[196]</sup></span></article><div id="references" class="min-w-0 scroll-mt-8 overflow-hidden"><div class="text-[16px]"><h2 id="references" node="[object Object]" class="mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden">References</h2></div><ol class="columns-1 gap-x-12 [counter-reset:item] md:columns-2"><li id="https://www.niddk.nih.gov/health-information/kidney-disease" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.niddk.nih.gov/health-information/kidney-disease" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.niddk.nih.gov/health-information/kidney-disease</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC7015670/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC7015670/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC7015670/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC5475438/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC5475438/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC5475438/</a></span></div></li><li id="https://www.cdc.gov/kidney-disease/about/index.html" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.cdc.gov/kidney-disease/about/index.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.cdc.gov/kidney-disease/about/index.html</a></span></div></li><li id="https://www.cdc.gov/kidney-disease/php/data-research/index.html" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.cdc.gov/kidney-disease/php/data-research/index.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.cdc.gov/kidney-disease/php/data-research/index.html</a></span></div></li><li id="https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases</a></span></div></li><li id="https://www.niddk.nih.gov/health-information/health-statistics/kidney-disease" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.niddk.nih.gov/health-information/health-statistics/kidney-disease" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.niddk.nih.gov/health-information/health-statistics/kidney-disease</a></span></div></li><li id="https://www.ncbi.nlm.nih.gov/books/NBK535404/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ncbi.nlm.nih.gov/books/NBK535404/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ncbi.nlm.nih.gov/books/NBK535404/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC10669155/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10669155/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC10669155/</a></span></div></li><li id="https://www.cdc.gov/kidney-disease/risk-factors/index.html" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.cdc.gov/kidney-disease/risk-factors/index.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.cdc.gov/kidney-disease/risk-factors/index.html</a></span></div></li><li id="https://medlineplus.gov/kidneydiseases.html" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://medlineplus.gov/kidneydiseases.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://medlineplus.gov/kidneydiseases.html</a></span></div></li><li id="https://www.ncbi.nlm.nih.gov/books/NBK441896/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ncbi.nlm.nih.gov/books/NBK441896/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ncbi.nlm.nih.gov/books/NBK441896/</a></span></div></li><li id="https://eclinpath.com/chemistry/kidney/types-of-renal-disease/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://eclinpath.com/chemistry/kidney/types-of-renal-disease/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://eclinpath.com/chemistry/kidney/types-of-renal-disease/</a></span></div></li><li id="https://www.kidneyfund.org/all-about-kidneys/types-kidney-diseases" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.kidneyfund.org/all-about-kidneys/types-kidney-diseases" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.kidneyfund.org/all-about-kidneys/types-kidney-diseases</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC9720902/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC9720902/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC9720902/</a></span></div></li><li id="https://www.merckmanuals.com/professional/genitourinary-disorders/acute-kidney-injury/acute-kidney-injury-aki" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.merckmanuals.com/professional/genitourinary-disorders/acute-kidney-injury/acute-kidney-injury-aki" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.merckmanuals.com/professional/genitourinary-disorders/acute-kidney-injury/acute-kidney-injury-aki</a></span></div></li><li id="https://emedicine.medscape.com/article/243492-overview" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://emedicine.medscape.com/article/243492-overview" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://emedicine.medscape.com/article/243492-overview</a></span></div></li><li id="https://kdigo.org/wp-content/uploads/2016/10/KDIGO-2012-AKI-Guideline-English.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://kdigo.org/wp-content/uploads/2016/10/KDIGO-2012-AKI-Guideline-English.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://kdigo.org/wp-content/uploads/2016/10/KDIGO-2012-AKI-Guideline-English.pdf</a></span></div></li><li id="https://www.merckmanuals.com/professional/multimedia/table/staging-criteria-for-acute-kidney-injury-kdigo-2012" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.merckmanuals.com/professional/multimedia/table/staging-criteria-for-acute-kidney-injury-kdigo-2012" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.merckmanuals.com/professional/multimedia/table/staging-criteria-for-acute-kidney-injury-kdigo-2012</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC6676729/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC6676729/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC6676729/</a></span></div></li><li id="https://www.aafp.org/pubs/afp/issues/2019/1201/p687.html" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.aafp.org/pubs/afp/issues/2019/1201/p687.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.aafp.org/pubs/afp/issues/2019/1201/p687.html</a></span></div></li><li id="https://www.kidney-international.org/article/S0085-2538%2822%2900267-8/fulltext" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.kidney-international.org/article/S0085-2538%2822%2900267-8/fulltext" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.kidney-international.org/article/S0085-2538%2822%2900267-8/fulltext</a></span></div></li><li id="https://www.mayoclinic.org/diseases-conditions/kidney-failure/symptoms-causes/syc-20369048" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.mayoclinic.org/diseases-conditions/kidney-failure/symptoms-causes/syc-20369048" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.mayoclinic.org/diseases-conditions/kidney-failure/symptoms-causes/syc-20369048</a></span></div></li><li id="https://www.mayoclinic.org/diseases-conditions/kidney-failure/diagnosis-treatment/drc-20369053" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.mayoclinic.org/diseases-conditions/kidney-failure/diagnosis-treatment/drc-20369053" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.mayoclinic.org/diseases-conditions/kidney-failure/diagnosis-treatment/drc-20369053</a></span></div></li><li id="https://www.kidney.org/kidney-topics/estimated-glomerular-filtration-rate-egfr" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.kidney.org/kidney-topics/estimated-glomerular-filtration-rate-egfr" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.kidney.org/kidney-topics/estimated-glomerular-filtration-rate-egfr</a></span></div></li><li id="https://kdigo.org/wp-content/uploads/2024/03/KDIGO-2024-CKD-Guideline.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://kdigo.org/wp-content/uploads/2024/03/KDIGO-2024-CKD-Guideline.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://kdigo.org/wp-content/uploads/2024/03/KDIGO-2024-CKD-Guideline.pdf</a></span></div></li><li id="https://www.kidney.org/how-to-classify-ckd" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.kidney.org/how-to-classify-ckd" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.kidney.org/how-to-classify-ckd</a></span></div></li><li id="https://kdigo.org/guidelines/ckd-evaluation-and-management/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://kdigo.org/guidelines/ckd-evaluation-and-management/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://kdigo.org/guidelines/ckd-evaluation-and-management/</a></span></div></li><li id="https://www.kidney.org/kidney-topics/stages-chronic-kidney-disease-ckd" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.kidney.org/kidney-topics/stages-chronic-kidney-disease-ckd" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.kidney.org/kidney-topics/stages-chronic-kidney-disease-ckd</a></span></div></li><li id="https://bmcpublichealth.biomedcentral.com/articles/10.1186/s12889-025-21851-z" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://bmcpublichealth.biomedcentral.com/articles/10.1186/s12889-025-21851-z" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://bmcpublichealth.biomedcentral.com/articles/10.1186/s12889-025-21851-z</a></span></div></li><li id="https://apps.who.int/gb/ebwha/pdf_files/EB156/B156_CONF6-en.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://apps.who.int/gb/ebwha/pdf_files/EB156/B156_CONF6-en.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://apps.who.int/gb/ebwha/pdf_files/EB156/B156_CONF6-en.pdf</a></span></div></li><li id="https://www.nature.com/articles/s41581-024-00820-6" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nature.com/articles/s41581-024-00820-6" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nature.com/articles/s41581-024-00820-6</a></span></div></li><li id="https://www.thelancet.com/journals/langlo/article/PIIS2214-109X%2824%2900050-0/fulltext" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.thelancet.com/journals/langlo/article/PIIS2214-109X%2824%2900050-0/fulltext" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.thelancet.com/journals/langlo/article/PIIS2214-109X%2824%2900050-0/fulltext</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC9073222/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC9073222/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC9073222/</a></span></div></li><li id="https://www.healthdata.org/research-analysis/library/global-regional-and-national-prevalence-kidney-failure-replacement" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.healthdata.org/research-analysis/library/global-regional-and-national-prevalence-kidney-failure-replacement" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.healthdata.org/research-analysis/library/global-regional-and-national-prevalence-kidney-failure-replacement</a></span></div></li><li id="https://www.sciencedirect.com/science/article/abs/pii/S0270929523001766" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/abs/pii/S0270929523001766" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/abs/pii/S0270929523001766</a></span></div></li><li id="https://academic.oup.com/ckj/article/18/6/sfaf169/8151575" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://academic.oup.com/ckj/article/18/6/sfaf169/8151575" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://academic.oup.com/ckj/article/18/6/sfaf169/8151575</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC3891141/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC3891141/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC3891141/</a></span></div></li><li id="https://kdigo.org/wp-content/uploads/2018/02/2.-Mehta-KDIGO-AKI-Conference_Global-Burden.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://kdigo.org/wp-content/uploads/2018/02/2.-Mehta-KDIGO-AKI-Conference_Global-Burden.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://kdigo.org/wp-content/uploads/2018/02/2.-Mehta-KDIGO-AKI-Conference_Global-Burden.pdf</a></span></div></li><li id="https://www.thelancet.com/journals/langas/article/PIIS2468-1253%2825%2900006-8/fulltext" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.thelancet.com/journals/langas/article/PIIS2468-1253%2825%2900006-8/fulltext" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.thelancet.com/journals/langas/article/PIIS2468-1253%2825%2900006-8/fulltext</a></span></div></li><li id="https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-025-04309-7" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-025-04309-7" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-025-04309-7</a></span></div></li><li id="https://usrds-adr.niddk.nih.gov/2024/chronic-kidney-disease/1-ckd-in-the-general-population" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://usrds-adr.niddk.nih.gov/2024/chronic-kidney-disease/1-ckd-in-the-general-population" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://usrds-adr.niddk.nih.gov/2024/chronic-kidney-disease/1-ckd-in-the-general-population</a></span></div></li><li id="https://academic.oup.com/ndt/article/39/7/1194/7603988" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://academic.oup.com/ndt/article/39/7/1194/7603988" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://academic.oup.com/ndt/article/39/7/1194/7603988</a></span></div></li><li id="https://usrds-adr.niddk.nih.gov/2022/chronic-kidney-disease/1-ckd-in-the-general-population" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://usrds-adr.niddk.nih.gov/2022/chronic-kidney-disease/1-ckd-in-the-general-population" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://usrds-adr.niddk.nih.gov/2022/chronic-kidney-disease/1-ckd-in-the-general-population</a></span></div></li><li id="https://www.cdc.gov/kidney-disease/media/pdfs/CKD-Factsheet-H.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.cdc.gov/kidney-disease/media/pdfs/CKD-Factsheet-H.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.cdc.gov/kidney-disease/media/pdfs/CKD-Factsheet-H.pdf</a></span></div></li><li id="https://usrds-adr.niddk.nih.gov/2024/chronic-kidney-disease/2-identification-and-care-of-patients-with-ckd" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://usrds-adr.niddk.nih.gov/2024/chronic-kidney-disease/2-identification-and-care-of-patients-with-ckd" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://usrds-adr.niddk.nih.gov/2024/chronic-kidney-disease/2-identification-and-care-of-patients-with-ckd</a></span></div></li><li id="https://www.journalrip.com/Inpress/jrip-38655.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.journalrip.com/Inpress/jrip-38655.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.journalrip.com/Inpress/jrip-38655.pdf</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC7710841/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC7710841/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC7710841/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC3919808/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC3919808/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC3919808/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC3204829/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC3204829/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC3204829/</a></span></div></li><li id="https://www.nature.com/articles/s41392-022-01036-5" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nature.com/articles/s41392-022-01036-5" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nature.com/articles/s41392-022-01036-5</a></span></div></li><li id="https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-025-04077-4" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-025-04077-4" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-025-04077-4</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC9338906/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC9338906/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC9338906/</a></span></div></li><li id="https://www.jci.org/articles/view/45161" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.jci.org/articles/view/45161" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.jci.org/articles/view/45161</a></span></div></li><li id="https://www.ncbi.nlm.nih.gov/books/NBK507815/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ncbi.nlm.nih.gov/books/NBK507815/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ncbi.nlm.nih.gov/books/NBK507815/</a></span></div></li><li id="https://www.mdpi.com/2077-0383/12/1/375" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.mdpi.com/2077-0383/12/1/375" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.mdpi.com/2077-0383/12/1/375</a></span></div></li><li id="https://academic.oup.com/ckj/article/14/3/780/5934685" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://academic.oup.com/ckj/article/14/3/780/5934685" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://academic.oup.com/ckj/article/14/3/780/5934685</a></span></div></li><li id="https://www.nature.com/articles/s41392-023-01379-7" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nature.com/articles/s41392-023-01379-7" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nature.com/articles/s41392-023-01379-7</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC5351778/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC5351778/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC5351778/</a></span></div></li><li id="https://www.kidney-international.org/article/S0085-2538%2815%2954475-X/fulltext" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.kidney-international.org/article/S0085-2538%2815%2954475-X/fulltext" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.kidney-international.org/article/S0085-2538%2815%2954475-X/fulltext</a></span></div></li><li id="https://www.mdpi.com/2218-273X/15/6/794" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.mdpi.com/2218-273X/15/6/794" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.mdpi.com/2218-273X/15/6/794</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/39298548/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/39298548/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/39298548/</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/22113526/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/22113526/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/22113526/</a></span></div></li><li id="https://www.kidney-international.org/article/S0085-2538%2815%2955323-4/fulltext" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.kidney-international.org/article/S0085-2538%2815%2955323-4/fulltext" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.kidney-international.org/article/S0085-2538%2815%2955323-4/fulltext</a></span></div></li><li id="https://www.kireports.org/article/S2468-0249%2824%2900044-5/fulltext" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.kireports.org/article/S2468-0249%2824%2900044-5/fulltext" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.kireports.org/article/S2468-0249%2824%2900044-5/fulltext</a></span></div></li><li id="https://eymj.org/DOIx.php?id=10.3349/ymj.2023.0306" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://eymj.org/DOIx.php?id=10.3349/ymj.2023.0306" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://eymj.org/DOIx.php?id=10.3349/ymj.2023.0306</a></span></div></li><li id="https://www.kidney-international.org/article/S0085-2538%2817%2930499-4/fulltext" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.kidney-international.org/article/S0085-2538%2817%2930499-4/fulltext" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.kidney-international.org/article/S0085-2538%2817%2930499-4/fulltext</a></span></div></li><li id="https://www.mdpi.com/1422-0067/24/22/16152" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.mdpi.com/1422-0067/24/22/16152" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.mdpi.com/1422-0067/24/22/16152</a></span></div></li><li id="https://academic.oup.com/ckj/article/15/12/2237/6652220" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://academic.oup.com/ckj/article/15/12/2237/6652220" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://academic.oup.com/ckj/article/15/12/2237/6652220</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC5718284/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC5718284/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC5718284/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC10588295/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10588295/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC10588295/</a></span></div></li><li id="https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-020-02151-7" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-020-02151-7" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-020-02151-7</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/37053276/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/37053276/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/37053276/</a></span></div></li><li id="https://onlinelibrary.wiley.com/doi/10.1111/obr.13649" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://onlinelibrary.wiley.com/doi/10.1111/obr.13649" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://onlinelibrary.wiley.com/doi/10.1111/obr.13649</a></span></div></li><li id="https://academic.oup.com/ckj/article/16/11/1737/7143784" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://academic.oup.com/ckj/article/16/11/1737/7143784" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://academic.oup.com/ckj/article/16/11/1737/7143784</a></span></div></li><li id="https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2022.904001/full" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2022.904001/full" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2022.904001/full</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC8598311/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC8598311/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC8598311/</a></span></div></li><li id="https://www.ncbi.nlm.nih.gov/books/NBK430718/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ncbi.nlm.nih.gov/books/NBK430718/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ncbi.nlm.nih.gov/books/NBK430718/</a></span></div></li><li id="https://www.ajkd.org/article/S0272-6386%2821%2900776-9/fulltext" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ajkd.org/article/S0272-6386%2821%2900776-9/fulltext" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ajkd.org/article/S0272-6386%2821%2900776-9/fulltext</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC8323147/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC8323147/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC8323147/</a></span></div></li><li id="https://karger.com/ajn/article/53/4/297/827404/Genetic-Etiologies-for-Chronic-Kidney-Disease" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://karger.com/ajn/article/53/4/297/827404/Genetic-Etiologies-for-Chronic-Kidney-Disease" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://karger.com/ajn/article/53/4/297/827404/Genetic-Etiologies-for-Chronic-Kidney-Disease</a></span></div></li><li id="https://www.sciencedirect.com/science/article/pii/S2590059522000425" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/pii/S2590059522000425" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/pii/S2590059522000425</a></span></div></li><li id="https://www.ncbi.nlm.nih.gov/books/NBK532934/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ncbi.nlm.nih.gov/books/NBK532934/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ncbi.nlm.nih.gov/books/NBK532934/</a></span></div></li><li id="https://www.ncbi.nlm.nih.gov/books/NBK470419/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ncbi.nlm.nih.gov/books/NBK470419/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ncbi.nlm.nih.gov/books/NBK470419/</a></span></div></li><li id="https://www.dynamed.com/condition/overview-of-congenital-anomalies-of-the-kidney-and-urinary-tract-cakut/PlatformHomeAbout" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.dynamed.com/condition/overview-of-congenital-anomalies-of-the-kidney-and-urinary-tract-cakut/PlatformHomeAbout" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.dynamed.com/condition/overview-of-congenital-anomalies-of-the-kidney-and-urinary-tract-cakut/PlatformHomeAbout</a></span></div></li><li id="https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2024.1384676/full" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2024.1384676/full" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2024.1384676/full</a></span></div></li><li id="https://publications.aap.org/neoreviews/article/25/2/e78/196493/Congenital-Anomalies-of-the-Kidneys-and-Urinary" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://publications.aap.org/neoreviews/article/25/2/e78/196493/Congenital-Anomalies-of-the-Kidneys-and-Urinary" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://publications.aap.org/neoreviews/article/25/2/e78/196493/Congenital-Anomalies-of-the-Kidneys-and-Urinary</a></span></div></li><li id="https://www.ncbi.nlm.nih.gov/books/NBK553144/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ncbi.nlm.nih.gov/books/NBK553144/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ncbi.nlm.nih.gov/books/NBK553144/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC4270362/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC4270362/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC4270362/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC6590508/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC6590508/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC6590508/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC6282040/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC6282040/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC6282040/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC7121468/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC7121468/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC7121468/</a></span></div></li><li id="https://www.ajkd.org/article/S0272-6386%2812%2901509-0/fulltext" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ajkd.org/article/S0272-6386%2812%2901509-0/fulltext" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ajkd.org/article/S0272-6386%2812%2901509-0/fulltext</a></span></div></li><li id="https://pure.johnshopkins.edu/en/publications/lifestyle-factors-obesity-and-the-risk-of-chronic-kidney-disease-5" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pure.johnshopkins.edu/en/publications/lifestyle-factors-obesity-and-the-risk-of-chronic-kidney-disease-5" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pure.johnshopkins.edu/en/publications/lifestyle-factors-obesity-and-the-risk-of-chronic-kidney-disease-5</a></span></div></li><li id="https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-022-02745-3" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-022-02745-3" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-022-02745-3</a></span></div></li><li id="https://www.sciencedirect.com/science/article/abs/pii/S1047279703000668" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/abs/pii/S1047279703000668" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/abs/pii/S1047279703000668</a></span></div></li><li id="https://journals.lww.com/kidney360/fulltext/2022/04000/modifiable_lifestyle_behaviors_and_ckd.24.aspx" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://journals.lww.com/kidney360/fulltext/2022/04000/modifiable_lifestyle_behaviors_and_ckd.24.aspx" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://journals.lww.com/kidney360/fulltext/2022/04000/modifiable_lifestyle_behaviors_and_ckd.24.aspx</a></span></div></li><li id="https://www.mayoclinic.org/diseases-conditions/chronic-kidney-disease/symptoms-causes/syc-20354521" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.mayoclinic.org/diseases-conditions/chronic-kidney-disease/symptoms-causes/syc-20354521" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.mayoclinic.org/diseases-conditions/chronic-kidney-disease/symptoms-causes/syc-20354521</a></span></div></li><li id="https://www.kidney.org/kidney-topics/acute-kidney-injury-aki" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.kidney.org/kidney-topics/acute-kidney-injury-aki" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.kidney.org/kidney-topics/acute-kidney-injury-aki</a></span></div></li><li id="https://www.ncbi.nlm.nih.gov/books/NBK568593/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ncbi.nlm.nih.gov/books/NBK568593/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ncbi.nlm.nih.gov/books/NBK568593/</a></span></div></li><li id="https://www.kidney.org/kidney-topics/chronic-kidney-disease-ckd" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.kidney.org/kidney-topics/chronic-kidney-disease-ckd" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.kidney.org/kidney-topics/chronic-kidney-disease-ckd</a></span></div></li><li id="https://www.kidney.org/news-stories/10-signs-you-may-have-kidney-disease" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.kidney.org/news-stories/10-signs-you-may-have-kidney-disease" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.kidney.org/news-stories/10-signs-you-may-have-kidney-disease</a></span></div></li><li id="https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-017-0638-y" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-017-0638-y" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-017-0638-y</a></span></div></li><li id="https://jamanetwork.com/journals/jama/fullarticle/2542635" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://jamanetwork.com/journals/jama/fullarticle/2542635" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://jamanetwork.com/journals/jama/fullarticle/2542635</a></span></div></li><li id="https://www.kidney.org/kidney-topics/signs-and-symptoms-kidney-disease" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.kidney.org/kidney-topics/signs-and-symptoms-kidney-disease" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.kidney.org/kidney-topics/signs-and-symptoms-kidney-disease</a></span></div></li><li id="https://www.mayoclinic.org/diseases-conditions/chronic-kidney-disease/diagnosis-treatment/drc-20354527" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.mayoclinic.org/diseases-conditions/chronic-kidney-disease/diagnosis-treatment/drc-20354527" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.mayoclinic.org/diseases-conditions/chronic-kidney-disease/diagnosis-treatment/drc-20354527</a></span></div></li><li id="https://www.kidneyfund.org/all-about-kidneys/tests-kidney-disease" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.kidneyfund.org/all-about-kidneys/tests-kidney-disease" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.kidneyfund.org/all-about-kidneys/tests-kidney-disease</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC8813013/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC8813013/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC8813013/</a></span></div></li><li id="https://www.mayoclinic.org/tests-procedures/kidney-biopsy/about/pac-20394494" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.mayoclinic.org/tests-procedures/kidney-biopsy/about/pac-20394494" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.mayoclinic.org/tests-procedures/kidney-biopsy/about/pac-20394494</a></span></div></li><li id="https://www.uptodate.com/contents/the-kidney-biopsy" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.uptodate.com/contents/the-kidney-biopsy" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.uptodate.com/contents/the-kidney-biopsy</a></span></div></li><li id="https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-025-04040-3" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-025-04040-3" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-025-04040-3</a></span></div></li><li id="https://annalsofintensivecare.springeropen.com/articles/10.1186/s13613-024-01360-9" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://annalsofintensivecare.springeropen.com/articles/10.1186/s13613-024-01360-9" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://annalsofintensivecare.springeropen.com/articles/10.1186/s13613-024-01360-9</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC12110191/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12110191/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC12110191/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC11512660/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC11512660/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC11512660/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC11084889/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC11084889/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC11084889/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC11399210/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC11399210/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC11399210/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC11905639/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC11905639/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC11905639/</a></span></div></li><li id="https://www.nejm.org/doi/full/10.1056/NEJMoa2210639" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2210639" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nejm.org/doi/full/10.1056/NEJMoa2210639</a></span></div></li><li id="https://www.ajkd.org/article/S0272-6386%2816%2900137-2/fulltext" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ajkd.org/article/S0272-6386%2816%2900137-2/fulltext" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ajkd.org/article/S0272-6386%2816%2900137-2/fulltext</a></span></div></li><li id="https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2021.645187/full" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2021.645187/full" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2021.645187/full</a></span></div></li><li id="https://www.sciencedirect.com/science/article/pii/S2214623724000255" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/pii/S2214623724000255" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/pii/S2214623724000255</a></span></div></li><li id="https://kdigo.org/wp-content/uploads/2017/02/7.-Tangri-KDIGO-Presentation.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://kdigo.org/wp-content/uploads/2017/02/7.-Tangri-KDIGO-Presentation.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://kdigo.org/wp-content/uploads/2017/02/7.-Tangri-KDIGO-Presentation.pdf</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC4089661/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC4089661/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC4089661/</a></span></div></li><li id="https://journals.lww.com/md-journal/fulltext/2023/06090/comprehensive_review_of_current_management.13.aspx" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://journals.lww.com/md-journal/fulltext/2023/06090/comprehensive_review_of_current_management.13.aspx" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://journals.lww.com/md-journal/fulltext/2023/06090/comprehensive_review_of_current_management.13.aspx</a></span></div></li><li id="https://www.ajmc.com/view/value-based-care-interventions-and-management-of-ckd-progression" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ajmc.com/view/value-based-care-interventions-and-management-of-ckd-progression" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ajmc.com/view/value-based-care-interventions-and-management-of-ckd-progression</a></span></div></li><li id="https://hospitalhandbook.ucsf.edu/07-indications-dialysis/07-indications-dialysis" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://hospitalhandbook.ucsf.edu/07-indications-dialysis/07-indications-dialysis" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://hospitalhandbook.ucsf.edu/07-indications-dialysis/07-indications-dialysis</a></span></div></li><li id="https://www.ncbi.nlm.nih.gov/books/NBK556028/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ncbi.nlm.nih.gov/books/NBK556028/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ncbi.nlm.nih.gov/books/NBK556028/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC10139729/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10139729/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC10139729/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC9717642/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC9717642/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC9717642/</a></span></div></li><li id="https://journal.chestnet.org/article/S0012-3692%2818%2932478-4/fulltext" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://journal.chestnet.org/article/S0012-3692%2818%2932478-4/fulltext" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://journal.chestnet.org/article/S0012-3692%2818%2932478-4/fulltext</a></span></div></li><li id="https://pharm.ucsf.edu/kidney/need/statistics" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pharm.ucsf.edu/kidney/need/statistics" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pharm.ucsf.edu/kidney/need/statistics</a></span></div></li><li id="https://usrds-adr.niddk.nih.gov/2023/end-stage-renal-disease/6-mortality" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://usrds-adr.niddk.nih.gov/2023/end-stage-renal-disease/6-mortality" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://usrds-adr.niddk.nih.gov/2023/end-stage-renal-disease/6-mortality</a></span></div></li><li id="https://www.sciencedirect.com/science/article/pii/S1600613523005786" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/pii/S1600613523005786" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/pii/S1600613523005786</a></span></div></li><li id="https://karger.com/ger/article/70/5/461/896692/Mortality-of-Peritoneal-Dialysis-versus" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://karger.com/ger/article/70/5/461/896692/Mortality-of-Peritoneal-Dialysis-versus" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://karger.com/ger/article/70/5/461/896692/Mortality-of-Peritoneal-Dialysis-versus</a></span></div></li><li id="https://www.kidney-international.org/article/S0085-2538%2815%2948687-9/fulltext" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.kidney-international.org/article/S0085-2538%2815%2948687-9/fulltext" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.kidney-international.org/article/S0085-2538%2815%2948687-9/fulltext</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC4931701/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC4931701/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC4931701/</a></span></div></li><li id="https://www.ahajournals.org/doi/10.1161/circulationaha.111.039909" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ahajournals.org/doi/10.1161/circulationaha.111.039909" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ahajournals.org/doi/10.1161/circulationaha.111.039909</a></span></div></li><li id="https://journals.lww.com/kidney360/fulltext/2022/02000/short__and_long_term_recovery_after.10.aspx" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://journals.lww.com/kidney360/fulltext/2022/02000/short__and_long_term_recovery_after.10.aspx" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://journals.lww.com/kidney360/fulltext/2022/02000/short__and_long_term_recovery_after.10.aspx</a></span></div></li><li id="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2764344" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2764344" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2764344</a></span></div></li><li id="https://www.nature.com/articles/s41598-021-94946-3" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nature.com/articles/s41598-021-94946-3" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nature.com/articles/s41598-021-94946-3</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC7732055/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC7732055/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC7732055/</a></span></div></li><li id="https://www.nature.com/articles/s41598-017-11861-2" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nature.com/articles/s41598-017-11861-2" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nature.com/articles/s41598-017-11861-2</a></span></div></li><li id="https://www.thepermanentejournal.org/doi/10.7812/TPP/18.273" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.thepermanentejournal.org/doi/10.7812/TPP/18.273" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.thepermanentejournal.org/doi/10.7812/TPP/18.273</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC4633789/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC4633789/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC4633789/</a></span></div></li><li id="https://www.sciencedirect.com/science/article/pii/S0741521413007830" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/pii/S0741521413007830" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/pii/S0741521413007830</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC2474786/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC2474786/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC2474786/</a></span></div></li><li id="https://www.kidneyfund.org/living-kidney-disease/health-problems-caused-kidney-disease" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.kidneyfund.org/living-kidney-disease/health-problems-caused-kidney-disease" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.kidneyfund.org/living-kidney-disease/health-problems-caused-kidney-disease</a></span></div></li><li id="https://www.healthline.com/health/kidney-disease/complications-of-chronic-kidney-disease" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.healthline.com/health/kidney-disease/complications-of-chronic-kidney-disease" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.healthline.com/health/kidney-disease/complications-of-chronic-kidney-disease</a></span></div></li><li id="https://www.pennmedicine.org/conditions/end-stage-kidney-disease" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.pennmedicine.org/conditions/end-stage-kidney-disease" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.pennmedicine.org/conditions/end-stage-kidney-disease</a></span></div></li><li id="https://karger.com/ajn/article/53/1/32/827379/Causes-of-Death-in-End-Stage-Kidney-Disease" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://karger.com/ajn/article/53/1/32/827379/Causes-of-Death-in-End-Stage-Kidney-Disease" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://karger.com/ajn/article/53/1/32/827379/Causes-of-Death-in-End-Stage-Kidney-Disease</a></span></div></li><li id="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2788381" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2788381" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2788381</a></span></div></li><li id="https://www.healthline.com/health/kidney-disease/renal-failure-death-rate" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.healthline.com/health/kidney-disease/renal-failure-death-rate" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.healthline.com/health/kidney-disease/renal-failure-death-rate</a></span></div></li><li id="https://www.webmd.com/a-to-z-guides/what-is-stage-3-kidney-disease-life-expectancy" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.webmd.com/a-to-z-guides/what-is-stage-3-kidney-disease-life-expectancy" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.webmd.com/a-to-z-guides/what-is-stage-3-kidney-disease-life-expectancy</a></span></div></li><li id="https://www.sciencedirect.com/science/article/pii/S259005952300033X" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/pii/S259005952300033X" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/pii/S259005952300033X</a></span></div></li><li id="https://www.cdc.gov/nchs/fastats/kidney-disease.htm" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.cdc.gov/nchs/fastats/kidney-disease.htm" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.cdc.gov/nchs/fastats/kidney-disease.htm</a></span></div></li><li id="https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-024-03720-w" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-024-03720-w" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-024-03720-w</a></span></div></li><li id="https://usrds-adr.niddk.nih.gov/2022/chronic-kidney-disease/3-morbidity-and-mortality-in-patients-with-ckd" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://usrds-adr.niddk.nih.gov/2022/chronic-kidney-disease/3-morbidity-and-mortality-in-patients-with-ckd" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://usrds-adr.niddk.nih.gov/2022/chronic-kidney-disease/3-morbidity-and-mortality-in-patients-with-ckd</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/34602599/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/34602599/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/34602599/</a></span></div></li><li id="https://www.kidney-international.org/article/S0085-2538%2823%2900764-0/fulltext" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.kidney-international.org/article/S0085-2538%2823%2900764-0/fulltext" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.kidney-international.org/article/S0085-2538%2823%2900764-0/fulltext</a></span></div></li><li id="https://kdigo.org/wp-content/uploads/2021/03/KDIGO-2021-BP-Guideline-Speakers-Guide.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://kdigo.org/wp-content/uploads/2021/03/KDIGO-2021-BP-Guideline-Speakers-Guide.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://kdigo.org/wp-content/uploads/2021/03/KDIGO-2021-BP-Guideline-Speakers-Guide.pdf</a></span></div></li><li id="https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-021-02618-1" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-021-02618-1" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-021-02618-1</a></span></div></li><li id="https://www.kidney.org/7-golden-rules-kidney-disease-prevention" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.kidney.org/7-golden-rules-kidney-disease-prevention" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.kidney.org/7-golden-rules-kidney-disease-prevention</a></span></div></li><li id="https://bmjopen.bmj.com/content/9/10/e031625" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://bmjopen.bmj.com/content/9/10/e031625" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://bmjopen.bmj.com/content/9/10/e031625</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/38490803/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/38490803/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/38490803/</a></span></div></li><li id="https://www.kidney.org/sites/default/files/02-10-6800_2303_manageckd_algorithmv4_final.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.kidney.org/sites/default/files/02-10-6800_2303_manageckd_algorithmv4_final.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.kidney.org/sites/default/files/02-10-6800_2303_manageckd_algorithmv4_final.pdf</a></span></div></li><li id="https://diabetesjournals.org/care/article/48/Supplement_1/S239/157554/11-Chronic-Kidney-Disease-and-Risk-Management" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://diabetesjournals.org/care/article/48/Supplement_1/S239/157554/11-Chronic-Kidney-Disease-and-Risk-Management" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://diabetesjournals.org/care/article/48/Supplement_1/S239/157554/11-Chronic-Kidney-Disease-and-Risk-Management</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC4571145/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC4571145/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC4571145/</a></span></div></li><li id="https://academic.oup.com/ckj/article/18/5/sfaf123/8120273" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://academic.oup.com/ckj/article/18/5/sfaf123/8120273" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://academic.oup.com/ckj/article/18/5/sfaf123/8120273</a></span></div></li><li id="https://www.cdc.gov/kidney-disease/risk-factors/chronic-kidney-disease-ckd-and-adults-with-high-blood-pressure.html" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.cdc.gov/kidney-disease/risk-factors/chronic-kidney-disease-ckd-and-adults-with-high-blood-pressure.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.cdc.gov/kidney-disease/risk-factors/chronic-kidney-disease-ckd-and-adults-with-high-blood-pressure.html</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC9827046/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC9827046/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC9827046/</a></span></div></li><li id="https://diabetesjournals.org/care/article/45/12/3075/147614/Diabetes-Management-in-Chronic-Kidney-Disease-A" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://diabetesjournals.org/care/article/45/12/3075/147614/Diabetes-Management-in-Chronic-Kidney-Disease-A" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://diabetesjournals.org/care/article/45/12/3075/147614/Diabetes-Management-in-Chronic-Kidney-Disease-A</a></span></div></li><li id="https://www.kidney.org/diabetes-and-chronic-kidney-disease" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.kidney.org/diabetes-and-chronic-kidney-disease" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.kidney.org/diabetes-and-chronic-kidney-disease</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC10856768/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10856768/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC10856768/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC4089662/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC4089662/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC4089662/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC10648605/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10648605/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC10648605/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC7567536/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC7567536/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC7567536/</a></span></div></li><li id="https://www.kisupplements.com/article/S2157-1716%2817%2930029-1/fulltext" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.kisupplements.com/article/S2157-1716%2817%2930029-1/fulltext" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.kisupplements.com/article/S2157-1716%2817%2930029-1/fulltext</a></span></div></li><li id="https://www.kidney-international.org/article/S0085-2538%2816%2930177-6/fulltext" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.kidney-international.org/article/S0085-2538%2816%2930177-6/fulltext" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.kidney-international.org/article/S0085-2538%2816%2930177-6/fulltext</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/32828236/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/32828236/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/32828236/</a></span></div></li><li id="https://www.ahajournals.org/doi/10.1161/HYPERTENSIONAHA.122.19354" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ahajournals.org/doi/10.1161/HYPERTENSIONAHA.122.19354" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ahajournals.org/doi/10.1161/HYPERTENSIONAHA.122.19354</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC3752955/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC3752955/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC3752955/</a></span></div></li><li id="https://www.nejm.org/doi/full/10.1056/NEJMoa2404211" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2404211" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nejm.org/doi/full/10.1056/NEJMoa2404211</a></span></div></li><li id="https://www.health.harvard.edu/blog/whats-behind-racial-disparities-in-kidney-disease-2021020321842" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.health.harvard.edu/blog/whats-behind-racial-disparities-in-kidney-disease-2021020321842" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.health.harvard.edu/blog/whats-behind-racial-disparities-in-kidney-disease-2021020321842</a></span></div></li><li id="https://www.kidney.org/kidney-topics/social-determinants-health-and-chronic-kidney-disease" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.kidney.org/kidney-topics/social-determinants-health-and-chronic-kidney-disease" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.kidney.org/kidney-topics/social-determinants-health-and-chronic-kidney-disease</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC10272583/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10272583/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC10272583/</a></span></div></li><li id="https://cromospharma.com/world-kidney-day-top-5-breakthroughs-in-kidney-disease-treatment/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://cromospharma.com/world-kidney-day-top-5-breakthroughs-in-kidney-disease-treatment/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://cromospharma.com/world-kidney-day-top-5-breakthroughs-in-kidney-disease-treatment/</a></span></div></li><li id="https://onlinelibrary.wiley.com/doi/10.1002/ehf2.15345" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://onlinelibrary.wiley.com/doi/10.1002/ehf2.15345" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://onlinelibrary.wiley.com/doi/10.1002/ehf2.15345</a></span></div></li><li id="https://news.ohsu.edu/2024/12/30/new-gene-therapy-research-offers-hope-for-people-with-chronic-kidney-disease" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://news.ohsu.edu/2024/12/30/new-gene-therapy-research-offers-hope-for-people-with-chronic-kidney-disease" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://news.ohsu.edu/2024/12/30/new-gene-therapy-research-offers-hope-for-people-with-chronic-kidney-disease</a></span></div></li><li id="https://health.ucdavis.edu/news/headlines/uc-davis-health-launches-new-cell-therapy-trial-for-chronic-kidney-disease-patients/2025/04" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://health.ucdavis.edu/news/headlines/uc-davis-health-launches-new-cell-therapy-trial-for-chronic-kidney-disease-patients/2025/04" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://health.ucdavis.edu/news/headlines/uc-davis-health-launches-new-cell-therapy-trial-for-chronic-kidney-disease-patients/2025/04</a></span></div></li><li id="https://www.kidneyfund.org/article/top-kidney-disease-research-advancements-2024" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.kidneyfund.org/article/top-kidney-disease-research-advancements-2024" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.kidneyfund.org/article/top-kidney-disease-research-advancements-2024</a></span></div></li><li id="https://www.ajkd.org/article/S0272-63862401120-X/fulltext" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ajkd.org/article/S0272-63862401120-X/fulltext" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ajkd.org/article/S0272-63862401120-X/fulltext</a></span></div></li><li id="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2815795" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2815795" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2815795</a></span></div></li><li id="https://www.ajkd.org/article/S0272-6386%2825%2900054-X/fulltext" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ajkd.org/article/S0272-6386%2825%2900054-X/fulltext" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ajkd.org/article/S0272-6386%2825%2900054-X/fulltext</a></span></div></li><li id="https://www.sciencedirect.com/science/article/pii/S2468024925006254" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/pii/S2468024925006254" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/pii/S2468024925006254</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC12304639/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12304639/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC12304639/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC11102772/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC11102772/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC11102772/</a></span></div></li></ol></div></div></div><div class="hidden min-[1400px]:block"></div></div></div><!--$--><!--/$--><div role="region" aria-label="Notifications (F8)" tabindex="-1" style="pointer-events:none"><ol tabindex="-1" class="pointer-events-none fixed top-0 z-[100] flex max-h-screen w-full flex-col-reverse p-4 max-sm:left-0 sm:bottom-0 sm:right-0 sm:top-auto sm:max-w-[420px] sm:flex-col pl-16 pr-2 pt-16 sm:px-4"></ol></div><script type="application/json" id="server-client-data-experimentation">{"status":"uninitialized"}</script><script src="/_next/static/chunks/webpack-e121ed42680f327e.js" nonce="YzBlMjE1NjMtYjg2MC00MmIzLWJmMzktNTk1ZDcyYjYzMzVi" id="_R_" async=""></script><script nonce="YzBlMjE1NjMtYjg2MC00MmIzLWJmMzktNTk1ZDcyYjYzMzVi">(self.__next_f=self.__next_f||[]).push([0])</script><script nonce="YzBlMjE1NjMtYjg2MC00MmIzLWJmMzktNTk1ZDcyYjYzMzVi">self.__next_f.push([1,"1:\"$Sreact.fragment\"\n3:I[91363,[],\"\"]\n4:I[23775,[],\"\"]\n5:I[57654,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"3699\",\"static/chunks/app/page/%5Bslug%5D/layout-55a344716dd57c44.js\"],\"PageHeaderProvider\"]\n6:I[17618,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"3699\",\"static/chunks/app/page/%5Bslug%5D/layout-55a344716dd57c44.js\"],\"HeaderContent\"]\n7:I[25529,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"6751\",\"static/chunks/app/page/%5Bslug%5D/not-found-69a3edc7db5749d6.js\"],\"default\"]\n9:I[6666,[],\"OutletBoundary\"]\nb:I[80415,[],\"AsyncMetadataOutlet\"]\nd:I[6666,[],\"ViewportBoundary\"]\nf:I[6666,[],\"MetadataBoundary\"]\n10:\"$Sreact.suspense\"\n12:I[95909,[\"4219\",\"static/chunks/app/global-error-4d07d20223cd4b4c.js\"],\"default\"]\n"])</script><script nonce="YzBlMjE1NjMtYjg2MC00MmIzLWJmMzktNTk1ZDcyYjYzMzVi">self.__next_f.push([1,"13:I[51498,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"ConstantsProvider\"]\n"])</script><script nonce="YzBlMjE1NjMtYjg2MC00MmIzLWJmMzktNTk1ZDcyYjYzMzVi">self.__next_f.push([1,"14:I[91073,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="YzBlMjE1NjMtYjg2MC00MmIzLWJmMzktNTk1ZDcyYjYzMzVi">self.__next_f.push([1,"15:I[38642,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="YzBlMjE1NjMtYjg2MC00MmIzLWJmMzktNTk1ZDcyYjYzMzVi">self.__next_f.push([1,"16:I[99648,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"default\"]\n"])</script><script nonce="YzBlMjE1NjMtYjg2MC00MmIzLWJmMzktNTk1ZDcyYjYzMzVi">self.__next_f.push([1,"17:I[78825,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="YzBlMjE1NjMtYjg2MC00MmIzLWJmMzktNTk1ZDcyYjYzMzVi">self.__next_f.push([1,"18:I[8550,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"MixpanelProvider\"]\n"])</script><script nonce="YzBlMjE1NjMtYjg2MC00MmIzLWJmMzktNTk1ZDcyYjYzMzVi">self.__next_f.push([1,"19:I[12290,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"MobileTocProvider\"]\n"])</script><script nonce="YzBlMjE1NjMtYjg2MC00MmIzLWJmMzktNTk1ZDcyYjYzMzVi">self.__next_f.push([1,"1a:I[53947,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"NuqsAdapter\"]\n"])</script><script nonce="YzBlMjE1NjMtYjg2MC00MmIzLWJmMzktNTk1ZDcyYjYzMzVi">self.__next_f.push([1,"1b:I[91873,[\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8039\",\"static/chunks/app/error-4a29e9399afba038.js\"],\"default\"]\n1c:I[5091,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"4345\",\"static/chunks/app/not-found-dd95690acf732f18.js\"],\"default\"]\n"])</script><script nonce="YzBlMjE1NjMtYjg2MC00MmIzLWJmMzktNTk1ZDcyYjYzMzVi">self.__next_f.push([1,"1d:I[16091,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="YzBlMjE1NjMtYjg2MC00MmIzLWJmMzktNTk1ZDcyYjYzMzVi">self.__next_f.push([1,":HL[\"/_next/static/media/1f2316909698f815.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"YzBlMjE1NjMtYjg2MC00MmIzLWJmMzktNTk1ZDcyYjYzMzVi\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/3d4419af2cf8609b.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"YzBlMjE1NjMtYjg2MC00MmIzLWJmMzktNTk1ZDcyYjYzMzVi\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/4dec29efcaeb336c.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"YzBlMjE1NjMtYjg2MC00MmIzLWJmMzktNTk1ZDcyYjYzMzVi\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/74452ea3ef0f9101.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"YzBlMjE1NjMtYjg2MC00MmIzLWJmMzktNTk1ZDcyYjYzMzVi\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/904ef0a86fe32a00.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"YzBlMjE1NjMtYjg2MC00MmIzLWJmMzktNTk1ZDcyYjYzMzVi\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/d886a03bcda7ad8f.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"YzBlMjE1NjMtYjg2MC00MmIzLWJmMzktNTk1ZDcyYjYzMzVi\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/e1447589d6f59c4b.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"YzBlMjE1NjMtYjg2MC00MmIzLWJmMzktNTk1ZDcyYjYzMzVi\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/f5a90156f8995c8c.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"YzBlMjE1NjMtYjg2MC00MmIzLWJmMzktNTk1ZDcyYjYzMzVi\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/css/62c4caba71dfda84.css\",\"style\",{\"nonce\":\"YzBlMjE1NjMtYjg2MC00MmIzLWJmMzktNTk1ZDcyYjYzMzVi\"}]\n:HL[\"/_next/static/css/eb3d87f98fe1565f.css\",\"style\",{\"nonce\":\"YzBlMjE1NjMtYjg2MC00MmIzLWJmMzktNTk1ZDcyYjYzMzVi\"}]\n:HL[\"/_next/static/css/1b5e561215938d4d.css\",\"style\",{\"nonce\":\"YzBlMjE1NjMtYjg2MC00MmIzLWJmMzktNTk1ZDcyYjYzMzVi\"}]\n:HL[\"/_next/static/css/0227d069a630d414.css\",\"style\",{\"nonce\":\"YzBlMjE1NjMtYjg2MC00MmIzLWJmMzktNTk1ZDcyYjYzMzVi\"}]\n:HL[\"/_next/static/css/f87fff2ab93d05a7.css\",\"style\",{\"nonce\":\"YzBlMjE1NjMtYjg2MC00MmIzLWJmMzktNTk1ZDcyYjYzMzVi\"}]\n"])</script><script nonce="YzBlMjE1NjMtYjg2MC00MmIzLWJmMzktNTk1ZDcyYjYzMzVi">self.__next_f.push([1,"0:{\"P\":null,\"b\":\"BpM29AX4fmgcUxZ_6t0le\",\"p\":\"\",\"c\":[\"\",\"page\",\"Kidney_disease\"],\"i\":false,\"f\":[[[\"\",{\"children\":[\"page\",{\"children\":[[\"slug\",\"Kidney_disease\",\"d\"],{\"children\":[\"__PAGE__\",{}]}]}]},\"$undefined\",\"$undefined\",true],[\"\",[\"$\",\"$1\",\"c\",{\"children\":[[[\"$\",\"link\",\"0\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/62c4caba71dfda84.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"YzBlMjE1NjMtYjg2MC00MmIzLWJmMzktNTk1ZDcyYjYzMzVi\"}],[\"$\",\"link\",\"1\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/eb3d87f98fe1565f.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"YzBlMjE1NjMtYjg2MC00MmIzLWJmMzktNTk1ZDcyYjYzMzVi\"}],[\"$\",\"link\",\"2\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/1b5e561215938d4d.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"YzBlMjE1NjMtYjg2MC00MmIzLWJmMzktNTk1ZDcyYjYzMzVi\"}],[\"$\",\"link\",\"3\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/0227d069a630d414.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"YzBlMjE1NjMtYjg2MC00MmIzLWJmMzktNTk1ZDcyYjYzMzVi\"}]],\"$L2\"]}],{\"children\":[\"page\",[\"$\",\"$1\",\"c\",{\"children\":[null,[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":\"$undefined\",\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}]]}],{\"children\":[[\"slug\",\"Kidney_disease\",\"d\"],[\"$\",\"$1\",\"c\",{\"children\":[null,[\"$\",\"$L5\",null,{\"children\":[[\"$\",\"$L6\",null,{\"maxWidth\":\"full\",\"mobileOptions\":{\"right\":{\"showFixedIssues\":true,\"showThemeSwitcher\":true,\"showSearch\":true,\"showTableOfContents\":true}}}],[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":[[\"$\",\"$L7\",null,{}],[]],\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}]]}]]}],{\"children\":[\"__PAGE__\",[\"$\",\"$1\",\"c\",{\"children\":[\"$L8\",[[\"$\",\"link\",\"0\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/f87fff2ab93d05a7.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"YzBlMjE1NjMtYjg2MC00MmIzLWJmMzktNTk1ZDcyYjYzMzVi\"}]],[\"$\",\"$L9\",null,{\"children\":[\"$La\",[\"$\",\"$Lb\",null,{\"promise\":\"$@c\"}]]}]]}],{},null,false]},null,false]},null,false]},null,false],[\"$\",\"$1\",\"h\",{\"children\":[null,[[\"$\",\"$Ld\",null,{\"children\":\"$Le\"}],[\"$\",\"meta\",null,{\"name\":\"next-size-adjust\",\"content\":\"\"}]],[\"$\",\"$Lf\",null,{\"children\":[\"$\",\"div\",null,{\"hidden\":true,\"children\":[\"$\",\"$10\",null,{\"fallback\":null,\"children\":\"$L11\"}]}]}]]}],false]],\"m\":\"$undefined\",\"G\":[\"$12\",[]],\"s\":false,\"S\":false}\n"])</script><script nonce="YzBlMjE1NjMtYjg2MC00MmIzLWJmMzktNTk1ZDcyYjYzMzVi">self.__next_f.push([1,"2:[\"$\",\"html\",null,{\"lang\":\"en\",\"className\":\"bg-surface-base antialiased\",\"suppressHydrationWarning\":true,\"children\":[[\"$\",\"head\",null,{\"children\":[[\"$\",\"title\",null,{\"children\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"description\",\"content\":\"Grokipedia is an open source, comprehensive collection of all knowledge.\"}],[\"$\",\"link\",null,{\"rel\":\"icon\",\"type\":\"image/x-icon\",\"href\":\"/favicon.ico\",\"sizes\":\"48x48\"}],[\"$\",\"link\",null,{\"rel\":\"icon\",\"href\":\"/images/icon-dark.png\",\"media\":\"(prefers-color-scheme: light)\",\"type\":\"image/png\"}],[\"$\",\"link\",null,{\"rel\":\"icon\",\"href\":\"/images/icon-light.png\",\"media\":\"(prefers-color-scheme: dark)\",\"type\":\"image/png\"}],[\"$\",\"link\",null,{\"rel\":\"apple-touch-icon\",\"href\":\"/icon-192x192.png\"}],[\"$\",\"link\",null,{\"rel\":\"manifest\",\"href\":\"/manifest.webmanifest\"}],[\"$\",\"meta\",null,{\"name\":\"robots\",\"content\":\"index, follow\"}],[\"$\",\"meta\",null,{\"name\":\"googlebot\",\"content\":\"index, follow, max-snippet:-1\"}],[\"$\",\"meta\",null,{\"property\":\"og:title\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"property\":\"og:description\",\"content\":\"Grokipedia is an open source, comprehensive collection of all knowledge.\"}],[\"$\",\"meta\",null,{\"property\":\"og:url\",\"content\":\"https://grokipedia.com\"}],[\"$\",\"meta\",null,{\"property\":\"og:site_name\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"property\":\"og:locale\",\"content\":\"en_US\"}],[\"$\",\"meta\",null,{\"property\":\"og:type\",\"content\":\"website\"}],[\"$\",\"meta\",null,{\"property\":\"og:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}],[\"$\",\"meta\",null,{\"property\":\"og:image:width\",\"content\":\"512\"}],[\"$\",\"meta\",null,{\"property\":\"og:image:height\",\"content\":\"512\"}],[\"$\",\"meta\",null,{\"property\":\"og:image:alt\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:card\",\"content\":\"summary\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:creator\",\"content\":\"@Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:title\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:description\",\"content\":\"Grokipedia is an open source, comprehensive collection of all knowledge.\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}]]}],[\"$\",\"body\",null,{\"className\":\"flex h-[100svh] w-full flex-col __variable_13c637 __variable_8a0ba0 __variable_779740 __variable_2484fd __variable_525cc3 __variable_13486b\",\"children\":[[\"$\",\"$L13\",null,{\"children\":[\"$\",\"$L14\",null,{\"children\":[\"$\",\"$L15\",null,{\"defaultTheme\":\"dark\",\"nonce\":\"YzBlMjE1NjMtYjg2MC00MmIzLWJmMzktNTk1ZDcyYjYzMzVi\",\"children\":[\"$\",\"$L16\",null,{\"children\":[\"$\",\"$L17\",null,{\"children\":[\"$\",\"$L18\",null,{\"children\":[\"$\",\"$L19\",null,{\"children\":[\"$\",\"$L1a\",null,{\"children\":[[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$1b\",\"errorStyles\":[],\"errorScripts\":[],\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":[[\"$\",\"$L1c\",null,{}],[]],\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}],[\"$\",\"$L1d\",null,{}]]}]}]}]}]}]}]}]}],[\"$\",\"script\",null,{\"type\":\"application/json\",\"id\":\"server-client-data-experimentation\",\"children\":\"{\\\"status\\\":\\\"uninitialized\\\"}\"}]]}]]}]\n"])</script><script nonce="YzBlMjE1NjMtYjg2MC00MmIzLWJmMzktNTk1ZDcyYjYzMzVi">self.__next_f.push([1,"e:[[\"$\",\"meta\",\"0\",{\"charSet\":\"utf-8\"}],[\"$\",\"meta\",\"1\",{\"name\":\"viewport\",\"content\":\"width=device-width, initial-scale=1, interactive-widget=resizes-content\"}]]\na:null\n"])</script><script nonce="YzBlMjE1NjMtYjg2MC00MmIzLWJmMzktNTk1ZDcyYjYzMzVi">self.__next_f.push([1,"1e:I[42712,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"HydrationBoundary\"]\n"])</script><script nonce="YzBlMjE1NjMtYjg2MC00MmIzLWJmMzktNTk1ZDcyYjYzMzVi">self.__next_f.push([1,"21:I[6367,[],\"IconMark\"]\n1f:T13418,"])</script><script nonce="YzBlMjE1NjMtYjg2MC00MmIzLWJmMzktNTk1ZDcyYjYzMzVi">self.__next_f.push([1,"# Kidney disease\n\nKidney disease comprises a range of disorders that impair the kidneys' capacity to filter blood, remove waste products, and regulate electrolytes and fluid balance, often resulting from damage to the nephrons, the functional units of the kidney. It includes **acute kidney injury (AKI)**, characterized by a sudden decline in renal function that may be reversible if addressed promptly, and **chronic kidney disease (CKD)**, defined as structural or functional abnormalities persisting for more than three months, leading to progressive loss of kidney function and potential end-stage renal disease necessitating dialysis or transplantation.[](https://www.niddk.nih.gov/health-information/kidney-disease)[](https://pmc.ncbi.nlm.nih.gov/articles/PMC7015670/)[](https://pmc.ncbi.nlm.nih.gov/articles/PMC5475438/)\n\nIn the United States, CKD affects more than 1 in 7 adults, or approximately 37 million people, with prevalence increasing with ageâ€”reaching 34% among those 65 and olderâ€”and disproportionately impacting certain demographics, though diabetes and hypertension remain the predominant causes across most adult populations.[](https://www.cdc.gov/kidney-disease/about/index.html)[](https://www.cdc.gov/kidney-disease/php/data-research/index.html) Globally, kidney disease contributes substantially to mortality from noncommunicable diseases, ranking as a leading cause of death in many regions, though data on precise burden highlight variations influenced by underdiagnosis and access to care.[](https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases)[](https://www.niddk.nih.gov/health-information/health-statistics/kidney-disease)\n\n![Kidney diseases world map - Deaths per million persons - WHO 2012](./_assets_/Kidney_diseases_world_map-Deaths_per_million_persons-WHO2012.svg.png)\n\nUntreated progression elevates risks of cardiovascular complications, anemia, and bone disorders due to disrupted hormone production and mineral metabolism, underscoring the causal links between sustained glomerular filtration rate decline and systemic health deterioration.[](https://www.ncbi.nlm.nih.gov/books/NBK535404/)[](https://pmc.ncbi.nlm.nih.gov/articles/PMC10669155/) Early detection via estimated glomerular filtration rate and albuminuria screening is critical, as interventions targeting modifiable risks like glycemic and blood pressure control can slow advancement, though irreversible scarring often limits full recovery in advanced CKD.[](https://www.cdc.gov/kidney-disease/risk-factors/index.html)[](https://pmc.ncbi.nlm.nih.gov/articles/PMC7015670/)\n\n## Overview and Classification\n\n### Definition and Types\n\nKidney disease, also termed renal disease, encompasses pathological conditions that damage kidney structure or impair function, hindering the organs' capacity to filter blood, excrete wastes such as urea and creatinine, regulate electrolytes, and maintain acid-base and fluid balance.[](https://www.niddk.nih.gov/health-information/kidney-disease) Healthy kidneys process approximately 180 liters of blood daily through roughly 1 million nephrons per kidney, removing excess fluids and toxins while reabsorbing essential nutrients; disease disrupts these processes, potentially leading to azotemia, electrolyte derangements, or uremia if untreated.[](https://www.ncbi.nlm.nih.gov/books/NBK535404/) Most kidney diseases target the nephrons, causing irreversible scarring or functional decline, with causes ranging from genetic defects to acquired insults like toxins or ischemia.[](https://medlineplus.gov/kidneydiseases.html)\n\nKidney diseases are broadly classified by onset and duration into acute kidney injury (AKI) and chronic kidney disease (CKD), with AKI reflecting sudden dysfunction and CKD indicating persistent impairment.[](https://www.ncbi.nlm.nih.gov/books/NBK441896/) AKI, formerly known as acute renal failure, involves a rapid decline in glomerular filtration rate (GFR) over hours to days, often defined by criteria such as a serum creatinine increase of â‰¥0.3 mg/dL within 48 hours or â‰¥1.5 times baseline within 7 days, or urine output \u003c0.5 mL/kg/hour for 6 hours.[](https://www.ncbi.nlm.nih.gov/books/NBK441896/) It frequently results from prerenal factors (e.g., hypovolemia), intrinsic renal damage (e.g., acute tubular necrosis or glomerulonephritis), or postrenal obstruction, and is potentially reversible if the underlying cause is addressed promptly, though severe cases can progress to CKD.[](https://eclinpath.com/chemistry/kidney/types-of-renal-disease/)\n\n![Kidney â€“ acute cortical necrosis](./_assets_/Kidney_%E2%80%93_acute_cortical_necrosis.jpg)\n\nCKD is characterized by abnormalities in kidney structure or function persisting for more than 3 months, with GFR \u003c60 mL/min/1.73 mÂ² or markers of kidney damage such as albuminuria, leading to progressive fibrosis and eventual end-stage renal disease requiring dialysis or transplantation in advanced stages.[](https://www.ncbi.nlm.nih.gov/books/NBK535404/) Unlike AKI, CKD develops insidiously over months to years, often asymptomatic until late stages, and is classified etiologically into types like diabetic nephropathy (the leading cause, affecting 30-40% of diabetes patients), hypertensive nephrosclerosis, primary glomerulopathies, and inherited disorders such as polycystic kidney disease.[](https://www.kidneyfund.org/all-about-kidneys/types-kidney-diseases) AKI episodes superimposed on CKD (\"acute-on-chronic\") exacerbate progression, with bidirectional risks wherein CKD predisposes to AKI and unresolved AKI fosters CKD development.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC9720902/) Other less common types include tubulointerstitial nephritis, obstructive uropathy, and vascular diseases like renal artery stenosis, each contributing variably to overall renal pathology based on histopathological patterns.[](https://www.ncbi.nlm.nih.gov/books/NBK535404/)\n\n### Acute Kidney Injury\n\n![Kidney â€“ acute cortical necrosis](./_assets_/Kidney_%E2%80%93_acute_cortical_necrosis.jpg)\nAcute kidney injury (AKI) is characterized by a rapid decline in kidney function over hours to days, leading to the accumulation of nitrogenous waste products such as urea and creatinine in the blood, known as azotemia.[](https://www.merckmanuals.com/professional/genitourinary-disorders/acute-kidney-injury/acute-kidney-injury-aki) [](https://www.ncbi.nlm.nih.gov/books/NBK441896/) This condition, formerly termed acute renal failure, often results in dysregulation of electrolytes, acid-base balance, and fluid homeostasis.[](https://emedicine.medscape.com/article/243492-overview) AKI is typically reversible if the underlying cause is promptly addressed, distinguishing it from chronic kidney disease.[](https://www.ncbi.nlm.nih.gov/books/NBK441896/)\n\nThe Kidney Disease: Improving Global Outcomes (KDIGO) criteria define AKI as an increase in serum creatinine by â‰¥0.3 mg/dL within 48 hours, or â‰¥1.5 times baseline within 7 days, or urine volume \u003c0.5 mL/kg/hour for 6 hours.[](https://kdigo.org/wp-content/uploads/2016/10/KDIGO-2012-AKI-Guideline-English.pdf) Staging classifies severity: stage 1 involves a creatinine rise of 1.5â€“1.9 times baseline or â‰¥0.3 mg/dL with oliguria for 6â€“12 hours; stage 2 a 2.0â€“2.9 times increase or oliguria â‰¥12 hours; stage 3 a â‰¥3 times rise, creatinine â‰¥4.0 mg/dL, oliguria â‰¥24 hours, anuria â‰¥12 hours, or need for renal replacement therapy (RRT).[](https://www.merckmanuals.com/professional/multimedia/table/staging-criteria-for-acute-kidney-injury-kdigo-2012) Higher stages correlate with worse outcomes, including in-hospital mortality rates escalating from approximately 5% in stage 1 to 25% in stage 3.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC6676729/)\n\nEtiologically, AKI is categorized into prerenal (reduced renal perfusion, e.g., hypovolemia, heart failure), intrinsic renal (direct parenchymal damage from ischemia, toxins, glomerulonephritis, or acute tubular necrosis), and postrenal (urinary tract obstruction, e.g., stones, tumors).[](https://www.aafp.org/pubs/afp/issues/2019/1201/p687.html) [](https://www.ncbi.nlm.nih.gov/books/NBK441896/) Common precipitants include sepsis, nephrotoxic medications like NSAIDs or aminoglycosides, and contrast agents.[](https://emedicine.medscape.com/article/243492-overview) In hospitalized patients, incidence varies but community-based estimates range from 134â€“162 events per 10,000 person-years, with hospital mortality around 20â€“50%, exceeding 50% in intensive care settings.[](https://www.kidney-international.org/article/S0085-2538%2822%2900267-8/fulltext) [](https://www.ncbi.nlm.nih.gov/books/NBK441896/)\n\nClinically, AKI manifests with oliguria or anuria, fluid retention causing edema, hypertension or hypotension, fatigue, nausea, and in severe cases, uremic symptoms like confusion, seizures, or pericarditis.[](https://www.mayoclinic.org/diseases-conditions/kidney-failure/symptoms-causes/syc-20369048) [](https://www.merckmanuals.com/professional/genitourinary-disorders/acute-kidney-injury/acute-kidney-injury-aki) Diagnosis relies on history, physical exam, serum creatinine trends, blood urea nitrogen elevation, and urinalysis to differentiate causes (e.g., muddy brown casts in acute tubular necrosis).[](https://www.aafp.org/pubs/afp/issues/2019/1201/p687.html) Imaging like ultrasound assesses obstruction, while biomarkers such as NGAL or cystatin C may aid early detection, though not routinely used.[](https://emedicine.medscape.com/article/243492-overview)\n\nManagement prioritizes treating the underlying cause: volume resuscitation for prerenal AKI, discontinuation of nephrotoxins, and relief of obstruction.[](https://www.mayoclinic.org/diseases-conditions/kidney-failure/diagnosis-treatment/drc-20369053) Supportive care includes fluid and electrolyte correction, nutritional support, and avoidance of further insults.[](https://www.aafp.org/pubs/afp/issues/2019/1201/p687.html) Indications for RRT, such as dialysis, include refractory hyperkalemia, acidosis, uremia, or volume overload.[](https://kdigo.org/wp-content/uploads/2016/10/KDIGO-2012-AKI-Guideline-English.pdf) Prognosis varies by etiology and comorbidities; prerenal causes often resolve fully, while intrinsic damage like cortical necrosis carries high morbidity and may progress to chronic kidney disease in 20â€“50% of survivors.[](https://www.ncbi.nlm.nih.gov/books/NBK441896/) Overall, AKI independently predicts long-term cardiovascular events and mortality.[](https://emedicine.medscape.com/article/243492-overview)\n\n### Chronic Kidney Disease Stages\n\nChronic kidney disease (CKD) staging relies on estimated glomerular filtration rate (eGFR), calculated from serum creatinine levels adjusted for age, sex, and race, to quantify the degree of kidney function loss.[](https://www.kidney.org/kidney-topics/estimated-glomerular-filtration-rate-egfr) The system, refined in guidelines from the Kidney Disease: Improving Global Outcomes (KDIGO) organization and the National Kidney Foundation (NKF), divides CKD into five stages (G1â€“G5) based on eGFR thresholds, with stage 3 subdivided into 3a and 3b for finer prognostic assessment; staging requires confirmation over at least three months to distinguish from acute changes.[](https://kdigo.org/wp-content/uploads/2024/03/KDIGO-2024-CKD-Guideline.pdf) [](https://www.kidney.org/how-to-classify-ckd) This GFR-based classification predicts risks of progression to end-stage kidney disease (ESKD), cardiovascular events, and mortality, with lower eGFR correlating to exponentially higher hazardsâ€”e.g., eGFR below 60 mL/min/1.73 mÂ² doubles five-year ESKD risk compared to higher levels in population studies.[](https://www.ncbi.nlm.nih.gov/books/NBK535404/) Albuminuria categories (A1: \u003c30 mg/g; A2: 30â€“300 mg/g; A3: \u003e300 mg/g, measured via urine albumin-to-creatinine ratio) overlay GFR stages to refine risk, as higher albuminuria accelerates progression independently of GFR in longitudinal cohorts.[](https://www.kidney.org/how-to-classify-ckd) [](https://kdigo.org/guidelines/ckd-evaluation-and-management/)\n\n| GFR Category | eGFR (mL/min/1.73 mÂ²) | Description |\n|--------------|-----------------------|-------------|\n| G1          | â‰¥90                  | Normal or high kidney function with markers of damage (e.g., persistent albuminuria â‰¥30 mg/g or structural abnormalities like cysts).[](https://www.kidney.org/kidney-topics/stages-chronic-kidney-disease-ckd) |\n| G2          | 60â€“89                | Mildly decreased function, often asymptomatic but with damage indicators; progression risk low unless albuminuria present.[](https://www.kidney.org/kidney-topics/stages-chronic-kidney-disease-ckd) |\n| G3a         | 45â€“59                | Mild to moderate decrease; subtle symptoms like fatigue may emerge, with elevated cardiovascular risk (hazard ratio ~1.4 for events vs. G1).[](https://www.kidney.org/kidney-topics/stages-chronic-kidney-disease-ckd) [](https://www.ncbi.nlm.nih.gov/books/NBK535404/) |\n| G3b         | 30â€“44                | Moderate to severe decrease; anemia, bone mineral changes, and hypertension complications more common, prompting specialist referral.[](https://www.kidney.org/kidney-topics/stages-chronic-kidney-disease-ckd) |\n| G4          | 15â€“29                | Severe decrease; uremic symptoms (e.g., nausea, pruritus) intensify, with preparation for dialysis or transplant advised as ESKD nears within 1â€“2 years absent intervention.[](https://www.kidney.org/kidney-topics/stages-chronic-kidney-disease-ckd) [](https://www.ncbi.nlm.nih.gov/books/NBK535404/) |\n| G5          | \u003c15                  | Kidney failure (ESKD); requires dialysis or transplantation for survival, with untreated mortality exceeding 50% within months from uremia and fluid overload.[](https://www.kidney.org/kidney-topics/stages-chronic-kidney-disease-ckd) [](https://www.ncbi.nlm.nih.gov/books/NBK535404/) |\n\nManagement escalates by stage: early stages (G1â€“G2) emphasize risk factor control (e.g., blood pressure \u003c130/80 mmHg via ACE inhibitors) to slow progression, evidenced by trials showing 20â€“30% GFR decline reduction with renin-angiotensin blockade in proteinuric patients.[](https://kdigo.org/wp-content/uploads/2024/03/KDIGO-2024-CKD-Guideline.pdf) Later stages (G4â€“G5) involve multidisciplinary care, including erythropoietin for anemia (hemoglobin target 10â€“11.5 g/dL to avoid transfusion risks) and phosphate binders to mitigate vascular calcification, as hyperphosphatemia in G3bâ€“G5 associates with 1.5â€“2-fold higher mortality in registries.[](https://www.ncbi.nlm.nih.gov/books/NBK535404/) Staging informs personalized prognostication tools like the Kidney Failure Risk Equation, which integrates age, sex, eGFR, and albuminuria to predict two-year ESKD probability with \u003e90% accuracy in validation studies.[](https://kdigo.org/guidelines/ckd-evaluation-and-management/) Limitations include eGFR overestimation in muscular individuals or underestimation in elderly due to creatinine variability, prompting KDIGO 2024 recommendations for cystatin C confirmation in ambiguous cases.[](https://kdigo.org/wp-content/uploads/2024/03/KDIGO-2024-CKD-Guideline.pdf)\n\n## Epidemiology\n\n### Global Prevalence and Incidence\n\nApproximately 10% of the global adult population is affected by chronic kidney disease (CKD), corresponding to an estimated 697.5 million cases as of 2017, with the age-standardized prevalence at 9.1%.[](https://bmcpublichealth.biomedcentral.com/articles/10.1186/s12889-025-21851-z) More recent estimates place the total burden at 674 million individuals, or about 9% of the world population, though figures up to 850 million have been reported, reflecting variations in diagnostic criteria and underreporting in low-resource settings.[](https://apps.who.int/gb/ebwha/pdf_files/EB156/B156_CONF6-en.pdf)[](https://www.nature.com/articles/s41581-024-00820-6) The global median prevalence of CKD stands at 9.5% (interquartile range 5.9â€“11.7%), with higher rates observed in regions like Central and Eastern Europe due to aging populations and comorbidities such as diabetes and hypertension.[](https://www.thelancet.com/journals/langlo/article/PIIS2214-109X%2824%2900050-0/fulltext)\n\nThe prevalence of CKD has risen substantially over time, increasing by 33% globally between 1990 and 2017, driven by epidemiological transitions including rising obesity, diabetes, and hypertension in low- and middle-income countries.[](https://www.nature.com/articles/s41581-024-00820-6) Age-standardized prevalence for CKD stages 3â€“5 among adults aged 20 years and older is approximately 4.7% in men and 5.8% in women.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC9073222/) Incidence rates for advanced CKD, particularly kidney failure requiring replacement therapy, reached 4.59 million cases globally in 2023, with an age-standardized prevalence of treated kidney failure at varying levels across regions.[](https://www.healthdata.org/research-analysis/library/global-regional-and-national-prevalence-kidney-failure-replacement)\n\nAcute kidney injury (AKI), distinct from CKD but often a precursor, affects an estimated 13.3 million people annually worldwide, with incidence rates in hospitalized patients ranging from 3.2% to 20% and up to 45% in intensive care units.[](https://www.sciencedirect.com/science/article/abs/pii/S0270929523001766)[](https://academic.oup.com/ckj/article/18/6/sfaf169/8151575)[](https://pmc.ncbi.nlm.nih.gov/articles/PMC3891141/) AKI incidence is notably higher in low- and middle-income countries, where factors like infections, dehydration, and limited access to care predominate, compared to high-income settings where iatrogenic causes such as surgery and nephrotoxins are more common.[](https://kdigo.org/wp-content/uploads/2018/02/2.-Mehta-KDIGO-AKI-Conference_Global-Burden.pdf) Age- and sex-standardized incidence rates for AKI hover around 134â€“162 events per 10,000 person-years across regions.[](https://www.kidney-international.org/article/S0085-2538%2822%2900267-8/fulltext) Underascertainment remains a challenge, particularly in community settings outside hospitals, potentially underestimating the true global burden.[](https://www.thelancet.com/journals/langas/article/PIIS2468-1253%2825%2900006-8/fulltext)\n\n### Demographic Risk Patterns\n\nCKD prevalence escalates with advancing age, reflecting cumulative exposure to risk factors such as hypertension and diabetes, as well as age-related declines in renal function. In the United States, data from 2023 indicate that 34% of adults aged 65 or older have CKD, compared to 12% of those aged 45-64 and 6% of individuals aged 18-44.[](https://www.cdc.gov/kidney-disease/php/data-research/index.html) Globally, population aging has driven a sustained increase in CKD burden since 1990, with older age groups bearing the majority of disability-adjusted life years (DALYs) lost to the disease.[](https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-025-04309-7)\n\n![Global map of kidney disease deaths per million persons (WHO 2012)](./_assets_/Kidney_diseases_world_map-Deaths_per_million_persons-WHO2012.svg.png)\n\nSex-based patterns show higher CKD prevalence among women than men, attributed in part to women's longer life expectancy and higher rates of autoimmune conditions affecting the kidneys, though men experience faster progression to end-stage kidney disease (ESKD) once diagnosed. U.S. estimates from 2017-2020 report 15.4% prevalence in women versus 12.6% in men.[](https://usrds-adr.niddk.nih.gov/2024/chronic-kidney-disease/1-ckd-in-the-general-population) Similar disparities appear in European cohorts, where age-adjusted prevalence ranges from 3.3% to 9.5% across groups but remains elevated in women overall.[](https://academic.oup.com/ndt/article/39/7/1194/7603988)\n\nRacial and ethnic variations in CKD risk are pronounced, linked to genetic predispositions like APOL1 variants in individuals of African ancestry, alongside socioeconomic factors influencing access to care and exposure to comorbidities. In the U.S., non-Hispanic Black adults face the highest prevalence at 18.9%, followed by American Indian/Alaska Native populations; Hispanic adults have rates around 14%, while non-Hispanic White rates are lower at approximately 13%.[](https://usrds-adr.niddk.nih.gov/2022/chronic-kidney-disease/1-ckd-in-the-general-population) [](https://www.cdc.gov/kidney-disease/media/pdfs/CKD-Factsheet-H.pdf) These patterns persist across age and sex subgroups, with Black individuals showing elevated risks even after adjusting for hypertension and diabetes.[](https://usrds-adr.niddk.nih.gov/2024/chronic-kidney-disease/2-identification-and-care-of-patients-with-ckd)\n\n| Demographic Group (U.S. Adults, 2023) | CKD Prevalence (%) |\n|---------------------------------------|---------------------|\n| Non-Hispanic Black                    | ~19                |\n| Hispanic                              | 14                 |\n| Non-Hispanic White                    | ~13                |\n| Overall Women                         | 15.4               |\n| Overall Men                           | 12.6               |\n| Aged â‰¥65 years                        | 34                 |[](https://www.cdc.gov/kidney-disease/media/pdfs/CKD-Factsheet-H.pdf)[](https://usrds-adr.niddk.nih.gov/2024/chronic-kidney-disease/1-ckd-in-the-general-population)[](https://www.cdc.gov/kidney-disease/php/data-research/index.html)\n\nGeographically, CKD risk clusters in regions with high metabolic syndrome prevalence, such as the U.S. \"diabetes belt,\" and in low socio-demographic index (SDI) areas where infectious and environmental toxins predominate. Globally, the age-standardized incidence of kidney failure rose from 2019-2023, with disproportionate impacts in aging populations of East Asia and low-income countries.[](https://www.journalrip.com/Inpress/jrip-38655.pdf) In high-income settings, incidence rates for kidney replacement therapy range from 89-378 per million, versus 22-222 per million in Central/Eastern Europe and lower in developing regions, underscoring causal roles of both affluence-driven comorbidities and resource-limited prevention.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC7710841/)\n\n## Pathophysiology\n\n### Core Mechanisms of Renal Damage\n\nRenal damage fundamentally arises from disruptions in the kidney's microvasculature, tubular epithelium, glomeruli, and interstitium, leading to impaired filtration, reabsorption, and secretion. Primary initiating mechanisms include ischemia-reperfusion injury, nephrotoxic insults, and inflammatory cascades, which converge on cellular pathways of necrosis, apoptosis, and necroptosis in proximal tubular cells.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC3919808/) These processes cause ATP depletion, mitochondrial dysfunction, and reactive oxygen species (ROS) accumulation, exacerbating endothelial permeability and vascular rarefaction.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC3204829/) Oxidative stress amplifies damage by oxidizing lipids, proteins, and DNA, while inflammation recruits macrophages and T-cells that release cytokines like TNF-Î± and IL-1Î², perpetuating a cycle of epithelial injury and maladaptive repair.[](https://www.nature.com/articles/s41392-022-01036-5)[](https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-025-04077-4)\n\nIschemic injury, common in hypoperfusion states, triggers endothelial cell activation and vasoconstriction via endothelin and thromboxane, reducing glomerular filtration rate (GFR) through afferent arteriolar narrowing.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC3919808/) Tubular epithelial cells respond with endoplasmic reticulum stress and unfolded protein response, leading to blebbing, brush border loss, and cast formation that obstructs tubular flow.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC9338906/) Reperfusion paradoxically worsens outcomes by generating ROS bursts and complement activation, promoting leukocyte infiltration and further parenchymal necrosis.[](https://www.jci.org/articles/view/45161) In severe cases, such as acute cortical necrosis, widespread vascular thrombosis and fibrinoid changes result in irreversible glomerular and tubular infarction.[](https://www.ncbi.nlm.nih.gov/books/NBK507815/)\n\nNephrotoxic mechanisms involve direct cellular uptake of agents like aminoglycosides or cisplatin, which impair mitochondrial respiration and induce lysosomal rupture in proximal tubules.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC3919808/) Heavy metals and contrast media provoke similar ATP-independent toxicity via calcium overload and phospholipase activation, culminating in tubular dilation and proteinaceous casts.[](https://www.mdpi.com/2077-0383/12/1/375) These insults often synergize with ischemia, as seen in sepsis-induced AKI, where bacterial endotoxins heighten vulnerability through Toll-like receptor signaling.[](https://academic.oup.com/ckj/article/14/3/780/5934685)\n\nProgression to chronic damage hinges on fibrogenic responses, where surviving epithelial cells undergo epithelial-mesenchymal transition (EMT), secreting transforming growth factor-Î² (TGF-Î²) to activate interstitial myofibroblasts.[](https://www.nature.com/articles/s41392-023-01379-7) This drives extracellular matrix (ECM) deposition of collagen types I and III, interstitial expansion, and glomerulosclerosis, with peritubular capillary rarefaction impairing oxygen delivery and fueling hypoxia-inducible factor (HIF) pathways.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC5351778/) Inflammatory persistence, via NF-ÎºB activation, sustains chemokine production (e.g., MCP-1), recruiting fibrocytes that amplify scarring independent of initial insults.[](https://www.kidney-international.org/article/S0085-2538%2815%2954475-X/fulltext) Maladaptive repair post-AKI, rather than regeneration, underlies transition to CKD, with incomplete tubular dedifferentiation preventing full nephron recovery.[](https://www.mdpi.com/2218-273X/15/6/794)\n\n### Progression from Acute to Chronic\n\nAcute kidney injury (AKI) transitions to chronic kidney disease (CKD) when initial tubular epithelial cell damage fails to resolve fully, leading to maladaptive repair characterized by persistent inflammation, epithelial-mesenchymal transition, and progressive fibrosis.[](https://pubmed.ncbi.nlm.nih.gov/39298548/) This process involves incomplete regeneration of nephrons, where surviving cells undergo maladaptive changes such as G2/M cell-cycle arrest, cellular senescence, and epigenetic reprogramming, which perpetuate tissue remodeling and extracellular matrix deposition.[](https://www.mdpi.com/2218-273X/15/6/794) Mitochondrial dysfunction and metabolic shifts, including altered lipid metabolism and oxidative stress, further exacerbate endothelial and podocyte injury, impairing vascular integrity and glomerular filtration over time.[](https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-025-04077-4)\n\nThe incidence of CKD following AKI varies by severity and context; systematic reviews report pooled rates of incident CKD at approximately 25.8 per 100 person-years and end-stage renal disease at 8.6 per 100 person-years among survivors.[](https://pubmed.ncbi.nlm.nih.gov/22113526/) For milder AKI, incident CKD occurs at 6.6 per 100 person-years, rising with prolonged recovery; over 20-year follow-up, CKD risk reaches 26.3% even in cases of rapid AKI reversal.[](https://www.kidney-international.org/article/S0085-2538%2815%2955323-4/fulltext) [](https://www.kireports.org/article/S2468-0249%2824%2900044-5/fulltext) Cumulative CKD incidence at 5 years post-AKI can approach 30%, particularly in trajectories showing linear eGFR decline.[](https://eymj.org/DOIx.php?id=10.3349/ymj.2023.0306)\n\nKey risk factors accelerating this progression include advanced age, pre-existing comorbidities such as diabetes and hypertension, repeated AKI episodes, and genetic predispositions influencing repair pathways.[](https://eymj.org/DOIx.php?id=10.3349/ymj.2023.0306) Patients with baseline CKD face heightened susceptibility due to suppressed reparative signaling in tubular cells, compounded by factors like metabolic syndrome and sustained uremic toxin exposure, which promote inflammation and ferroptosis.[](https://www.kidney-international.org/article/S0085-2538%2817%2930499-4/fulltext) [](https://www.mdpi.com/1422-0067/24/22/16152) Early post-AKI eGFR loss and persistent azotemia signal higher transition risk, underscoring the need for vigilant monitoring to interrupt fibrotic cascades.[](https://academic.oup.com/ckj/article/15/12/2237/6652220)\n\n## Causes and Risk Factors\n\n### Metabolic and Vascular Contributors\n\nDiabetes mellitus is the leading cause of chronic kidney disease (CKD) globally, with diabetic kidney disease developing in approximately 40% of diabetic patients through mechanisms involving hyperglycemia-induced glomerular hyperfiltration, oxidative stress, and podocyte injury.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC5718284/) Hyperglycemia promotes advanced glycation end-products that damage renal vasculature and interstitium, accelerating progression to end-stage renal disease (ESRD).[](https://pmc.ncbi.nlm.nih.gov/articles/PMC10588295/)\n\nHypertension independently contributes to CKD by inducing afferent arteriolar sclerosis and glomerular ischemia, with sustained elevations in blood pressure directly correlating with renal function decline; studies show it increases ESRD risk by impairing autoregulation in renal arterioles.[](https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-020-02151-7) [](https://pubmed.ncbi.nlm.nih.gov/37053276/)\n\nMetabolic syndrome, encompassing central obesity, dyslipidemia, insulin resistance, and hypertension, synergistically elevates CKD incidence, with affected individuals facing up to twofold higher risk due to combined endothelial dysfunction and inflammatory pathways.[](https://onlinelibrary.wiley.com/doi/10.1111/obr.13649) Obesity exacerbates this via adipokine dysregulation and intrarenal fat deposition, where a body mass index increase exceeding 10% from baseline heightens CKD onset by approximately 30% in longitudinal cohorts.[](https://academic.oup.com/ckj/article/16/11/1737/7143784) Dyslipidemia, particularly hypertriglyceridemia and low HDL, fosters renal lipid accumulation and foam cell formation, further promoting tubulointerstitial fibrosis independent of diabetes.[](https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2022.904001/full)\n\nVascular factors such as atherosclerosis underlie renovascular disease, where plaque buildup narrows renal arteries, reducing perfusion and triggering ischemic nephropathy; atherosclerotic renal artery stenosis accounts for over 90% of cases and frequently culminates in CKD among those with bilateral involvement.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC8598311/) Renal artery stenosis impairs pressure-flow dynamics, leading to renin-mediated hypertension that perpetuates a vicious cycle of vascular remodeling and parenchymal atrophy.[](https://www.ncbi.nlm.nih.gov/books/NBK430718/) Endothelial dysfunction from systemic atherosclerosis also manifests intrarenally, with reduced nitric oxide bioavailability contributing to microvascular rarefaction observed in advanced CKD.[](https://www.ajkd.org/article/S0272-6386%2821%2900776-9/fulltext)\n\n### Genetic and Congenital Factors\n\nInherited kidney diseases account for approximately 10-15% of cases of early-onset chronic kidney disease, with genetic variants identifiable in about 10% of adults and up to 20-50% of pediatric cohorts requiring dialysis or transplantation.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC8323147/)[](https://karger.com/ajn/article/53/4/297/827404/Genetic-Etiologies-for-Chronic-Kidney-Disease) Over 625 genes have been linked to chronic kidney disease development, often through monogenic mutations disrupting renal structure, filtration, or tubular function.[](https://www.sciencedirect.com/science/article/pii/S2590059522000425) These conditions frequently manifest as progressive glomerular or tubulointerstitial damage, independent of common acquired risks like diabetes or hypertension.\n\nAutosomal dominant polycystic kidney disease (ADPKD), the most prevalent monogenic kidney disorder, arises from heterozygous mutations in *PKD1* (encoding polycystin-1) in 85% of cases or *PKD2* (polycystin-2) in 15%, leading to cyst formation, renal enlargement, and end-stage renal disease by age 60 in many patients.[](https://www.ncbi.nlm.nih.gov/books/NBK532934/) Less commonly, mutations in genes like *GANAB* contribute, with disease penetrance nearing 100% by age 80 due to disrupted ciliary signaling and fluid secretion in tubular epithelia.[](https://www.ncbi.nlm.nih.gov/books/NBK532934/) Alport syndrome, another hereditary nephropathy, results from mutations in type IV collagen genes (*COL4A3*, *COL4A4*, or *COL4A5*), causing basement membrane defects that provoke hematuria, proteinuria, and progression to end-stage kidney disease, often by the third decade in males with X-linked forms.[](https://www.ncbi.nlm.nih.gov/books/NBK470419/) These genetic etiologies underscore disrupted extracellular matrix integrity and podocyte function as core pathogenic mechanisms.[](https://www.ncbi.nlm.nih.gov/books/NBK470419/)\n\nCongenital anomalies of the kidney and urinary tract (CAKUT) represent structural malformations present at birth, occurring in 0.3-1.6 per 1,000 live births and comprising 20-30% of all pediatric renal disorders, with many linked to genetic factors like *PAX2* or *HNF1B* mutations.[](https://www.dynamed.com/condition/overview-of-congenital-anomalies-of-the-kidney-and-urinary-tract-cakut/PlatformHomeAbout)[](https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2024.1384676/full) CAKUT accounts for 40-50% of chronic kidney failure cases in children, encompassing conditions such as renal agenesis (unilateral in 1:1,000-2,000 births), dysplasia, and obstructive uropathies like posterior urethral valves, which impair nephrogenesis or urine flow and precipitate hydronephrosis or vesicoureteral reflux.[](https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2024.1384676/full) While some cases stem from multifactorial inheritance or de novo variants, early detection via prenatal ultrasound enables intervention to mitigate progression to chronic kidney disease.[](https://publications.aap.org/neoreviews/article/25/2/e78/196493/Congenital-Anomalies-of-the-Kidneys-and-Urinary)\n\n### Toxic, Infectious, and Lifestyle Triggers\n\nNephrotoxic agents, including certain medications and environmental toxins, contribute to both acute kidney injury (AKI) and progression of chronic kidney disease (CKD) through mechanisms such as tubular damage, interstitial nephritis, and glomerular injury.[](https://www.ncbi.nlm.nih.gov/books/NBK553144/) Common pharmaceuticals implicated include nonsteroidal anti-inflammatory drugs (NSAIDs), which inhibit renal prostaglandins and reduce glomerular filtration rate, particularly in volume-depleted patients; aminoglycoside antibiotics, which accumulate in proximal tubules causing necrosis; and iodinated contrast media used in imaging, leading to vasoconstriction and direct cytotoxicity in up to 17% of AKI cases attributed to drugs.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC4270362/) Heavy metals like arsenic, cadmium, and lead, often from occupational or environmental exposure, induce oxidative stress and fibrosis, with systematic reviews linking chronic low-level exposure to elevated CKD risk and end-stage renal disease incidence.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC6590508/)\n\nInfectious agents provoke kidney disease via direct invasion, immune-mediated damage, or systemic effects like sepsis. Bacterial infections, such as *Escherichia coli* causing pyelonephritis, ascend from the urinary tract and inflame renal parenchyma, potentially leading to abscesses or scarring if untreated; sepsis from gram-negative bacteria accounts for a significant portion of AKI in hospitalized patients.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC6282040/) Viral pathogens including HIV, hepatitis B, and hepatitis C viruses establish chronic infections that accelerate glomerular sclerosis and proteinuria, with HIV-associated nephropathy featuring collapsing focal segmental glomerulosclerosis in up to 10% of untreated cases.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC7121468/) Parasitic infections like schistosomiasis (*Schistosoma haematobium*) and malaria (*Plasmodium* spp.) cause obstructive uropathy or hemolytic-uremic syndromes, respectively, with evidence from endemic regions showing associations with CKD in 20 parasite species affecting humans.[](https://www.ajkd.org/article/S0272-6386%2812%2901509-0/fulltext)\n\nLifestyle factors independently elevate kidney disease risk through vascular, metabolic, and inflammatory pathways. Smoking accelerates CKD progression by promoting endothelial dysfunction and proteinuria, with cohort studies indicating a dose-dependent increase in incidence among current smokers compared to never-smokers.[](https://pure.johnshopkins.edu/en/publications/lifestyle-factors-obesity-and-the-risk-of-chronic-kidney-disease-5) Obesity, defined by BMI â‰¥30 kg/mÂ², correlates with hyperfiltration and glomerular hypertension, contributing to CKD onset in morbidly obese individuals via adipokine dysregulation and insulin resistance.[](https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-022-02745-3) Physical inactivity and diets high in processed foods exacerbate risks, while excessive alcohol consumption shows inconsistent links, with no broad association except for high-proof distilled spirits like moonshine potentially causing lead contamination-related damage.[](https://www.sciencedirect.com/science/article/abs/pii/S1047279703000668) Modifiable behaviors such as tobacco cessation and weight management can mitigate progression, as evidenced by longitudinal data linking healthier profiles to slower eGFR decline.[](https://journals.lww.com/kidney360/fulltext/2022/04000/modifiable_lifestyle_behaviors_and_ckd.24.aspx)\n\n## Diagnosis\n\n### Symptoms and Clinical Signs\n\nKidney disease manifests through a spectrum of symptoms and clinical signs that vary by acuity and stage, with acute kidney injury (AKI) often presenting abruptly and chronic kidney disease (CKD) progressing insidiously, frequently remaining asymptomatic in early phases.[](https://www.ncbi.nlm.nih.gov/books/NBK441896/)[](https://www.mayoclinic.org/diseases-conditions/chronic-kidney-disease/symptoms-causes/syc-20354521) In AKI, patients commonly report decreased urine output (oliguria) or anuria, alongside fluid retention leading to edema in the legs, ankles, or feet and shortness of breath from pulmonary congestion.[](https://www.mayoclinic.org/diseases-conditions/kidney-failure/symptoms-causes/syc-20369048)[](https://www.kidney.org/kidney-topics/acute-kidney-injury-aki) Fatigue, nausea, and confusion may arise due to uremic toxin accumulation, with severe cases progressing to seizures, coma, or chest pain from pericardial effusion.[](https://www.ncbi.nlm.nih.gov/books/NBK568593/)\n\nFor CKD, symptoms typically emerge in stages 3â€“5 (glomerular filtration rate \u003c60 mL/min/1.73 mÂ²), including fatigue and weakness from anemia or electrolyte imbalances, loss of appetite, nausea, and unintentional weight loss.[](https://www.mayoclinic.org/diseases-conditions/chronic-kidney-disease/symptoms-causes/syc-20354521)[](https://www.ncbi.nlm.nih.gov/books/NBK535404/) Changes in urination such as nocturia, polyuria, or foamy urine (indicating proteinuria) are frequent, accompanied by pruritus and dry skin from phosphate retention.[](https://www.kidney.org/kidney-topics/chronic-kidney-disease-ckd)[](https://www.kidney.org/news-stories/10-signs-you-may-have-kidney-disease) Cognitive effects like decreased mental sharpness, sleep disturbances, and muscle cramps further contribute to reduced quality of life.[](https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-017-0638-y)\n\nClinical signs in both conditions include hypertension, often exacerbated by sodium retention and renin-angiotensin activation, and peripheral edema reflecting impaired sodium excretion.[](https://www.ncbi.nlm.nih.gov/books/NBK535404/) In advanced CKD, observable features encompass pallor from anemia, uremic frost (rare crystalline urea deposits on skin), and scratch marks from pruritus-induced excoriations.[](https://www.ncbi.nlm.nih.gov/books/NBK535404/) Cardiac signs such as left ventricular hypertrophy or fluid overload-related dyspnea indicate systemic involvement, while AKI may show rapid rises in serum creatinine alongside these.[](https://www.ncbi.nlm.nih.gov/books/NBK441896/)[](https://jamanetwork.com/journals/jama/fullarticle/2542635) Early detection relies on recognizing nonspecific signs like persistent fatigue or edema, as overt symptoms correlate with poorer prognosis.[](https://www.kidney.org/kidney-topics/signs-and-symptoms-kidney-disease)[](https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-017-0638-y)\n\n### Diagnostic Tests and Biomarkers\n\nDiagnosis of kidney disease relies primarily on laboratory assessments of glomerular filtration rate (GFR) and markers of kidney damage. Estimated GFR (eGFR) is calculated from serum creatinine levels using equations such as the CKD-EPI formula, which incorporates age, sex, and race; values below 60 mL/min/1.73 mÂ² for three months or more indicate chronic kidney disease (CKD).[](https://kdigo.org/wp-content/uploads/2024/03/KDIGO-2024-CKD-Guideline.pdf) Blood urea nitrogen (BUN) levels provide supportive evidence of reduced kidney function, though they are influenced by factors like dehydration and diet.[](https://www.mayoclinic.org/diseases-conditions/chronic-kidney-disease/diagnosis-treatment/drc-20354527)\n\nUrine tests detect proteinuria or albuminuria, key indicators of glomerular damage. The urine albumin-to-creatinine ratio (uACR) is preferred over total proteinuria, with levels above 30 mg/g signaling early CKD; spot urine samples suffice for screening, while 24-hour collections offer precision in ambiguous cases.[](https://kdigo.org/wp-content/uploads/2024/03/KDIGO-2024-CKD-Guideline.pdf) Urinalysis identifies hematuria, casts, or crystals, aiding differentiation of causes like glomerulonephritis or infection.[](https://www.kidneyfund.org/all-about-kidneys/tests-kidney-disease)\n\nImaging modalities assess structural abnormalities. Renal ultrasound, the initial choice due to its non-invasiveness and low cost, evaluates kidney size, echogenicity, and obstruction; small kidneys (\u003c9-10 cm) suggest chronicity.[](https://kdigo.org/guidelines/ckd-evaluation-and-management/) Computed tomography (CT) or magnetic resonance imaging (MRI) is reserved for suspected stones, cysts, or tumors, though contrast agents pose risks in impaired renal function.[](https://www.mayoclinic.org/diseases-conditions/chronic-kidney-disease/diagnosis-treatment/drc-20354527)\n\nRenal biopsy provides histopathological confirmation when etiology remains unclear, such as in nephrotic syndrome, rapidly progressive glomerulonephritis, or unexplained acute kidney injury (AKI) with persistent dysfunction.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC8813013/) Performed percutaneously under ultrasound guidance, it involves risks including macroscopic hematuria (5-10% incidence), perinephric hematoma (up to 90% subclinical), and rare arteriovenous fistula formation; contraindications include uncontrolled hypertension or bleeding diathesis.[](https://www.mayoclinic.org/tests-procedures/kidney-biopsy/about/pac-20394494) [](https://www.uptodate.com/contents/the-kidney-biopsy)\n\nEmerging biomarkers enhance early detection beyond traditional markers. For AKI, neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury molecule-1 (KIM-1) in urine predict tubular injury hours before creatinine rises, with NGAL showing sensitivity in cardiac surgery cohorts.[](https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-025-04040-3) The product of urinary tissue inhibitor of metalloproteinases-2 (TIMP-2) and insulin-like growth factor-binding protein 7 (IGFBP7) outperforms other panels for risk stratification in critically ill patients, as validated in the Sapphire trial.[](https://annalsofintensivecare.springeropen.com/articles/10.1186/s13613-024-01360-9) In CKD, cystatin C offers a more accurate eGFR estimate independent of muscle mass, while soluble urokinase plasminogen activator receptor (suPAR) correlates with progression risk, though routine clinical adoption awaits larger validation studies.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC12110191/) These biomarkers, derived from peer-reviewed cohorts, promise refined prognostication but require integration with standard tests for causal attribution.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC11512660/)\n\n## Treatment and Management\n\n### Supportive Care for Acute Cases\n\nSupportive care in acute kidney injury (AKI) focuses on stabilizing hemodynamics, correcting metabolic derangements, and preventing additional renal insult pending resolution of the precipitating cause, such as hypovolemia, sepsis, or obstruction.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC11084889/) This approach emphasizes individualized management to maintain renal perfusion without exacerbating injury from overload or under-resuscitation.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC11084889/) Evidence from randomized controlled trials, including the SMART and CLASSIC studies, supports tailored interventions over liberal fluid strategies, as excessive volumes associate with worsened outcomes like prolonged ventilation and higher mortality.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC11084889/)\n\nHemodynamic optimization targets a mean arterial pressure of 65-85 mmHg, adjusted for patient comorbidities, using volume assessment via physical exam, point-of-care ultrasound (e.g., inferior vena cava collapsibility or VExUS scoring), or dynamic maneuvers like passive leg raising.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC11084889/) In hypovolemic states, initial resuscitation employs balanced crystalloids (e.g., Plasma-Lyte or lactated Ringer's) at doses guided by response rather than fixed boluses like 30 mL/kg, as hyperchloremic acidosis from normal saline can impair renal function.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC11084889/)[](https://www.aafp.org/pubs/afp/issues/2019/1201/p687.html) If fluids alone fail, vasopressorsâ€”norepinephrine as first-line, with vasopressin as an adjunct in septic shockâ€”preserve perfusion; vasopressin may confer renal benefits by reducing norepinephrine requirements and mitigating vasoconstriction.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC11084889/)\n\nFluid balance monitoring is critical, aiming for neutral or negative balance in oliguric AKI to avert pulmonary edema and intra-abdominal hypertension, which independently predict non-recovery; conservative strategies in perioperative settings have reduced AKI duration compared to liberal ones in meta-analyses.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC11084889/) Diuretics like furosemide are reserved for volume overload unresponsive to fluids, not for converting oliguric to non-oliguric AKI, as routine use lacks efficacy and risks worsening depletion.[](https://www.aafp.org/pubs/afp/issues/2019/1201/p687.html)\n\nElectrolyte and acid-base management addresses common imbalances: hyperkalemia (\u003e6.5 mEq/L or with ECG changes) warrants stabilization with calcium gluconate, followed by shifting agents (insulin-glucose, beta-agonists, or sodium bicarbonate) and, if refractory, dialysis; hyponatremia correction avoids rapid shifts to prevent osmotic demyelination.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC11084889/) Hyperphosphatemia and metabolic acidosis are monitored, with phosphate binders or bicarbonate considered based on severity, though evidence for routine buffering in non-severe cases is limited.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC11084889/)\n\nMinimizing nephrotoxins involves immediate discontinuation of agents like NSAIDs, aminoglycosides, and contrast media, alongside dose adjustments for renally cleared drugs using estimated glomerular filtration rate or pharmacokinetic monitoring to prevent accumulation (e.g., reduced cefepime dosing in stage 3 AKI).[](https://pmc.ncbi.nlm.nih.gov/articles/PMC11084889/)[](https://www.aafp.org/pubs/afp/issues/2019/1201/p687.html) Pharmacist-led protocols have demonstrated up to 64% reductions in nephrotoxic exposures.[](https://www.aafp.org/pubs/afp/issues/2019/1201/p687.html) Nutritional support prioritizes enteral over parenteral routes, limiting protein to 0.8-1.0 g/kg/day in azotemia to curb uremia while ensuring caloric needs (25-30 kcal/kg/day) to support recovery, with evidence from cohort studies linking early nutrition to shorter AKI duration.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC11084889/)\n\nClose monitoring includes serial serum creatinine, urine output (target \u003e0.5 mL/kg/h), and biomarkers like cystatin C for early trends, with nephrology consultation recommended for persistent stage 2-3 AKI to guide escalation to renal replacement therapy if indications (e.g., refractory hyperkalemia, uremia, or overload) arise.[](https://www.aafp.org/pubs/afp/issues/2019/1201/p687.html) Glycemic control targeting 140-180 mg/dL reduces infection risk without proven direct renal benefit in AKI.[](https://www.aafp.org/pubs/afp/issues/2019/1201/p687.html)\n\n### Progression Control in Chronic Cases\n\nControl of chronic kidney disease (CKD) progression involves targeted interventions to mitigate glomerular filtration rate (GFR) decline, reduce proteinuria, and avert end-stage kidney disease (ESKD), with evidence from randomized trials and meta-analyses supporting multifaceted approaches. The Kidney Disease: Improving Global Outcomes (KDIGO) 2024 guidelines emphasize early risk assessment and multimodal strategies, including blood pressure management below 130/80 mmHg, particularly in proteinuric cases, to yield long-term benefits in delaying kidney failure.[](https://kdigo.org/wp-content/uploads/2024/03/KDIGO-2024-CKD-Guideline.pdf) These measures, when implemented comprehensively, have demonstrated up to 30-50% reductions in progression rates in high-risk cohorts, though individual responses vary based on baseline GFR and comorbidities.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC11399210/)\n\nRenin-angiotensin system (RAS) blockade with angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) constitutes foundational pharmacotherapy, especially for patients with hypertension, diabetes, or albuminuria exceeding 30 mg/day, as these agents confer renoprotective effects independent of blood pressure reduction by decreasing intraglomerular pressure and proteinuria. Meta-analyses of trials involving over 10,000 CKD patients show RAS inhibitors slow GFR decline by 2-4 mL/min/1.73 mÂ² per year compared to placebo or other antihypertensives, with benefits persisting in advanced stages (GFR \u003c30 mL/min/1.73 mÂ²) absent severe hyperkalemia.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC11905639/) [](https://www.nejm.org/doi/full/10.1056/NEJMoa2210639) Continuation of RAS therapy in stage 4-5 CKD, versus discontinuation, correlates with lower ESKD incidence in observational data adjusted for confounders, though monitoring for acute GFR drops (up to 30% initially) and potassium elevation is essential.[](https://www.ajkd.org/article/S0272-6386%2816%2900137-2/fulltext)\n\nSodium-glucose cotransporter-2 (SGLT2) inhibitors, such as dapagliflozin and empagliflozin, have emerged as disease-modifying agents across CKD etiologies, reducing progression risk by 30-40% in trials like DAPA-CKD and EMPA-KIDNEY, through mechanisms including afferent arteriolar vasodilation, reduced tubular hypoxia, and inflammation suppression, even in non-diabetic patients.[](https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2021.645187/full) These benefits accrue irrespective of baseline albuminuria or diabetes status, with number-needed-to-treat values of 12-20 over 2-4 years to prevent ESKD events.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC11399210/) Adjunctive therapies like mineralocorticoid receptor antagonists (e.g., finerenone) show promise in diabetic CKD by further curbing albuminuria and fibrosis, per phase 3 data, but require caution for hyperkalemia risk.[](https://www.sciencedirect.com/science/article/pii/S2214623724000255)\n\nNon-pharmacological measures complement drugs, with moderate protein intake capped at 0.8 g/kg/day in non-dialysis CKD to lessen uremic toxin load and GFR stress, supported by meta-analyses indicating 1-2 mL/min/1.73 mÂ² annual preservation versus unrestricted diets.[](https://kdigo.org/wp-content/uploads/2017/02/7.-Tangri-KDIGO-Presentation.pdf) Bicarbonate supplementation for metabolic acidosis (serum bicarbonate \u003c22 mEq/L) slows progression by 1-2 mL/min/1.73 mÂ² yearly in randomized studies, countering tubulointerstitial damage from chronic acidemia.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC4089661/) Lifestyle factors, including smoking cessation (reducing progression odds by 20-30% per cohort studies) and weight management via calorie-restricted diets, address obesity-driven hyperfiltration, while avoiding nephrotoxins like NSAIDs preserves function.[](https://journals.lww.com/md-journal/fulltext/2023/06090/comprehensive_review_of_current_management.13.aspx) Integrated care models, incorporating patient education and multidisciplinary follow-up, enhance adherence and outcomes, as evidenced by programs halving ESRD transitions in value-based settings.[](https://www.ajmc.com/view/value-based-care-interventions-and-management-of-ckd-progression) Regular monitoring of GFR, electrolytes, and albuminuria guides adjustments, prioritizing empirical response over rigid protocols.\n\n### Renal Replacement Therapies\n\nRenal replacement therapy (RRT) encompasses modalities that substitute for lost kidney function in patients with acute kidney injury (AKI) or end-stage renal disease (ESRD), primarily by removing waste products, excess fluid, and correcting electrolyte imbalances when conservative management fails. Indications include severe uremia (e.g., blood urea nitrogen \u003e100 mg/dL), refractory hyperkalemia (\u003e6.5 mEq/L), metabolic acidosis (pH \u003c7.15), or volume overload unresponsive to diuretics.[](https://hospitalhandbook.ucsf.edu/07-indications-dialysis/07-indications-dialysis) [](https://www.ncbi.nlm.nih.gov/books/NBK556028/) In ESRD, RRT is initiated when estimated glomerular filtration rate falls below 10-15 mL/min/1.73 mÂ² with symptoms, though timing debates persist without clear survival benefits from early versus delayed start in AKI.[](https://kdigo.org/wp-content/uploads/2024/03/KDIGO-2024-CKD-Guideline.pdf)\n\nDialysis, the most common RRT form, includes hemodialysis (HD) and peritoneal dialysis (PD). HD involves extracorporeal blood filtration via a dialyzer, typically performed thrice weekly for 3-5 hours per session using arteriovenous fistulas or grafts for access; it excels in rapid solute clearance but risks intradialytic hypotension from ultrafiltration and solute shifts.[](https://www.ncbi.nlm.nih.gov/books/NBK556028/) PD employs the peritoneal membrane as a natural filter by infusing dialysate into the abdomen, allowing continuous ambulatory or automated cycles; it offers home-based flexibility and better hemodynamic stability but carries peritonitis risk from bacterial contamination.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC10139729/) Continuous RRT (CRRT), used mainly in critically ill AKI patients, provides slow, steady clearance to minimize instability, though circuit clotting affects up to 30% of sessions due to inadequate anticoagulation or catheter issues.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC9717642/) [](https://journal.chestnet.org/article/S0012-3692%2818%2932478-4/fulltext)\n\nKidney transplantation represents the optimal long-term RRT, restoring near-normal function via donor organ implantation, with living donors yielding superior graft survival (median 15-20 years) over deceased donors (10-15 years).[](https://pharm.ucsf.edu/kidney/need/statistics) One-year patient survival post-transplant exceeds 94%, surpassing dialysis rates, while five-year survival reaches 80-90% versus under 50% on dialysis; however, allograft rejection (acute in 10-15%, chronic in 30-50% by five years) necessitates lifelong immunosuppression, elevating infection and malignancy risks.[](https://usrds-adr.niddk.nih.gov/2023/end-stage-renal-disease/6-mortality) [](https://www.sciencedirect.com/science/article/pii/S1600613523005786)\n\nSurvival comparisons favor transplantation over dialysis, where HD and PD yield similar adjusted mortality (hazard ratio ~1.0-1.2), though PD associates with higher early mortality in elderly patients (hazard ratio 1.17) due to technique failure and comorbidities.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC10139729/) [](https://karger.com/ger/article/70/5/461/896692/Mortality-of-Peritoneal-Dialysis-versus) RRT complications include vascular access thrombosis (20-30% annually in HD), infections (peritonitis in 0.2-0.5 episodes/patient-year for PD), and cardiovascular events, which account for 40-50% of dialysis deaths; no modality universally dominates, with choice guided by patient factors like age, vascular status, and lifestyle.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC9717642/) Evidence from registries like USRDS underscores dialysis as a bridge to transplant, where pre-transplant PD may confer slight graft advantage over HD in select cohorts.[](https://www.kidney-international.org/article/S0085-2538%2815%2948687-9/fulltext)\n\n## Prognosis and Complications\n\n### Short-Term Outcomes\n\nShort-term outcomes in kidney disease predominantly pertain to acute kidney injury (AKI), where in-hospital mortality rates typically range from 10% to 30%, varying by severity, comorbidities, and care setting.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC4931701/) 00021-9/fulltext) In critically ill patients, AKI elevates 30-day mortality to 17.5% versus 5.8% in non-AKI cohorts, driven by factors such as multi-organ failure and prolonged hospital stays.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC4931701/) Severe AKI (stage 3) in contexts like myocardial infarction yields in-hospital mortality up to 31.8%, compared to 2.1% without AKI.[](https://www.ahajournals.org/doi/10.1161/circulationaha.111.039909)\n\nRenal recovery post-AKI occurs in 40-70% of survivors within days to weeks, with complete recovery in about 44% of moderate-to-severe cases; however, partial recovery predominates, and failure to recover within 1-4 days correlates with higher short-term kidney failure risk.[](https://journals.lww.com/kidney360/fulltext/2022/02000/short__and_long_term_recovery_after.10.aspx) [](https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2764344) Duration and severity of AKI, alongside hyperkalemia and short hospital stays, independently predict 30-day in-hospital mortality.[](https://www.nature.com/articles/s41598-021-94946-3) Acute complications include fluid overload, electrolyte derangements, and sepsis exacerbation, often necessitating temporary renal replacement therapy, which further increases mortality odds by 2-3 fold in dialysis-requiring cases.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC4931701/)\n\nIn chronic kidney disease (CKD), short-term outcomes manifest during acute deteriorations or hospitalizations, where CKD patients exhibit 1.5-2 times higher admission rates and in-hospital mortality than non-CKD peers, particularly with infections or heart failure.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC7732055/) [](https://www.nature.com/articles/s41598-017-11861-2) For instance, CKD stage 4-5 elevates hospitalization risks and short-term death in heart failure by 20-40%, underscoring vulnerability to decompensation.[](https://www.thepermanentejournal.org/doi/10.7812/TPP/18.273) Rapid eGFR decline in CKD predicts prolonged stays and readmissions, with one-year post-hospitalization mortality reaching 16-44% across stages.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC4633789/) [](https://www.sciencedirect.com/science/article/pii/S0741521413007830)\n\n### Long-Term Risks and Mortality\n\n![Kidney diseases world map showing deaths per million persons (WHO 2012)](./_assets_/Kidney_diseases_world_map-Deaths_per_million_persons-WHO2012.svg.png)\n\nChronic kidney disease (CKD) substantially elevates the risk of cardiovascular disease, which manifests as accelerated atherosclerosis, left ventricular hypertrophy, and increased incidence of myocardial infarction and stroke due to uremic toxins, hypertension, and dyslipidemia.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC2474786/) Anemia arises from reduced erythropoietin production and contributes to fatigue, cardiovascular strain, and shortened erythrocyte lifespan.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC2474786/) Mineral and bone disorders, including hyperphosphatemia and secondary hyperparathyroidism, lead to vascular calcification and fragile bones prone to fractures.[](https://www.kidneyfund.org/living-kidney-disease/health-problems-caused-kidney-disease) Hyperkalemia and fluid retention heighten risks of arrhythmias and pulmonary edema, respectively.[](https://www.healthline.com/health/kidney-disease/complications-of-chronic-kidney-disease) Infections occur more frequently owing to uremia-induced immune dysfunction, while gout stems from uric acid accumulation.[](https://www.kidneyfund.org/living-kidney-disease/health-problems-caused-kidney-disease) Neurological complications, such as peripheral neuropathy and encephalopathy, emerge in advanced stages from toxin buildup.[](https://www.pennmedicine.org/conditions/end-stage-kidney-disease)\n\nIn end-stage renal disease (ESRD), progression to dialysis or transplantation amplifies these risks, with cardiovascular events predominating despite renal replacement therapy.[](https://karger.com/ajn/article/53/1/32/827379/Causes-of-Death-in-End-Stage-Kidney-Disease) Mortality in CKD patients exceeds that of the general population, with 5-year survival rates around 55% for those with CKD compared to 77% without, based on large cohort analyses.[](https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2788381) For patients on long-term dialysis, the 5-year survival rate is approximately 35%, declining further with age and comorbidities.[](https://www.healthline.com/health/kidney-disease/renal-failure-death-rate) In stage 3 CKD, all-cause mortality ranges from 6% over 3 years to 51% over 10 years across surveyed studies.[](https://www.webmd.com/a-to-z-guides/what-is-stage-3-kidney-disease-life-expectancy) Cardiovascular disease accounts for 40-50% of deaths in CKD, surpassing infection and withdrawal from dialysis as subsequent causes.[](https://www.sciencedirect.com/science/article/pii/S259005952300033X) In the United States, nephritis, nephrotic syndrome, and nephrosis caused 55,253 deaths in recent data, ranking as the 8th leading cause at 16.5 per 100,000 population.[](https://www.cdc.gov/nchs/fastats/kidney-disease.htm) Globally, age-adjusted CKD mortality rose from 15.95 to 18.35 per 100,000 between specified periods, projecting continued increases.[](https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-024-03720-w) Among Medicare beneficiaries aged 66 and older with CKD, unadjusted mortality fell over 20% in a decade to below 145 per 1,000 person-years, reflecting improvements in management yet persistent high burden.[](https://usrds-adr.niddk.nih.gov/2022/chronic-kidney-disease/3-morbidity-and-mortality-in-patients-with-ckd)\n\n## Prevention Strategies\n\n### Lifestyle and Behavioral Interventions\n\nLifestyle interventions targeting modifiable risk factors, including diet, physical activity, smoking, and weight management, form the cornerstone of chronic kidney disease (CKD) prevention, with evidence from cohort studies and guidelines demonstrating reductions in incidence and progression through improved blood pressure control, glycemic regulation, and vascular health. A 2021 systematic review of randomized trials found that multifaceted lifestyle programs, emphasizing dietary changes and exercise, lowered CKD risk markers such as albuminuria and estimated glomerular filtration rate decline in high-risk groups, including those with prediabetes or hypertension.[](https://pubmed.ncbi.nlm.nih.gov/34602599/) The KDIGO 2024 guideline endorses these approaches, recommending physical activity compatible with cardiovascular tolerance and achievement of optimal body mass index to mitigate obesity-related renal strain, supported by observational data linking adiposity to glomerular hyperfiltration.[](https://www.kidney-international.org/article/S0085-2538%2823%2900764-0/fulltext)\n\nDietary modifications prioritize sodium restriction to less than 2 g per day and adoption of patterns like the Dietary Approaches to Stop Hypertension (DASH) diet, which emphasizes fruits, vegetables, whole grains, and low-fat dairy while limiting processed meats and sweets; such regimens have been associated with 20-30% reductions in hypertension incidence, a primary CKD driver, in meta-analyses of over 10,000 participants.[](https://kdigo.org/wp-content/uploads/2021/03/KDIGO-2021-BP-Guideline-Speakers-Guide.pdf) Potassium-rich salt substitutes may aid blood pressure control but require caution in advanced CKD stages due to hyperkalemia risk. Regular physical activity, targeting 150 minutes of moderate aerobic exercise weekly (e.g., brisk walking), enhances endothelial function and insulin sensitivity, with trials showing 10-15% improvements in renal blood flow and reduced proteinuria in prediabetic adults.[](https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-021-02618-1)\n\nSmoking cessation is critical, as tobacco exposure promotes oxidative stress and endothelial dysfunction, accelerating CKD progression by up to 50% in smokers per pack-year; longitudinal studies report glomerular filtration rate stabilization post-quitting, with benefits evident within 1-2 years.[](https://journals.lww.com/kidney360/fulltext/2022/04000/modifiable_lifestyle_behaviors_and_ckd.24.aspx) Moderation of alcohol to less than 14 units weekly prevents dehydration and hepatic-renal interactions, while avoiding overuse of nonsteroidal anti-inflammatory drugs preserves tubular integrity, as overuse doubles acute kidney injury risk in susceptible individuals.[](https://www.kidney.org/7-golden-rules-kidney-disease-prevention) Comprehensive programs combining self-monitoring, goal-setting, and counseling yield adherence rates of 60-70% at 12 months, underscoring behavioral support's role in sustaining these interventions.[](https://bmjopen.bmj.com/content/9/10/e031625)\n\n### Medical Screening and Risk Mitigation\n\nScreening for chronic kidney disease (CKD) targets individuals at elevated risk, including those with diabetes, hypertension, cardiovascular disease, family history of CKD, age over 60 years, obesity, or exposure to nephrotoxins, using estimated glomerular filtration rate (eGFR) calculated from serum creatinine and urine albumin-to-creatinine ratio (uACR) to detect albuminuria.[](https://kdigo.org/wp-content/uploads/2024/03/KDIGO-2024-CKD-Guideline.pdf)[](https://pubmed.ncbi.nlm.nih.gov/38490803/) These tests enable early identification, as CKD often progresses asymptomatically until advanced stages, with eGFR below 60 mL/min/1.73 mÂ² or uACR above 30 mg/g indicating potential disease.[](https://www.kidney.org/sites/default/files/02-10-6800_2303_manageckd_algorithmv4_final.pdf)[](https://diabetesjournals.org/care/article/48/Supplement_1/S239/157554/11-Chronic-Kidney-Disease-and-Risk-Management) Screening is recommended annually for high-risk groups, with confirmatory testing if initial results are abnormal, though universal population screening lacks strong evidence due to low prevalence in low-risk individuals.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC4571145/)[](https://academic.oup.com/ckj/article/18/5/sfaf123/8120273)\n\nRisk mitigation focuses on modifiable factors to prevent CKD onset or slow progression in at-risk populations. Primary strategies include tight control of blood pressure to below 140/90 mm Hg in hypertensive individuals, as sustained hypertension accelerates glomerular damage through vascular stiffness and endothelial dysfunction.[](https://www.cdc.gov/kidney-disease/risk-factors/chronic-kidney-disease-ckd-and-adults-with-high-blood-pressure.html)[](https://pmc.ncbi.nlm.nih.gov/articles/PMC9827046/) In diabetic patients, glycemic management targeting HbA1c below 7% reduces hyperfiltration and mesangial expansion, key causal mechanisms in diabetic kidney disease.[](https://diabetesjournals.org/care/article/45/12/3075/147614/Diabetes-Management-in-Chronic-Kidney-Disease-A)[](https://www.kidney.org/diabetes-and-chronic-kidney-disease) Lifestyle interventions such as weight loss in obesity (aiming for BMI reduction via diet and exercise), smoking cessation to preserve vascular integrity, and avoidance of nonsteroidal anti-inflammatory drugs limit podocyte injury and interstitial fibrosis.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC10856768/)[](https://pmc.ncbi.nlm.nih.gov/articles/PMC4089662/)\n\n- **Hypertension management**: Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers are preferred for their renoprotective effects beyond BP lowering, reducing proteinuria by 30-50% in proteinuric states.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC10648605/)\n- **Diabetes control**: SGLT2 inhibitors and GLP-1 receptor agonists provide additive kidney protection by mitigating glomerular hyperfiltration and inflammation, independent of glucose effects.\n- **Other measures**: Addressing dyslipidemia with statins in high-risk adults over 40 reduces cardiovascular-renal interplay, while population-level policies targeting environmental toxins like heavy metals further mitigate non-genetic risks.[](https://diabetesjournals.org/care/article/45/12/3075/147614/Diabetes-Management-in-Chronic-Kidney-Disease-A)[](https://pmc.ncbi.nlm.nih.gov/articles/PMC10856768/)\n\nEmpirical data from cohort studies show that combined risk factor control can delay CKD progression by 20-30%, emphasizing causal pathways like oxidative stress and hemodynamic overload over correlative associations.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC7567536/)[](https://www.kisupplements.com/article/S2157-1716%2817%2930029-1/fulltext)\n\n## Controversies and Research Frontiers\n\n### Debated Risk Attributions\n\nThe bidirectional relationship between hypertension and chronic kidney disease (CKD) remains a subject of ongoing debate, with evidence indicating that while severe or malignant hypertension can directly damage renal vasculature leading to nephrosclerosis, milder essential hypertension may not independently cause significant glomerular injury or progression to end-stage renal disease (ESRD). Physiological models, such as those emphasizing renal sodium handling and pressure-natriuresis mechanisms, suggest that much of population-level hypertension arises as a consequence of subtle, undetected renal dysfunction rather than as a primary driver, challenging the traditional attribution of \"hypertensive kidney disease\" without histopathological confirmation.[](https://www.kidney-international.org/article/S0085-2538%2816%2930177-6/fulltext) Longitudinal studies using Mendelian randomization have found no causal effect of moderately elevated blood pressure on CKD progression, supporting the view that reduced nephron mass or function often precedes and perpetuates hypertension through mechanisms like salt retention and renin-angiotensin activation.[](https://pubmed.ncbi.nlm.nih.gov/32828236/) This perspective implies overestimation of hypertension's causal role in biopsy-unproven cases, potentially leading to misattribution in up to 20-30% of ESRD listings where renal parenchymal disease is the underlying initiator.[](https://www.ahajournals.org/doi/10.1161/HYPERTENSIONAHA.122.19354)\n\nRacial and ethnic disparities in CKD incidence and progression, particularly the four- to fivefold higher ESRD rates among individuals of African ancestry compared to Europeans, have sparked debate over genetic versus socioeconomic and environmental attributions. High-risk variants in the APOL1 gene (G1 and G2 alleles), prevalent in 13-15% of African Americans, confer a 7- to 30-fold increased risk for nondiabetic CKD forms like focal segmental glomerulosclerosis (FSGS) and hypertension-attributed ESRD, accounting for a substantial portion of excess burden through podocyte injury and endothelial dysfunction.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC3752955/) However, critics argue that social determinantsâ€”such as disparities in access to care, higher prevalence of uncontrolled comorbidities, and historical inequitiesâ€”amplify these genetic risks, with some analyses attributing up to 70% of variance to modifiable factors rather than biology alone, though empirical data show APOL1's effect persists even after adjusting for socioeconomic status.[](https://www.nejm.org/doi/full/10.1056/NEJMoa2404211)[](https://www.health.harvard.edu/blog/whats-behind-racial-disparities-in-kidney-disease-2021020321842) This tension highlights potential biases in source interpretations, where institutional emphases on structural inequities may underplay genetic causality supported by genome-wide association studies.[](https://www.kidney.org/kidney-topics/social-determinants-health-and-chronic-kidney-disease)\n\nNon-traditional environmental exposures, including heat stress and agrochemicals, are increasingly debated as attributable risks in clusters of CKD of unknown etiology (CKDu), such as Mesoamerican nephropathy affecting agricultural workers since the early 2000s, with incidence rates exceeding 15% in some Nicaraguan and Salvadoran communities. Proponents cite epidemiological links to repetitive dehydration and toxin-induced tubular injury (e.g., paraquat exposure with hazard ratio 2.23), yet causal attribution remains contested due to confounding by poverty, limited diagnostic access, and inconsistent biopsy findings, contrasting with traditional risks like diabetes (attributable to 40-50% of global CKD).[](https://pmc.ncbi.nlm.nih.gov/articles/PMC10272583/) Similarly, the role of certain medications, such as nonsteroidal anti-inflammatory drugs (NSAIDs), in accelerating progression (odds ratio up to 2.54 for ketorolac) is debated, with acute kidney injury risks well-documented but chronic attribution questioned in observational data prone to reverse causation. These debates underscore gaps in randomized evidence, urging caution against over-relying on associative studies from potentially biased registries.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC10272583/)\n\n### Emerging Therapies and Evidence Gaps\n\nRecent pharmacological advancements include the approval of semaglutide, a GLP-1 receptor agonist, by the FDA on January 28, 2025, for reducing the risk of kidney disease progression in patients with type 2 diabetes and chronic kidney disease (CKD), building on evidence from cardiovascular outcome trials demonstrating renal protective effects independent of glycemic control.[](https://cromospharma.com/world-kidney-day-top-5-breakthroughs-in-kidney-disease-treatment/) Non-steroidal mineralocorticoid receptor antagonists like finerenone, combined with SGLT2 inhibitors and renin-angiotensin system blockers, represent a multifaceted approach targeting inflammation and fibrosis, with ongoing trials evaluating additive benefits in non-diabetic CKD.[](https://onlinelibrary.wiley.com/doi/10.1002/ehf2.15345) Emerging non-pharmacological therapies encompass gene therapies using adeno-associated viruses to target genetic causes of CKD, such as polycystic kidney disease, with preclinical models showing promise in halting cyst growth as of December 2024.[](https://news.ohsu.edu/2024/12/30/new-gene-therapy-research-offers-hope-for-people-with-chronic-kidney-disease)\n\nRegenerative strategies, including mesenchymal stem cell therapies, entered phase II trials in April 2025 for preserving kidney function in diabetic CKD, aiming to modulate immune responses and reduce tubular injury through paracrine effects rather than direct engraftment.[](https://health.ucdavis.edu/news/headlines/uc-davis-health-launches-new-cell-therapy-trial-for-chronic-kidney-disease-patients/2025/04) In renal replacement therapy, xenotransplantation advanced with gene-edited porcine kidneys transplanted into humans in 2024, addressing organ shortages but facing immunological and ethical hurdles, with short-term graft survival reported up to 60 days in brain-dead recipients.[](https://www.kidneyfund.org/article/top-kidney-disease-research-advancements-2024) Bioengineered kidneys and implantable devices remain in early preclinical stages, with innovations in continuous kidney replacement therapies focusing on improved biocompatibility and reduced anticoagulation needs in intensive care settings.[](https://www.ajkd.org/article/S0272-63862401120-X/fulltext)\n\nDespite these developments, significant evidence gaps persist, including underrepresentation of advanced CKD stages (eGFR \u003c30 mL/min/1.73 mÂ²) and comorbid populations in cardiovascular-renal-metabolic trials, leading to extrapolated rather than direct efficacy data for high-risk groups.[](https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2815795) The evidence-practice gap is pronounced, with only a fraction of eligible patients receiving guideline-recommended therapies like SGLT2 inhibitors due to barriers in prescribing, adherence, and continuity of care, as evidenced by US cohort studies from 2001â€“2020 showing suboptimal uptake.[](https://www.ajkd.org/article/S0272-6386%2825%2900054-X/fulltext)[](https://www.sciencedirect.com/science/article/pii/S2468024925006254) Long-term outcomes for novel agents, such as gene therapies, lack robust human data, while inequities in trial enrollment exacerbate disparities, with Black and Hispanic patients less likely to benefit from early detection and interventions.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC12304639/) Head-to-head comparisons of emerging drugs and personalized biomarkers for therapy response remain underdeveloped, hindering causal attribution of benefits amid heterogeneous CKD etiologies.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC11102772/)"])</script><script nonce="YzBlMjE1NjMtYjg2MC00MmIzLWJmMzktNTk1ZDcyYjYzMzVi">self.__next_f.push([1,"8:[\"$\",\"$L1e\",null,{\"state\":{\"mutations\":[],\"queries\":[{\"dehydratedAt\":1761887025703,\"state\":{\"data\":{\"page\":{\"citations\":[{\"id\":\"1\",\"title\":\"Kidney Disease - NIDDK\",\"description\":\"Kidney disease means your kidneys are damaged and can't filter blood the way they should. You are at greater risk for kidney disease if you have diabetes orÂ ...Chronic Kidney Disease (CKD) Â· Kidney Disease Statistics Â· Kidney Failure\",\"url\":\"https://www.niddk.nih.gov/health-information/kidney-disease\",\"favicon\":\"\"},{\"id\":\"2\",\"title\":\"Chronic Kidney Disease Diagnosis and Management: A Review - NIH\",\"description\":\"CKD Definition and Staging. Chronic kidney disease is defined as the presence of an abnormality in kidney structure or function persisting for more than 3Â ...Chronic Kidney Disease... Â· Ckd Definition And Staging Â· Screening For Ckd\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC7015670/\",\"favicon\":\"\"},{\"id\":\"3\",\"title\":\"Acute kidney injury and chronic kidney disease - NIH\",\"description\":\"Chronic kidney disease and acute kidney injury have traditionally been considered as separate entities with different etiologies.\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC5475438/\",\"favicon\":\"\"},{\"id\":\"4\",\"title\":\"Chronic Kidney Disease Basics - CDC\",\"description\":\"May 15, 2024 Â· More than 1 in 7 American adults has chronic kidney disease (CKD) ... In the United States, diabetes and high blood pressure are the leading causesÂ ...Missing:  epidemiology | Show results with:epidemiology\",\"url\":\"https://www.cdc.gov/kidney-disease/about/index.html\",\"favicon\":\"\"},{\"id\":\"5\",\"title\":\"Chronic Kidney Disease in the United States, 2023 - CDC\",\"description\":\"May 15, 2024 Â· CKD is more common in people aged 65 years or older (34%) than in people aged 45â€“64 years (12%) or 18â€“44 years (6%). CKD is slightly more commonÂ ...\",\"url\":\"https://www.cdc.gov/kidney-disease/php/data-research/index.html\",\"favicon\":\"\"},{\"id\":\"6\",\"title\":\"Noncommunicable diseases - World Health Organization (WHO)\",\"description\":\"Sep 25, 2025 Â· (1) Global Burden of Disease Collaborative Network, Global Burden of Disease Study 2021 (GBD 2021) Results (2024, Institute for Health MetricsÂ ...\",\"url\":\"https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases\",\"favicon\":\"\"},{\"id\":\"7\",\"title\":\"Kidney Disease Statistics for the United States - NIDDK\",\"description\":\"Overview of kidney disease facts and statistics for the United States, including chronic kidney disease (CKD) and end-stage kidney disease (ESKD).Fast Facts On Kidney Disease Â· Key Kidney Disease... Â· End-Stage Kidney Disease...\",\"url\":\"https://www.niddk.nih.gov/health-information/health-statistics/kidney-disease\",\"favicon\":\"\"},{\"id\":\"8\",\"title\":\"Chronic Kidney Disease - StatPearls - NCBI Bookshelf\",\"description\":\"Jul 31, 2024 Â· CKD is a state of progressive loss of kidney function, ultimately resulting in the need for renal replacement therapy, such as dialysis or transplantation.\",\"url\":\"https://www.ncbi.nlm.nih.gov/books/NBK535404/\",\"favicon\":\"\"},{\"id\":\"9\",\"title\":\"An Overview of Chronic Kidney Disease Pathophysiology\",\"description\":\"Chronic kidney disease (CKD) is a devastating condition resulting from different disease pathways that irreversibly alter the kidney structure and function overÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC10669155/\",\"favicon\":\"\"},{\"id\":\"10\",\"title\":\"Risk Factors for Chronic Kidney Disease - CDC\",\"description\":\"May 15, 2024 Â· Having overweight or obesity raises your risk for high blood pressure and diabetes, the two biggest causes of CKD.Missing:  epidemiology | Show results with:epidemiology\",\"url\":\"https://www.cdc.gov/kidney-disease/risk-factors/index.html\",\"favicon\":\"\"},{\"id\":\"11\",\"title\":\"Kidney Diseases | Renal Disease - MedlinePlus\",\"description\":\"Sep 23, 2025 Â· Most kidney diseases attack the nephrons. This damage may leave kidneys unable to remove wastes. Causes can include genetic problems, injuries, or medicines.Missing:  reliable | Show results with:reliable\",\"url\":\"https://medlineplus.gov/kidneydiseases.html\",\"favicon\":\"\"},{\"id\":\"12\",\"title\":\"Acute Kidney Injury - StatPearls - NCBI Bookshelf - NIH\",\"description\":\"Nov 25, 2023 Â· Differentiating between AKI and chronic kidney disease (CKD) is essential, as CKD itself is not an uncommon risk factor for AKI.Introduction Â· Etiology Â· History and Physical Â· Evaluation\",\"url\":\"https://www.ncbi.nlm.nih.gov/books/NBK441896/\",\"favicon\":\"\"},{\"id\":\"13\",\"title\":\"Types of renal disease - eClinpath\",\"description\":\"Acute kidney injury (AKI) is characterized by a rapid deterioration in renal function over hours to days (48 hours to 7 days), resulting in a failure of theÂ ...\u003c|separator|\u003e\",\"url\":\"https://eclinpath.com/chemistry/kidney/types-of-renal-disease/\",\"favicon\":\"\"},{\"id\":\"14\",\"title\":\"Types of Kidney Disease\",\"description\":\"There are many types of kidney diseases, each with different causes and effects on the body. Some kidney diseases are genetic, meaning they run in families.aHUS (atypical hemolytic... Â· Cardiovascular-kidney... Â· Focal segmental...Missing:  reliable | Show results with:reliable\",\"url\":\"https://www.kidneyfund.org/all-about-kidneys/types-kidney-diseases\",\"favicon\":\"\"},{\"id\":\"15\",\"title\":\"Acute Kidney Injury and Chronic Kidney Disease as Interconnected ...\",\"description\":\"Chronic kidney disease is a risk factor for acute kidney injury, acute kidney injury is a risk factor for the development of chronic kidney disease.Missing:  peer | Show results with:peer\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC9720902/\",\"favicon\":\"\"},{\"id\":\"16\",\"title\":\"Acute Kidney Injury (AKI) - Genitourinary Disorders - Merck Manuals\",\"description\":\"Acute kidney injury is a rapid decrease in renal function over days to weeks, causing an accumulation of nitrogenous products in the blood (azotemia)\",\"url\":\"https://www.merckmanuals.com/professional/genitourinary-disorders/acute-kidney-injury/acute-kidney-injury-aki\",\"favicon\":\"\"},{\"id\":\"17\",\"title\":\"Acute Kidney Injury (AKI) - Medscape Reference\",\"description\":\"Sep 11, 2024 Â· Acute kidney injury (AKI) is a clinical syndrome manifested by a rapid or abrupt decline in kidney function and subsequent dysregulation of the bodyÂ ...Treatment Â· Presentation Â· Workup\",\"url\":\"https://emedicine.medscape.com/article/243492-overview\",\"favicon\":\"\"},{\"id\":\"18\",\"title\":\"[PDF] KDIGO Clinical Practice Guideline for Acute Kidney Injury\",\"description\":\"Jul 2, 2012 Â· ... stages ... are based on the Risk, Injury, Failure; Loss, End-Stage Renal Disease (RIFLE) and Acute Kidney. Injury Network (AKIN) criteria andÂ ...\",\"url\":\"https://kdigo.org/wp-content/uploads/2016/10/KDIGO-2012-AKI-Guideline-English.pdf\",\"favicon\":\"\"},{\"id\":\"19\",\"title\":\"Staging Criteria for Acute Kidney Injury (KDIGO 2012) - Merck Manuals\",\"description\":\"Staging Criteria for Acute Kidney Injury (KDIGO 2012)* Â· Rise in serum creatinine Â· Decline in the amount of urine output Â· Renal replacement therapy. 1. â‰¥ 0.3Â ...\",\"url\":\"https://www.merckmanuals.com/professional/multimedia/table/staging-criteria-for-acute-kidney-injury-kdigo-2012\",\"favicon\":\"\"},{\"id\":\"20\",\"title\":\"The Incidence of Acute Kidney Injury and Associated Hospital Mortality\",\"description\":\"The in-hospital mortality was 5.1% for patients with stage 1 AKI, 13.7% for patients with stage 2 AKI, and 24.8% for patients with stage 3 AKI. AnÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC6676729/\",\"favicon\":\"\"},{\"id\":\"21\",\"title\":\"Acute Kidney Injury: Diagnosis and Management - AAFP\",\"description\":\"Dec 1, 2019 Â· Acute kidney injury is defined as the sudden loss of kidney function over hours to days resulting in the inability to maintain electrolyte, acidÂ ...\",\"url\":\"https://www.aafp.org/pubs/afp/issues/2019/1201/p687.html\",\"favicon\":\"\"},{\"id\":\"22\",\"title\":\"Harmonization of epidemiology of acute kidney injury and acute ...\",\"description\":\"Apr 7, 2022 Â· Age- and sex-standardised incidence rates for AKI or AKD were similar between regions and years; range 134.3-162.4 events/10,000 person years.\",\"url\":\"https://www.kidney-international.org/article/S0085-2538%2822%2900267-8/fulltext\",\"favicon\":\"\"},{\"id\":\"23\",\"title\":\"Acute kidney injury - Symptoms and causes - Mayo Clinic\",\"description\":\"Jul 10, 2024 Â· Acute kidney injury happens when the kidneys suddenly can't filter waste products from the blood. When the kidneys can't filter wastes, harmful levels ofÂ ...\",\"url\":\"https://www.mayoclinic.org/diseases-conditions/kidney-failure/symptoms-causes/syc-20369048\",\"favicon\":\"\"},{\"id\":\"24\",\"title\":\"Acute kidney injury - Diagnosis and treatment - Mayo Clinic\",\"description\":\"Jul 10, 2024 Â· Learn what happens when the kidneys suddenly stop working, what causes this condition and how it's treated.Diagnosis Â· Treatment Â· Treating Complications Until...\",\"url\":\"https://www.mayoclinic.org/diseases-conditions/kidney-failure/diagnosis-treatment/drc-20369053\",\"favicon\":\"\"},{\"id\":\"25\",\"title\":\"Estimated Glomerular Filtration Rate (eGFR)\",\"description\":\"What are the stages of chronic kidney disease (CKD)? ; 3a, Mild to moderate loss of kidney function, 45-59 ; 3b, Moderate to severe loss of kidney function, 30-44.Can my GFR get better? Â· Know Your Kidney Numbers Â· Glomerular filtration rate\",\"url\":\"https://www.kidney.org/kidney-topics/estimated-glomerular-filtration-rate-egfr\",\"favicon\":\"\"},{\"id\":\"26\",\"title\":\"[PDF] KDIGO-2024-CKD-Guideline.pdf\",\"description\":\"This article is published as part of a supplement sponsored by Kidney Disease: Improving Global Outcomes (KDIGO). The opinions or views expressed in thisÂ ...\u003c|separator|\u003e\",\"url\":\"https://kdigo.org/wp-content/uploads/2024/03/KDIGO-2024-CKD-Guideline.pdf\",\"favicon\":\"\"},{\"id\":\"27\",\"title\":\"How to Classify CKD | National Kidney Foundation\",\"description\":\"GFR categories in CKD. Category, GFR ml/min/1.73 m2, Terms. G1, â‰¥90, Normal or high. G2, 60-89, Mildly decreased*. G3a, 45-59, Mildly to moderatelyÂ ...\",\"url\":\"https://www.kidney.org/how-to-classify-ckd\",\"favicon\":\"\"},{\"id\":\"28\",\"title\":\"CKD Evaluation and Management - KDIGO\",\"description\":\"The guideline is intended for healthcare professionals who provide kidney care, for people with suspected or diagnosed CKD and their caregivers.\",\"url\":\"https://kdigo.org/guidelines/ckd-evaluation-and-management/\",\"favicon\":\"\"},{\"id\":\"29\",\"title\":\"Stages of Chronic Kidney Disease (CKD)\",\"description\":\"Stage 1 CKD. eGFR 90 or higher and kidney damage (e.g. uACR 30 or higher) for 3 months or more ; Stage 2 CKD. eGFR 60-89 and kidney damage (e.g. uACR 30 orÂ ...\",\"url\":\"https://www.kidney.org/kidney-topics/stages-chronic-kidney-disease-ckd\",\"favicon\":\"\"},{\"id\":\"30\",\"title\":\"Global, regional, and national burden of chronic kidney disease and ...\",\"description\":\"Feb 17, 2025 Â· In 2017, 697.5 million cases of all-stage CKD were recorded, with a global prevalence of 9.1%. Since 1990, the global all-age prevalence of CKDÂ ...\",\"url\":\"https://bmcpublichealth.biomedcentral.com/articles/10.1186/s12889-025-21851-z\",\"favicon\":\"\"},{\"id\":\"31\",\"title\":\"[PDF] Reducing the burden of noncommunicable diseases through ...\",\"description\":\"Feb 3, 2025 Â· ... and control of NCDs 2013-2030 (WHA66.10 and. WHA72(11));. (4) strengthen and integrate the monitoring of kidney disease burden, access to careÂ ...\",\"url\":\"https://apps.who.int/gb/ebwha/pdf_files/EB156/B156_CONF6-en.pdf\",\"favicon\":\"\"},{\"id\":\"32\",\"title\":\"Chronic kidney disease and the global public health agenda - Nature\",\"description\":\"Apr 3, 2024 Â· According to the Global Burden of Disease (GBD) study, the global prevalence of CKD increased by 33% between 1990 and 2017. Crucially, theÂ ...\",\"url\":\"https://www.nature.com/articles/s41581-024-00820-6\",\"favicon\":\"\"},{\"id\":\"33\",\"title\":\"The major global burden of chronic kidney disease - The Lancet\",\"description\":\"The global median prevalence of chronic kidney disease is 9Â·5% (IQR 5Â·9â€“11Â·7). Haemodialysis (defined as provided to \u003e50% of people with kidney failure, aÂ ...\",\"url\":\"https://www.thelancet.com/journals/langlo/article/PIIS2214-109X%2824%2900050-0/fulltext\",\"favicon\":\"\"},{\"id\":\"34\",\"title\":\"Epidemiology of chronic kidney disease: an update 2022 - PMC - NIH\",\"description\":\"Mar 18, 2022 Â· The age-standardized global prevalence of CKD stages 3â€“5 in adults aged â‰¥20 years in the same study was 4.7% in men and 5.8% in women. A moreÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC9073222/\",\"favicon\":\"\"},{\"id\":\"35\",\"title\":\"a systematic analysis for the Global Burden of Disease Study 2023\",\"description\":\"Jul 22, 2025 Â· In 2023, the number of global cases of KFRT was 4Â·59 million (95% UI 4Â·17â€“5Â·08) for both sexes and all ages, with an age-standardised prevalenceÂ ...\",\"url\":\"https://www.healthdata.org/research-analysis/library/global-regional-and-national-prevalence-kidney-failure-replacement\",\"favicon\":\"\"},{\"id\":\"36\",\"title\":\"Infections and Acute Kidney Injury: A Global Perspective\",\"description\":\"Globally, there are an estimated 13.3 million cases of acute kidney injury (AKI) annually. Although infections are a common cause of AKI globally,Â ...\",\"url\":\"https://www.sciencedirect.com/science/article/abs/pii/S0270929523001766\",\"favicon\":\"\"},{\"id\":\"37\",\"title\":\"The burden of acute kidney disease: an epidemiological review and ...\",\"description\":\"May 27, 2025 Â· AKI is thought to affect \u003e13 million individuals annually worldwide, with an incidence that varies from 3.2% to 20% in hospitalized patients andÂ ...\",\"url\":\"https://academic.oup.com/ckj/article/18/6/sfaf169/8151575\",\"favicon\":\"\"},{\"id\":\"38\",\"title\":\"Acute kidney injury: Global health alert - PMC - PubMed Central\",\"description\":\"AKI is now encountered in 45% of patients admitted to the ICU and 20% of hospitalized patients (16,17). This increased prevalence likely reflects an agingÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC3891141/\",\"favicon\":\"\"},{\"id\":\"39\",\"title\":\"[PDF] Global Burden of AKI | KDIGO\",\"description\":\"Chief factors associated with AKI in HIC were hypotension (30%), post-surgical complications (27%) and dehydration (26%). In contrast, dehydration was theÂ ...\",\"url\":\"https://kdigo.org/wp-content/uploads/2018/02/2.-Mehta-KDIGO-AKI-Conference_Global-Burden.pdf\",\"favicon\":\"\"},{\"id\":\"40\",\"title\":\"Global epidemiology of acute kidney injury in hospitalised patients ...\",\"description\":\"Mar 6, 2025 Â· The prevalence of AKI was highest in Africa (118 [63Â·1%] of 187 patients) and lowest in Asia (205 [27Â·6%] of 743 patients; appendix p 18).\",\"url\":\"https://www.thelancet.com/journals/langas/article/PIIS2468-1253%2825%2900006-8/fulltext\",\"favicon\":\"\"},{\"id\":\"41\",\"title\":\"Global trends of chronic kidney disease from 1990 to 2021\",\"description\":\"Jul 14, 2025 Â· The global burden of CKD continued to rise, driven by population aging, increasing prevalence of risk factors, and improved case detection.\",\"url\":\"https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-025-04309-7\",\"favicon\":\"\"},{\"id\":\"42\",\"title\":\"CKD in the General Population - Annual Data Report | USRDS\",\"description\":\"A higher percentage of women (15.4% in 2017-March 2020) than men (12.6%) have CKD, a finding that has been consistent since 2005-2008. In the most recent surveyÂ ...\",\"url\":\"https://usrds-adr.niddk.nih.gov/2024/chronic-kidney-disease/1-ckd-in-the-general-population\",\"favicon\":\"\"},{\"id\":\"43\",\"title\":\"Sex differences in CKD risk factors across ethnic groups\",\"description\":\"Feb 8, 2024 Â· The overall age-adjusted CKD prevalence was higher in women than in men and ranged between 3.3% and 9.5% across groups.\",\"url\":\"https://academic.oup.com/ndt/article/39/7/1194/7603988\",\"favicon\":\"\"},{\"id\":\"44\",\"title\":\"CKD in the General Population - Annual Data Report | USRDS\",\"description\":\"In the most recent survey period, CKD prevalence was highest among non-Hispanic Black individuals (18.9%) and lowest among Hispanic individuals (12.0%). TheÂ ...\",\"url\":\"https://usrds-adr.niddk.nih.gov/2022/chronic-kidney-disease/1-ckd-in-the-general-population\",\"favicon\":\"\"},{\"id\":\"45\",\"title\":\"[PDF] Chronic Kidney Disease in the United States, 2023 - CDC\",\"description\":\"Diabetes and high blood pressure are the more common causes of. CKD in most adults. Other risk factors include heart disease, obesity, a family history of CKD,.\",\"url\":\"https://www.cdc.gov/kidney-disease/media/pdfs/CKD-Factsheet-H.pdf\",\"favicon\":\"\"},{\"id\":\"46\",\"title\":\"Identification and Care of Patients with CKD\",\"description\":\"The higher prevalence of CKD in the general population (NHANES) was evident across all age, sex, and race/ethnicity groups.\",\"url\":\"https://usrds-adr.niddk.nih.gov/2024/chronic-kidney-disease/2-identification-and-care-of-patients-with-ckd\",\"favicon\":\"\"},{\"id\":\"47\",\"title\":\"[PDF] Global trends in kidney failure incidence over a 5-year period of ...\",\"description\":\"May 22, 2025 Â· This study aimed to comprehensively analyze global and regional trends in kidney failure incidence over the five-year period from 2019 to 2023,Â ...\u003c|separator|\u003e\",\"url\":\"https://www.journalrip.com/Inpress/jrip-38655.pdf\",\"favicon\":\"\"},{\"id\":\"48\",\"title\":\"Worldwide Disparity in the Relation Between CKD Prevalence and ...\",\"description\":\"The incidence of KRT ranged from 89 to 378 per million population in high-income regions, 32 to 222 per million population in Central and Eastern Europe, and 22Â ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC7710841/\",\"favicon\":\"\"},{\"id\":\"49\",\"title\":\"Pathophysiology of Acute Kidney Injury - PMC - PubMed Central - NIH\",\"description\":\"The primary causes of AKI include ischemia, hypoxia or nephrotoxicity. An underlying feature is a rapid decline in GFR usually associated with decreases inÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC3919808/\",\"favicon\":\"\"},{\"id\":\"50\",\"title\":\"Cellular pathophysiology of ischemic acute kidney injury - PMC - NIH\",\"description\":\"Ischemia results in an increase in epithelial cell heme oxygenaseâ€“1, which confers an antiinflammatory response and protects against IRI (72).\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC3204829/\",\"favicon\":\"\"},{\"id\":\"51\",\"title\":\"Signaling pathways of chronic kidney diseases, implications for ...\",\"description\":\"Jun 9, 2022 Â· In this review, we update the key signaling pathways of lipotoxicity, oxidative stress, inflammation, and myofibroblasts activation in kidneys with chronicÂ ...\",\"url\":\"https://www.nature.com/articles/s41392-022-01036-5\",\"favicon\":\"\"},{\"id\":\"52\",\"title\":\"Molecular mechanisms and therapeutic interventions in acute ...\",\"description\":\"Mar 22, 2025 Â· This review comprehensively reviewed the molecular mechanisms underlying AKI, including oxidative stress, inflammatory pathways, immune cell-mediated injury.\",\"url\":\"https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-025-04077-4\",\"favicon\":\"\"},{\"id\":\"53\",\"title\":\"Metabolic mechanisms of acute proximal tubular injury - PMC - NIH\",\"description\":\"May 14, 2022 Â· ATP depletion induces acute changes in PT cell morphology, including retraction of the brush border, membrane blebbing, and shedding of cellularÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC9338906/\",\"favicon\":\"\"},{\"id\":\"54\",\"title\":\"Cellular pathophysiology of ischemic acute kidney injury - JCI\",\"description\":\"Ischemia results in an increase in epithelial cell heme oxygenaseâ€“1, which confers an antiinflammatory response and protects against IRI (72).\",\"url\":\"https://www.jci.org/articles/view/45161\",\"favicon\":\"\"},{\"id\":\"55\",\"title\":\"Acute Renal Tubular Necrosis - StatPearls - NCBI Bookshelf - NIH\",\"description\":\"Aug 8, 2025 Â· A decreased glomerular filtration rate (GFR) is associated with acute tubular necrosis, leading to 3 possible mechanisms of injury to the renalÂ ...Continuing Education Activity Â· Etiology Â· Pathophysiology Â· Histopathology\",\"url\":\"https://www.ncbi.nlm.nih.gov/books/NBK507815/\",\"favicon\":\"\"},{\"id\":\"56\",\"title\":\"Acute Kidney Injury: Medical Causes and Pathogenesis - MDPI\",\"description\":\"Jan 3, 2023 Â· Suggested mechanisms include renal ischemia, vasoconstriction, formation of reactive oxygen species and direct tubular toxicity [32]. AKI thatÂ ...\u003c|separator|\u003e\",\"url\":\"https://www.mdpi.com/2077-0383/12/1/375\",\"favicon\":\"\"},{\"id\":\"57\",\"title\":\"The complex interplay between kidney injury and inflammation\",\"description\":\"Oct 21, 2020 Â· AKI is characterized by some degree of renal cell death through either apoptosis or necrosis, together with a strong inflammatory response.Aki And Its Progression To... Â· Aki Following Cardiac Bypass... Â· Future Directions\",\"url\":\"https://academic.oup.com/ckj/article/14/3/780/5934685\",\"favicon\":\"\"},{\"id\":\"58\",\"title\":\"Kidney fibrosis: from mechanisms to therapeutic medicines - Nature\",\"description\":\"Mar 17, 2023 Â· Kidney fibrosis is identified by tubule atrophy, interstitial chronic inflammation and fibrogenesis, glomerulosclerosis, and vascular rarefaction.\",\"url\":\"https://www.nature.com/articles/s41392-023-01379-7\",\"favicon\":\"\"},{\"id\":\"59\",\"title\":\"The tubulointerstitial pathophysiology of progressive kidney disease\",\"description\":\"As damage to the kidney causes nephron loss, physical forces, altered processing of glomerular filtrate and changes in distal tubular delivery of fluid andÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC5351778/\",\"favicon\":\"\"},{\"id\":\"60\",\"title\":\"Mechanistic connection between inflammation and fibrosis\",\"description\":\"Renal fibrosis involves a complex multistage inflammatory process that is orchestrated by a network of cytokines/chemokines, growth factors, adhesion molecules,Â ...\",\"url\":\"https://www.kidney-international.org/article/S0085-2538%2815%2954475-X/fulltext\",\"favicon\":\"\"},{\"id\":\"61\",\"title\":\"Mechanisms of Acute Kidney Injuryâ€“Chronic Kidney Disease ... - MDPI\",\"description\":\"This review provides a comprehensive examination of the multifactorial mechanisms underlying the initiation and progression of AKI.\",\"url\":\"https://www.mdpi.com/2218-273X/15/6/794\",\"favicon\":\"\"},{\"id\":\"62\",\"title\":\"Transition from acute kidney injury to chronic kidney disease - PubMed\",\"description\":\"Nov 1, 2024 Â· AKI often progresses to CKD due to maladaptive repair processes, persistent inflammation, and fibrosis, with both conditions sharing commonÂ ...\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/39298548/\",\"favicon\":\"\"},{\"id\":\"63\",\"title\":\"Chronic kidney disease after acute kidney injury - PubMed - NIH\",\"description\":\"The pooled incidence of CKD and ESRD were 25.8 per 100 person-years and 8.6 per 100 person-years, respectively. Patients with AKI had higher risks forÂ ...\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/22113526/\",\"favicon\":\"\"},{\"id\":\"64\",\"title\":\"Chronic kidney disease after acute kidney injury: a systematic ...\",\"description\":\"â€”The rate of incident CKD was 6.6 per 100 person-years and mortality was 4.1 per 100 person-years for those with mild AKI, and 10.5 per 100 person-years and 6.6Â ...\",\"url\":\"https://www.kidney-international.org/article/S0085-2538%2815%2955323-4/fulltext\",\"favicon\":\"\"},{\"id\":\"65\",\"title\":\"Acute Kidney Injury Duration and 20-Year Risks of CKD and ...\",\"description\":\"Jan 22, 2024 Â· During the 20 years of follow-up, the risk of CKD was 26.3% (95% CI, 25.4â€“27.2) for rapid reversal AKI, 29.5% (95% CI, 28.4â€“30.6) for persistentÂ ...\",\"url\":\"https://www.kireports.org/article/S2468-0249%2824%2900044-5/fulltext\",\"favicon\":\"\"},{\"id\":\"66\",\"title\":\"Recent Update on Acute Kidney Injury-to-Chronic Kidney Disease ...\",\"description\":\"Mar 11, 2024 Â· 3 A meta-analysis has indicated that patients with AKI have significantly higher risks of developing CKD, ESKD, and mortality (approximately 9,Â ...\",\"url\":\"https://eymj.org/DOIx.php?id=10.3349/ymj.2023.0306\",\"favicon\":\"\"},{\"id\":\"67\",\"title\":\"AKI on CKD: heightened injury, suppressed repair, and the ...\",\"description\":\"Drastic alterations of cell signaling in renal tubular cells during the initiation and progression of CKD may contribute to the susceptibility of CKD kidneysÂ ...\",\"url\":\"https://www.kidney-international.org/article/S0085-2538%2817%2930499-4/fulltext\",\"favicon\":\"\"},{\"id\":\"68\",\"title\":\"The AKI-to-CKD Transition: The Role of Uremic Toxins - MDPI\",\"description\":\"There are several risk factors for AKI, including patient-related factors, such as older age, pre-existing chronic organ failure (especially kidney, heart, orÂ ...\u003c|control11|\u003e\u003c|separator|\u003e\",\"url\":\"https://www.mdpi.com/1422-0067/24/22/16152\",\"favicon\":\"\"},{\"id\":\"69\",\"title\":\"Infectious consequences of the AKI-to-CKD transition\",\"description\":\"Jul 30, 2022 Â· Factors associated with infection were older age, cognitive impairment, lower post-AKI eGFR, eGFR loss from baseline to 3 months and AKI-to-CKDÂ ...\",\"url\":\"https://academic.oup.com/ckj/article/15/12/2237/6652220\",\"favicon\":\"\"},{\"id\":\"70\",\"title\":\"Diabetic Kidney Disease: Challenges, Progress, and Possibilities\",\"description\":\"Diabetic kidney disease develops in approximately 40% of patients who are diabetic and is the leading cause of CKD worldwide.\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC5718284/\",\"favicon\":\"\"},{\"id\":\"71\",\"title\":\"The Bidirectional Link Between Diabetes and Kidney Disease - NIH\",\"description\":\"Sep 20, 2023 Â· Diabetes is recognized as a significant risk factor for CKD, as individuals with diabetes are considerably more vulnerable to developing renalÂ ...Missing:  statistics | Show results with:statistics\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC10588295/\",\"favicon\":\"\"},{\"id\":\"72\",\"title\":\"The impact of hypertension on chronic kidney disease and end ...\",\"description\":\"Nov 25, 2020 Â· Hypertension (HTN) is an established risk factor for chronic kidney disease (CKD) and end-stage renal disease (ESRD).\",\"url\":\"https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-020-02151-7\",\"favicon\":\"\"},{\"id\":\"73\",\"title\":\"Hypertension as Cardiovascular Risk Factor in Chronic Kidney ...\",\"description\":\"Apr 14, 2023 Â· Both hypertension and CKD are intrinsically related, as hypertension is a strong determinant of worse renal and cardiovascular outcomes and renal functionÂ ...\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/37053276/\",\"favicon\":\"\"},{\"id\":\"74\",\"title\":\"Association of metabolic syndrome and chronic kidney disease\",\"description\":\"Oct 2, 2023 Â· The MetS is a cluster of cardiovascular risk factors that adversely affect the development and progression of chronic kidney failure.Summary Â· INTRODUCTION Â· MANAGEMENT Â· CONCLUSION\",\"url\":\"https://onlinelibrary.wiley.com/doi/10.1111/obr.13649\",\"favicon\":\"\"},{\"id\":\"75\",\"title\":\"Management of traditional risk factors for the development and ...\",\"description\":\"Apr 26, 2023 Â· In one study, an increase in weight of \u003e10% of the baseline BMI resulted in an approximately 30% increase in the risk for developing CKD in menÂ ...\",\"url\":\"https://academic.oup.com/ckj/article/16/11/1737/7143784\",\"favicon\":\"\"},{\"id\":\"76\",\"title\":\"Metabolic Syndrome-Related Kidney Injury: A Review and Update\",\"description\":\"3 Association Between MetS and CKD. MetS and CKD are causal and influence each other. A large number of studies have confirmed that MetS can lead to changes inÂ ...Abstract Â· Association Between MetS... Â· Management of MetS-Related...\u003c|separator|\u003e\",\"url\":\"https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2022.904001/full\",\"favicon\":\"\"},{\"id\":\"77\",\"title\":\"Atherosclerotic Renal Artery Stenosis: A Review - PMC - NIH\",\"description\":\"Renal artery stenosis (RAS) is associated with hypertension and renal impairment. Atherosclerosis is the leading etiologic factor which accounts for \u003e90% ofÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC8598311/\",\"favicon\":\"\"},{\"id\":\"78\",\"title\":\"Renal Artery Stenosis - StatPearls - NCBI Bookshelf\",\"description\":\"Atherosclerosis or fibromuscular dysplasia most often cause it. Other associated complications of renal artery stenosis are chronic kidney disease and end-stageÂ ...\",\"url\":\"https://www.ncbi.nlm.nih.gov/books/NBK430718/\",\"favicon\":\"\"},{\"id\":\"79\",\"title\":\"Atherosclerotic Renovascular Disease: A KDIGO (Kidney Disease\",\"description\":\"Aug 9, 2021 Â· The comorbidity most strongly associated with ARVD is heart failure (HF). De Silva et al identified that 54% of patients with systolic HF whoÂ ...\",\"url\":\"https://www.ajkd.org/article/S0272-6386%2821%2900776-9/fulltext\",\"favicon\":\"\"},{\"id\":\"80\",\"title\":\"Genetic kidney diseases as an underrecognized cause of chronic ...\",\"description\":\"Inherited kidney diseases (IKDs) are among the leading causes of early-onset chronic kidney disease (CKD) and are responsible for at least 10â€“15% of casesÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC8323147/\",\"favicon\":\"\"},{\"id\":\"81\",\"title\":\"Genetic Etiologies for Chronic Kidney Disease Revealed through ...\",\"description\":\"Mar 24, 2022 Â· Recent studies suggest that disease-causing genetic variants are identifiable in âˆ¼10% of adults and ~20% of children with CKD [2, 3], most ofÂ ...\",\"url\":\"https://karger.com/ajn/article/53/4/297/827404/Genetic-Etiologies-for-Chronic-Kidney-Disease\",\"favicon\":\"\"},{\"id\":\"82\",\"title\":\"Emerging Role of Clinical Genetics in CKD - ScienceDirect.com\",\"description\":\"Presently, approximately 625 genes have been demonstrated to contribute to the development of CKD, and it has been suggested that the heritability for estimatedÂ ...\",\"url\":\"https://www.sciencedirect.com/science/article/pii/S2590059522000425\",\"favicon\":\"\"},{\"id\":\"83\",\"title\":\"Autosomal Dominant Polycystic Kidney Disease - StatPearls - NCBI\",\"description\":\"Eighty-five percent of patients with ADPKD have PKD1 mutations, 15% have the PKD2 gene mutation, and about 1% have GANAB gene mutations. Other mutations leadingÂ ...Continuing Education Activity Â· Introduction Â· Evaluation Â· Treatment / Management\",\"url\":\"https://www.ncbi.nlm.nih.gov/books/NBK532934/\",\"favicon\":\"\"},{\"id\":\"84\",\"title\":\"Alport Syndrome - StatPearls - NCBI Bookshelf\",\"description\":\"Aug 14, 2023 Â· Alport syndrome is a genetic condition characterized by kidney disease, loss of hearing, and eye abnormalities. It occurs due to an abnormalityÂ ...\",\"url\":\"https://www.ncbi.nlm.nih.gov/books/NBK470419/\",\"favicon\":\"\"},{\"id\":\"85\",\"title\":\"Overview of Congenital Anomalies of the Kidney and Urinary Tract ...\",\"description\":\"Nov 12, 2024 Â· Incidence/Prevalence Â· reported incidence of CAKUT 0.3-1.6 per 1,000 births Â· CAKUT reported to account for almost 25% of all birth defects.\",\"url\":\"https://www.dynamed.com/condition/overview-of-congenital-anomalies-of-the-kidney-and-urinary-tract-cakut/PlatformHomeAbout\",\"favicon\":\"\"},{\"id\":\"86\",\"title\":\"Congenital anomalies of the kidney and urinary tract - Frontiers\",\"description\":\"Jul 14, 2024 Â· CAKUT affects over 1% of live births and accounts for 40â€“50% of cases of chronic kidney failure in children. The pathogenesis of CAKUT is causedÂ ...Abstract Â· Introduction Â· Epidemiology of CAKUT Â· The phenotypic spectrum of...\",\"url\":\"https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2024.1384676/full\",\"favicon\":\"\"},{\"id\":\"87\",\"title\":\"Congenital Anomalies of the Kidneys and Urinary Tract | NeoReviews\",\"description\":\"Feb 1, 2024 Â· Though the etiology of each of these conditions can be variable, it is known that the collection of these defects represent 40% to 50% of allÂ ...Hydronephrosis Â· Renal Parenchymal... Â· Disordered Renal Migration...\",\"url\":\"https://publications.aap.org/neoreviews/article/25/2/e78/196493/Congenital-Anomalies-of-the-Kidneys-and-Urinary\",\"favicon\":\"\"},{\"id\":\"88\",\"title\":\"Nephrotoxic Medications - StatPearls - NCBI Bookshelf\",\"description\":\"Jun 21, 2023 Â· Nephrotoxic medications can elicit damage to the kidney via various mechanisms, including alteration in its structure and function.\",\"url\":\"https://www.ncbi.nlm.nih.gov/books/NBK553144/\",\"favicon\":\"\"},{\"id\":\"89\",\"title\":\"Drug-induced impairment of renal function - PMC - PubMed Central\",\"description\":\"Nephrotoxicity results in serious clinical syndromes, including acute kidney injury (AKI). Nephrotoxic agents have been implicated as etiologic factors in 17%â€“Â ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC4270362/\",\"favicon\":\"\"},{\"id\":\"90\",\"title\":\"Toxic metals and chronic kidney disease: A systematic review ... - NIH\",\"description\":\"Arsenic (As), cadmium (Cd), and lead (Pb) are ubiquitous toxicants with evidence of adverse kidney impacts at high exposure levels.\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC6590508/\",\"favicon\":\"\"},{\"id\":\"91\",\"title\":\"Infection-Induced Kidney Diseases - PMC - PubMed Central\",\"description\":\"Nov 28, 2018 Â· All microbials virus, bacteria, mycobacteria, fungus, and protozoa have been implicated in kidney diseases either causing direct kidney injuriesÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC6282040/\",\"favicon\":\"\"},{\"id\":\"92\",\"title\":\"Infectious Diseases and the Kidney - PMC - PubMed Central\",\"description\":\"The kidney is involved in a wide range of bacterial, viral, fungal, and parasitic diseases. In most systemic infections, renal involvement is a minor componentÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC7121468/\",\"favicon\":\"\"},{\"id\":\"93\",\"title\":\"Parasitic Kidney Disease: Milestones in the Evolution of Our ...\",\"description\":\"Jan 21, 2013 Â· Of the 342 parasites that infect humans, 20 are associated with kidney disease, yet of these, only schistosomes, plasmodia, filariae,Â ...\",\"url\":\"https://www.ajkd.org/article/S0272-6386%2812%2901509-0/fulltext\",\"favicon\":\"\"},{\"id\":\"94\",\"title\":\"Lifestyle factors, obesity and the risk of chronic kidney disease\",\"description\":\"Conclusions: These data suggest that physical inactivity, smoking and morbid obesity contribute to the risk of chronic kidney disease. AB - Background: SomeÂ ...Missing:  meta- | Show results with:meta-\",\"url\":\"https://pure.johnshopkins.edu/en/publications/lifestyle-factors-obesity-and-the-risk-of-chronic-kidney-disease-5\",\"favicon\":\"\"},{\"id\":\"95\",\"title\":\"Relationship between modifiable lifestyle factors and chronic kidney ...\",\"description\":\"Mar 25, 2022 Â· Evidence shows that the incidence and rapid progression of CKD can be protected via modifiable lifestyle factors, ie. diet, physical activity, alcoholÂ ...\",\"url\":\"https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-022-02745-3\",\"favicon\":\"\"},{\"id\":\"96\",\"title\":\"Lifestyle risk factors and chronic kidney disease - ScienceDirect.com\",\"description\":\"We did not observe any significant risk of chronic kidney disease associated with cigarette smoking or alcohol consumption, other than moonshine.\",\"url\":\"https://www.sciencedirect.com/science/article/abs/pii/S1047279703000668\",\"favicon\":\"\"},{\"id\":\"97\",\"title\":\"Modifiable Lifestyle Behaviors and CKD Progression - Kidney360\",\"description\":\"In the CKD population, lifestyle behaviors, such as diet, physical activity, weight management, alcohol consumption, and tobacco use, have mainly been studiedÂ ...\",\"url\":\"https://journals.lww.com/kidney360/fulltext/2022/04000/modifiable_lifestyle_behaviors_and_ckd.24.aspx\",\"favicon\":\"\"},{\"id\":\"98\",\"title\":\"Chronic kidney disease - Symptoms and causes - Mayo Clinic\",\"description\":\"Sep 6, 2023 Â· Chronic kidney disease is a disease characterized by progressive damage and loss of function in the kidneys. It's estimated that chronic kidneyÂ ...Missing:  reliable | Show results with:reliable\",\"url\":\"https://www.mayoclinic.org/diseases-conditions/chronic-kidney-disease/symptoms-causes/syc-20354521\",\"favicon\":\"\"},{\"id\":\"99\",\"title\":\"Acute Kidney Injury - Symptoms, causes, treatment\",\"description\":\"Acute kidney injury (AKI) occurs when kidneys suddenly lose their ability to filter waste from the blood, developing within hours or days.Missing:  prognosis | Show results with:prognosis\",\"url\":\"https://www.kidney.org/kidney-topics/acute-kidney-injury-aki\",\"favicon\":\"\"},{\"id\":\"100\",\"title\":\"Acute Kidney Injury (Nursing) - StatPearls - NCBI Bookshelf - NIH\",\"description\":\"Decreased or no urine output Â· Anxiety Â· Fluid retention Â· General malaise Â· Nausea Â· Weight gain Â· Shortness of breath Â· Hypertension.\",\"url\":\"https://www.ncbi.nlm.nih.gov/books/NBK568593/\",\"favicon\":\"\"},{\"id\":\"101\",\"title\":\"Chronic kidney disease (CKD) - Symptoms, causes, treatment\",\"description\":\"Signs and symptoms Â· Foamy urine Â· Urinating (peeing) more often or less often than usual Â· Itchy and/or dry skin Â· Feeling tired Â· Nausea Â· Loss of appetite Â· WeightÂ ...Stage of CKD Â· Signs and symptoms Â· Chronic kidney disease\",\"url\":\"https://www.kidney.org/kidney-topics/chronic-kidney-disease-ckd\",\"favicon\":\"\"},{\"id\":\"102\",\"title\":\"10 Signs You May Have Kidney Disease\",\"description\":\"1. Less Energy or Trouble Concentrating A severe decrease in kidney function can lead to a buildup of toxins and impurities in the blood.Signs and symptoms Â· Itching and Kidney Disease Â· Anemia and Chronic Kidney...\",\"url\":\"https://www.kidney.org/news-stories/10-signs-you-may-have-kidney-disease\",\"favicon\":\"\"},{\"id\":\"103\",\"title\":\"Symptom burden in chronic kidney disease - BMC Nephrology\",\"description\":\"Jul 10, 2017 Â· Common symptoms experienced by CKD patients are fatigue, pruritus, irritability, anxiety and nausea. An assessment of the symptom burden of allÂ ...\",\"url\":\"https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-017-0638-y\",\"favicon\":\"\"},{\"id\":\"104\",\"title\":\"Clinical Manifestations of Kidney Disease Among US Adults\",\"description\":\"Aug 9, 2016 Â· This study uses National Health and Nutrition Examination Survey data from 1988 through 2014 to characterize clinical manifestations ofÂ ...\",\"url\":\"https://jamanetwork.com/journals/jama/fullarticle/2542635\",\"favicon\":\"\"},{\"id\":\"105\",\"title\":\"Signs and Symptoms of Kidney Disease\",\"description\":\"Sep 15, 2025 Â· About kidney disease symptom Â· One: Foamy urine (pee) Â· Two: Seeing blood in your urine (pee) Â· Three: Feeling the need to pee more often Â· Four:Â ...\",\"url\":\"https://www.kidney.org/kidney-topics/signs-and-symptoms-kidney-disease\",\"favicon\":\"\"},{\"id\":\"106\",\"title\":\"Chronic kidney disease - Diagnosis and treatment - Mayo Clinic\",\"description\":\"Sep 6, 2023 Â· Blood tests. Kidney function tests look for the level of waste products, such as creatinine and urea, in your blood. Â· Medications to relieveÂ ...\",\"url\":\"https://www.mayoclinic.org/diseases-conditions/chronic-kidney-disease/diagnosis-treatment/drc-20354527\",\"favicon\":\"\"},{\"id\":\"107\",\"title\":\"Tests for kidney disease - American Kidney Fund\",\"description\":\"Jul 23, 2025 Â· Blood tests can look for and measure substances (such as antibodies or proteins) that are signs of other health problems that may cause kidney disease.Blood tests Â· Urine tests Â· Albumin-to-creatinine ratio... Â· Imaging tests\",\"url\":\"https://www.kidneyfund.org/all-about-kidneys/tests-kidney-disease\",\"favicon\":\"\"},{\"id\":\"108\",\"title\":\"Indications and considerations for kidney biopsy - NIH\",\"description\":\"This article summarises common indications for kidney biopsy in acute and chronic presentations of kidney disease for non-specialists.\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC8813013/\",\"favicon\":\"\"},{\"id\":\"109\",\"title\":\"Kidney biopsy - Mayo Clinic\",\"description\":\"Jan 25, 2023 Â· Risks Â· Bleeding. The most common complication of a kidney biopsy is blood in the urine. Â· Pain. Pain at the biopsy site is common after a kidneyÂ ...\",\"url\":\"https://www.mayoclinic.org/tests-procedures/kidney-biopsy/about/pac-20394494\",\"favicon\":\"\"},{\"id\":\"110\",\"title\":\"The kidney biopsy - UpToDate\",\"description\":\"May 26, 2025 Â· The indications for performing a kidney biopsy vary among ... risk of bleeding and other complications associated with the kidney biopsy.\",\"url\":\"https://www.uptodate.com/contents/the-kidney-biopsy\",\"favicon\":\"\"},{\"id\":\"111\",\"title\":\"Advances in the diagnosis of early biomarkers for acute kidney injury\",\"description\":\"Mar 5, 2025 Â· This review summarizes the progress in AKI biomarker research, highlighting their clinical utility and exploring their potential to refine early diagnosis andÂ ...\",\"url\":\"https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-025-04040-3\",\"favicon\":\"\"},{\"id\":\"112\",\"title\":\"Biomarkers in acute kidney injury | Annals of Intensive Care | Full Text\",\"description\":\"Sep 15, 2024 Â· The Sapphire study showed that urinary [TIMP-2] Ã— [IGFBP7] concentration was superior to all other biomarkers in critically ill patients forÂ ...\",\"url\":\"https://annalsofintensivecare.springeropen.com/articles/10.1186/s13613-024-01360-9\",\"favicon\":\"\"},{\"id\":\"113\",\"title\":\"Emerging Biomarkers and Advanced Diagnostics in Chronic Kidney ...\",\"description\":\"May 13, 2025 Â· This review aims to critically evaluate recent advancements in novel biomarkers, multi-omics technologies, and artificial intelligence (AI)-driven diagnosticÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC12110191/\",\"favicon\":\"\"},{\"id\":\"114\",\"title\":\"A Comprehensive Review of Biomarkers for Chronic Kidney ... - NIH\",\"description\":\"Sep 26, 2024 Â· This review explores the current state of biomarker research in CKD, focusing on their application in older populations.\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC11512660/\",\"favicon\":\"\"},{\"id\":\"115\",\"title\":\"Treatment of Acute Kidney Injury: A Review of Current Approaches ...\",\"description\":\"Apr 23, 2024 Â· Management is founded on treating the underlying cause of AKI, but supportive careâ€”via fluid management, vasopressor therapy, kidney replacementÂ ...\u003c|separator|\u003e\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC11084889/\",\"favicon\":\"\"},{\"id\":\"116\",\"title\":\"Early Identification and Management of Chronic Kidney Disease - NIH\",\"description\":\"Aug 20, 2024 Â· Early identification and intervention are critical in slowing CKD progression and reducing the associated kidney and cardiovascular morbidityÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC11399210/\",\"favicon\":\"\"},{\"id\":\"117\",\"title\":\"Comparative Efficacy and Safety of Angiotensin-Converting Enzyme ...\",\"description\":\"Feb 11, 2025 Â· Prior studies have demonstrated that ACEis and ARBs not only effectively reduce blood pressure but also slow CKD progression and decreaseÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC11905639/\",\"favicon\":\"\"},{\"id\":\"118\",\"title\":\"Reninâ€“Angiotensin System Inhibition in Advanced Chronic Kidney ...\",\"description\":\"Nov 3, 2022 Â· The analysis of a large observational registry also suggested that the discontinuation of RAS inhibitors reduced the risk of progression to ESKDÂ ...\",\"url\":\"https://www.nejm.org/doi/full/10.1056/NEJMoa2210639\",\"favicon\":\"\"},{\"id\":\"119\",\"title\":\"Comparative Superiority of ACE Inhibitors Over Angiotensin ...\",\"description\":\"Evidence also arose that the newer ARBs, predominantly studied in clinical trials in people with diabetes and CKD, reduce progression to end-stage kidneyÂ ...\",\"url\":\"https://www.ajkd.org/article/S0272-6386%2816%2900137-2/fulltext\",\"favicon\":\"\"},{\"id\":\"120\",\"title\":\"Therapeutic Insights in Chronic Kidney Disease Progression\",\"description\":\"In addition to RAS blockade, SGLT2 inhibitors and bicarbonate therapy have proved to retard CKD progression, and new drugs targeting fibrosis and inflammation,Â ...\",\"url\":\"https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2021.645187/full\",\"favicon\":\"\"},{\"id\":\"121\",\"title\":\"Management of chronic kidney disease: The current novel and ...\",\"description\":\"Recent studies have provided evidence of the effectiveness of the Mediterranean diet in managing CKD. Specifically, adherence to this diet is associatedÂ ...\u003c|separator|\u003e\",\"url\":\"https://www.sciencedirect.com/science/article/pii/S2214623724000255\",\"favicon\":\"\"},{\"id\":\"122\",\"title\":\"[PDF] Strategies to halt the progression of CKD G4+: Evidence ... - KDIGO\",\"description\":\"â€¢ Decrease in serum potassium (0.7 mEq/L). KDIGO. Page 9. Uric Acid ReducJon. â€¢ Uric acid levels are strongly and consistently associated with CKD and. CVD inÂ ...\u003c|separator|\u003e\",\"url\":\"https://kdigo.org/wp-content/uploads/2017/02/7.-Tangri-KDIGO-Presentation.pdf\",\"favicon\":\"\"},{\"id\":\"123\",\"title\":\"Slowing progression of chronic kidney disease - PMC\",\"description\":\"Other therapies that may be used include correction of metabolic acidosis, dietary protein restriction, and new models for delivering care to patients with CKD.\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC4089661/\",\"favicon\":\"\"},{\"id\":\"124\",\"title\":\"Comprehensive review of current management guidelines of chronic ...\",\"description\":\"Jun 9, 2023 Â· The guidelines recommend several interventions to slow the progression of CKD, including blood pressure control, glycemic control in diabetic patients, andÂ ...\",\"url\":\"https://journals.lww.com/md-journal/fulltext/2023/06090/comprehensive_review_of_current_management.13.aspx\",\"favicon\":\"\"},{\"id\":\"125\",\"title\":\"\",\"description\":\"\",\"url\":\"https://www.ajmc.com/view/value-based-care-interventions-and-management-of-ckd-progression\",\"favicon\":\"\"},{\"id\":\"126\",\"title\":\"07. Indications for Dialysis | Hospital Handbook\",\"description\":\"Modes of Renal Replacement Therapy (RRT) Â· Mechanism: volume removal over short period. Â· Advantages: less hypotension than IHD because less solute shifts.\",\"url\":\"https://hospitalhandbook.ucsf.edu/07-indications-dialysis/07-indications-dialysis\",\"favicon\":\"\"},{\"id\":\"127\",\"title\":\"Continuous Renal Replacement Therapy - StatPearls - NCBI - NIH\",\"description\":\"Mar 10, 2024 Â· CRRT's indications span volume overload, electrolyte disturbances, and uremia complications. This intervention excels in managingÂ ...\",\"url\":\"https://www.ncbi.nlm.nih.gov/books/NBK556028/\",\"favicon\":\"\"},{\"id\":\"128\",\"title\":\"Comparative analysis of patients' survival on hemodialysis vs ...\",\"description\":\"The analysis reinforced that the survival of patients on HD and PD was similar. Higher age and shorter infection-free time were associated with death.\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC10139729/\",\"favicon\":\"\"},{\"id\":\"129\",\"title\":\"Complications Associated with Continuous RRT - PMC\",\"description\":\"Nov 24, 2022 Â· Our overarching goal in this article is to review and discuss the most significant CRRT-related complications at the different stage of management of CRRT.\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC9717642/\",\"favicon\":\"\"},{\"id\":\"130\",\"title\":\"Continuous Renal Replacement Therapy - CHEST Journal\",\"description\":\"Oct 22, 2018 Â· The most common complication during CRRT is circuit clotting, and the most common reason for circuit clotting is inadequate catheter functionÂ ...\",\"url\":\"https://journal.chestnet.org/article/S0012-3692%2818%2932478-4/fulltext\",\"favicon\":\"\"},{\"id\":\"131\",\"title\":\"Statistics Â· The Kidney Project Â· UCSF\",\"description\":\"After one year of treatment, those on dialysis have a 15-20% mortality rate, with a 5-year survival rate of under 50%. Persons who receive transplants have aÂ ...\",\"url\":\"https://pharm.ucsf.edu/kidney/need/statistics\",\"favicon\":\"\"},{\"id\":\"132\",\"title\":\"Mortality - Annual Data Report | USRDS\",\"description\":\"Receipt of a kidney transplant was associated with far lower mortality compared with remaining on dialysis, but mortality for beneficiaries aged 66-74 with aÂ ...\",\"url\":\"https://usrds-adr.niddk.nih.gov/2023/end-stage-renal-disease/6-mortality\",\"favicon\":\"\"},{\"id\":\"133\",\"title\":\"Survival after kidney transplantation compared with ongoing dialysis ...\",\"description\":\"One-year survival rates were comparable between the 2 groups (kidney recipients 94% vs remaining on dialysis 95%); however, after the first year, a clear andÂ ...\",\"url\":\"https://www.sciencedirect.com/science/article/pii/S1600613523005786\",\"favicon\":\"\"},{\"id\":\"134\",\"title\":\"Mortality of Peritoneal Dialysis versus Hemodialysis in Older Adults\",\"description\":\"Feb 7, 2024 Â· Pooled analysis showed that PD had a higher mortality rate than HD in older dialysis population (HR 1.17, 95% CI: 1.10â€“1.25). When stratified byÂ ...Abstract Â· Introduction Â· Results Â· Discussion\u003c|separator|\u003e\",\"url\":\"https://karger.com/ger/article/70/5/461/896692/Mortality-of-Peritoneal-Dialysis-versus\",\"favicon\":\"\"},{\"id\":\"135\",\"title\":\"A comparison of transplant outcomes in peritoneal and hemodialysis ...\",\"description\":\"There were 5621 (25%) patients on peritoneal dialysis and 17,155 (75%) patients on hemodialysis prior to transplantation. In unadjusted (Kaplan-Meier) analysis,Â ...\",\"url\":\"https://www.kidney-international.org/article/S0085-2538%2815%2948687-9/fulltext\",\"favicon\":\"\"},{\"id\":\"136\",\"title\":\"Acute kidney injury: short-term and long-term effects - PMC - NIH\",\"description\":\"Jul 4, 2016 Â· For example, in critically unwell trauma patients, the rate of 30-day mortality was 17.5 % in an AKI cohort versus 5.8 % in the non-AKI cohortÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC4931701/\",\"favicon\":\"\"},{\"id\":\"137\",\"title\":\"Short-Term Outcomes of Acute Myocardial Infarction in Patients With ...\",\"description\":\"Dec 16, 2011 Â· In-hospital mortality rates for those with mild, moderate, and severe AKI were 6.6%, 14.2%, and 31.8% compared with 2.1% in those without AKI.\",\"url\":\"https://www.ahajournals.org/doi/10.1161/circulationaha.111.039909\",\"favicon\":\"\"},{\"id\":\"138\",\"title\":\"Short- and Long-Term Recovery after Moderate/Severe AKI in... - LWW\",\"description\":\"Among the 172 COVID-19-negative patients with AKI-2/3, 74% had partial and 44% complete renal recovery, whereas 12% died. Among 255 COVID-19 positive patientsÂ ...\",\"url\":\"https://journals.lww.com/kidney360/fulltext/2022/02000/short__and_long_term_recovery_after.10.aspx\",\"favicon\":\"\"},{\"id\":\"139\",\"title\":\"Renal Recovery After Acute Kidney Injury and Long-term Outcomes\",\"description\":\"Apr 13, 2020 Â· During a median of 42 months of follow-up, patients with recovery within 1 to 4 days had the lowest rates of kidney failure or a continued 40%Â ...\",\"url\":\"https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2764344\",\"favicon\":\"\"},{\"id\":\"140\",\"title\":\"Mortality and predictors of acute kidney injury in adults - Nature\",\"description\":\"Aug 2, 2021 Â· The severity of AKI, hyperkalemia duration of AKI, and a short length of hospital stay were predictors of 30-days in-hospital mortality.\u003c|separator|\u003e\",\"url\":\"https://www.nature.com/articles/s41598-021-94946-3\",\"favicon\":\"\"},{\"id\":\"141\",\"title\":\"Hospitalizations among adults with chronic kidney disease in the ...\",\"description\":\"In this study, we observed that adults with CKD had a higher hospitalization rate than the general population that is hospitalized, and even moderate reductionsÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC7732055/\",\"favicon\":\"\"},{\"id\":\"142\",\"title\":\"Chronic kidney disease is associated with poorer in-hospital ...\",\"description\":\"Sep 14, 2017 Â· Patients with CKD hospitalized with infections are at increased risk of poorer in-hospital outcomes, conveying higher medical costs.\",\"url\":\"https://www.nature.com/articles/s41598-017-11861-2\",\"favicon\":\"\"},{\"id\":\"143\",\"title\":\"Prognostic Impact of Chronic Kidney Disease in Patients with Heart ...\",\"description\":\"Dec 1, 2019 Â· Stage 4 and 5 CKD is a significant contributor to poor prognosis in patients with HF, leading to significantly higher rates of hospitalization,Â ...\",\"url\":\"https://www.thepermanentejournal.org/doi/10.7812/TPP/18.273\",\"favicon\":\"\"},{\"id\":\"144\",\"title\":\"Rate of Kidney Function Decline and Risk of Hospitalizations ... - NIH\",\"description\":\"The rate of kidney function decline is associated with a higher risk of hospitalizations, readmissions, and prolonged length of hospital stay.\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC4633789/\",\"favicon\":\"\"},{\"id\":\"145\",\"title\":\"Chronic kidney disease and the short-term risk of mortality and ...\",\"description\":\"One-year mortality was respectively at 16%, 18%, 31.7%, and 44.3% in groups 1 through 4 (P \u003c .0001). Similarly, major amputation rates were at 23.7%Â ...\",\"url\":\"https://www.sciencedirect.com/science/article/pii/S0741521413007830\",\"favicon\":\"\"},{\"id\":\"146\",\"title\":\"Chronic Kidney Disease and Its Complications - PMC - NIH\",\"description\":\"Progression of CKD is associated with a number of serious complications, including increased incidence of cardiovascular disease, hyperlipidemia, anemia andÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC2474786/\",\"favicon\":\"\"},{\"id\":\"147\",\"title\":\"Health problems caused by kidney disease | American Kidney Fund\",\"description\":\"Health problems caused by kidney disease Â· Gout Â· Anemia Â· High phosphorus (hyperphosphatemia) Â· Heart disease Â· High potassium (hyperkalemia) Â· Pruritus (itchy skin).\",\"url\":\"https://www.kidneyfund.org/living-kidney-disease/health-problems-caused-kidney-disease\",\"favicon\":\"\"},{\"id\":\"148\",\"title\":\"Complications of Chronic Kidney Disease: Anemia and More\",\"description\":\"Complications of chronic kidney disease Â· Anemia Â· Bone weakness Â· Fluid retention Â· Gout Â· Heart disease Â· High blood pressure (hypertension) Â· Hyperkalemia.Complications Â· Neurological Â· Secondary Â· Prevention\",\"url\":\"https://www.healthline.com/health/kidney-disease/complications-of-chronic-kidney-disease\",\"favicon\":\"\"},{\"id\":\"149\",\"title\":\"End-stage kidney disease - Penn Medicine\",\"description\":\"Possible Complications Â· Anemia Â· Bleeding from the stomach or intestines Â· Bone, joint, and muscle pain Â· Changes in blood sugar (glucose) Â· Damage to nerves of theÂ ...\",\"url\":\"https://www.pennmedicine.org/conditions/end-stage-kidney-disease\",\"favicon\":\"\"},{\"id\":\"150\",\"title\":\"Causes of Death in End-Stage Kidney Disease - Karger Publishers\",\"description\":\"Jan 11, 2022 Â· Cardiovascular disease is reported as the leading cause of death (COD) among dialysis patients, followed by sepsis/infection [7, 8].Introduction Â· Methods Â· Results Â· Discussion\",\"url\":\"https://karger.com/ajn/article/53/1/32/827379/Causes-of-Death-in-End-Stage-Kidney-Disease\",\"favicon\":\"\"},{\"id\":\"151\",\"title\":\"Mortality and Resource Use Among Individuals With Chronic Kidney ...\",\"description\":\"Jan 25, 2022 Â· The Kaplan-Meier 5-year survival was 54.6% (95% CI, 54.2%-55.1%) for individuals with CKD, 76.6% (95% CI, 76.3%-76.8%) for individuals withÂ ...\",\"url\":\"https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2788381\",\"favicon\":\"\"},{\"id\":\"152\",\"title\":\"What Is the Mortality Rate of Renal (Kidney) Failure? - Healthline\",\"description\":\"Feb 19, 2025 Â· The 5-year survival rateTrusted Source for a person undergoing long-term dialysis in the United States is about 35%. It decreases to aboutÂ ...Mortality rate Â· Factors Â· Condition management\",\"url\":\"https://www.healthline.com/health/kidney-disease/renal-failure-death-rate\",\"favicon\":\"\"},{\"id\":\"153\",\"title\":\"What Is Stage 3 Kidney Disease Life Expectancy? - WebMD\",\"description\":\"Apr 16, 2025 Â· A survey of 13 studies on stage 3 kidney disease found that the all-cause mortality rate varied from 6% in 3 years to 51% in ten years.\u003c|separator|\u003e\",\"url\":\"https://www.webmd.com/a-to-z-guides/what-is-stage-3-kidney-disease-life-expectancy\",\"favicon\":\"\"},{\"id\":\"154\",\"title\":\"All-Cause and Cardiovascular-Related Mortality in CKD Patients ...\",\"description\":\"Cardiovascular disease is the leading cause of death in patients with chronic kidney disease (CKD). 1, 2, 3 An estimated 40%-50% of all deaths in patients withÂ ...\",\"url\":\"https://www.sciencedirect.com/science/article/pii/S259005952300033X\",\"favicon\":\"\"},{\"id\":\"155\",\"title\":\"FastStats - Kidney Disease - CDC\",\"description\":\"Number of adults age 18 and older with diagnosed kidney disease: 6.0 million Â· Percent of adults age 18 and older with diagnosed kidney disease: 2.4%.\",\"url\":\"https://www.cdc.gov/nchs/fastats/kidney-disease.htm\",\"favicon\":\"\"},{\"id\":\"156\",\"title\":\"Global forecasting of chronic kidney disease mortality rates and ...\",\"description\":\"Sep 2, 2024 Â· The CKD age-adjusted mortality rate increased from 15.95 per 100,000 people to 18.35 per 100,000 people during the same period. Between 2020 andÂ ...\",\"url\":\"https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-024-03720-w\",\"favicon\":\"\"},{\"id\":\"157\",\"title\":\"3. Morbidity and Mortality in Patients with CKD\",\"description\":\"Unadjusted mortality rate among Medicare FFS beneficiaries aged â‰¥66 years with CKD declined by more than 20% over a decade, from 144.9 per 1,000 person-years (Â ...\",\"url\":\"https://usrds-adr.niddk.nih.gov/2022/chronic-kidney-disease/3-morbidity-and-mortality-in-patients-with-ckd\",\"favicon\":\"\"},{\"id\":\"158\",\"title\":\"Lifestyle interventions for preventing and ameliorating CKD in ...\",\"description\":\"Nov 1, 2021 Â· Recent findings: Emerging data have shown lifestyle modification strategies for primary CKD prevention with the most evidence favoring a healthyÂ ...\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/34602599/\",\"favicon\":\"\"},{\"id\":\"159\",\"title\":\"Executive summary of the KDIGO 2024 Clinical Practice Guideline ...\",\"description\":\"2.1: We recommend that people with CKD be advised to undertake moderate-intensity physical activity for a cumulative duration of at least 150 minutes per week,Â ...\",\"url\":\"https://www.kidney-international.org/article/S0085-2538%2823%2900764-0/fulltext\",\"favicon\":\"\"},{\"id\":\"160\",\"title\":\"[PDF] KDIGO 2021 CLINICAL PRACTICE GUIDELINE FOR\",\"description\":\"2: The Dietary Approaches to Stop Hypertension (DASH)-type diet or use of salt substitutes that are rich in potassium may not be appropriate for patients withÂ ...\",\"url\":\"https://kdigo.org/wp-content/uploads/2021/03/KDIGO-2021-BP-Guideline-Speakers-Guide.pdf\",\"favicon\":\"\"},{\"id\":\"161\",\"title\":\"Clinical practice guideline exercise and lifestyle in chronic kidney ...\",\"description\":\"Feb 22, 2022 Â· There is emerging evidence that light physical activity and even short periods of standing can benefit health and physical function and are thusÂ ...\",\"url\":\"https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-021-02618-1\",\"favicon\":\"\"},{\"id\":\"162\",\"title\":\"7 Golden Rules of Kidney Disease Prevention\",\"description\":\"1. Get regular check-ups Â· 2. Control Blood Pressure Â· 3. Manage Blood Sugar Â· 4. Eat a Healthy Diet Â· 5. Exercise Â· 6. Quit Smoking Â· 7. Do not overuse painÂ ...\",\"url\":\"https://www.kidney.org/7-golden-rules-kidney-disease-prevention\",\"favicon\":\"\"},{\"id\":\"163\",\"title\":\"Lifestyle behaviour change for preventing the progression of chronic ...\",\"description\":\"Lifestyle behaviour change interventions for CKD patients frequently used education, goal setting, feedback, monitoring and social support.\u003c|separator|\u003e\",\"url\":\"https://bmjopen.bmj.com/content/9/10/e031625\",\"favicon\":\"\"},{\"id\":\"164\",\"title\":\"KDIGO 2024 Clinical Practice Guideline for the Evaluation ... - PubMed\",\"description\":\"KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024 Apr;105(4S):S117-S314.\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/38490803/\",\"favicon\":\"\"},{\"id\":\"165\",\"title\":\"[PDF] How to Manage CKD - National Kidney Foundation\",\"description\":\"Screen for CKD with two simple tests. â€¢ â€œSpotâ€ urine for albumin-to-creatinine ratio (uACR) to detect albuminuria.\",\"url\":\"https://www.kidney.org/sites/default/files/02-10-6800_2303_manageckd_algorithmv4_final.pdf\",\"favicon\":\"\"},{\"id\":\"166\",\"title\":\"11. Chronic Kidney Disease and Risk Management: Standards of ...\",\"description\":\"Dec 9, 2024 Â· Both albuminuria and eGFR should be monitored annually to enable timely diagnosis of CKD, monitor progression of CKD, detect superimposed kidneyÂ ...\",\"url\":\"https://diabetesjournals.org/care/article/48/Supplement_1/S239/157554/11-Chronic-Kidney-Disease-and-Risk-Management\",\"favicon\":\"\"},{\"id\":\"167\",\"title\":\"Screening for CKD with eGFR: Doubts and Dangers - PMC - NIH\",\"description\":\"Universal screening for CKD based on eGFR alone cannot be recommended, but targeted screening based on the existence of hypertension, diabetes, or a familyÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC4571145/\",\"favicon\":\"\"},{\"id\":\"168\",\"title\":\"Impact of albuminuria screening in primary care on the detection ...\",\"description\":\"Apr 25, 2025 Â· Prior studies highlight combining albuminuria with estimated glomerular filtration rate (eGFR) measurements could improve CKD detection and riskÂ ...\",\"url\":\"https://academic.oup.com/ckj/article/18/5/sfaf123/8120273\",\"favicon\":\"\"},{\"id\":\"169\",\"title\":\"Chronic Kidney Disease and High Blood Pressure - CDC\",\"description\":\"May 15, 2024 Â· Keep your blood pressure below 140/90 mm Hg (or ask your doctor what the best blood pressure target is for you). Â· Take medications as prescribedÂ ...\",\"url\":\"https://www.cdc.gov/kidney-disease/risk-factors/chronic-kidney-disease-ckd-and-adults-with-high-blood-pressure.html\",\"favicon\":\"\"},{\"id\":\"170\",\"title\":\"Blood Pressure Control in Patients with Diabetic Kidney Disease - NIH\",\"description\":\"The optimal BP control goal in patients with DKD should include the attenuation of renal functional deterioration and improvement of CV outcomes.\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC9827046/\",\"favicon\":\"\"},{\"id\":\"171\",\"title\":\"Diabetes Management in Chronic Kidney Disease: A Consensus ...\",\"description\":\"Oct 3, 2022 Â· For primary prevention of ASCVD, the ADA recommends a moderate-intensity statin for all adults with diabetes aged 40â€“75 years, those aged 20â€“39Â ...\",\"url\":\"https://diabetesjournals.org/care/article/45/12/3075/147614/Diabetes-Management-in-Chronic-Kidney-Disease-A\",\"favicon\":\"\"},{\"id\":\"172\",\"title\":\"Diabetes and Chronic Kidney Disease - National Kidney Foundation\",\"description\":\"Treatment for diabetic kidney disease includes controlling blood pressure and blood sugar levels, reducing dietary protein intake, avoiding medications that mayÂ ...\",\"url\":\"https://www.kidney.org/diabetes-and-chronic-kidney-disease\",\"favicon\":\"\"},{\"id\":\"173\",\"title\":\"Risk Factors of Chronic Kidney Disease Progression - PubMed Central\",\"description\":\"Jan 24, 2024 Â· The most important risk factors for chronic kidney disease are age, arterial hypertension, diabetes, obesity, proteinuria, dyslipidemia, and environmental riskÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC10856768/\",\"favicon\":\"\"},{\"id\":\"174\",\"title\":\"Risk factors for chronic kidney disease: an update - PMC\",\"description\":\"This paper aims to review the risk factors, such as age, gender, race and ethnicity, family history, drug use, smoking, and socioeconomic status.\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC4089662/\",\"favicon\":\"\"},{\"id\":\"175\",\"title\":\"Management of Hypertension in Diabetic Kidney Disease - PMC - NIH\",\"description\":\"Oct 31, 2023 Â· Novel therapies such as pentoxifylline and GLP-1 agonists may provide some blood pressure-neutral interventions for diabetic kidney disease andÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC10648605/\",\"favicon\":\"\"},{\"id\":\"176\",\"title\":\"Current Management Strategies of Chronic Kidney Disease in ...\",\"description\":\"CKD prevention programs include primary prevention, which aims to prevent the occurrence of CKD risk factors; secondary prevention, which employs screening toÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC7567536/\",\"favicon\":\"\"},{\"id\":\"177\",\"title\":\"Reducing major risk factors for chronic kidney disease\",\"description\":\"A broad approach to CKD prevention begins with the identification of CKD risk factors in the population, followed by the development of appropriate mitigationÂ ...Kidney Stones And Ckd Risk Â· Infections As Ckd Risk... Â· Aki As A Ckd Risk Factor\",\"url\":\"https://www.kisupplements.com/article/S2157-1716%2817%2930029-1/fulltext\",\"favicon\":\"\"},{\"id\":\"178\",\"title\":\"Hypertension and glomerular function decline: the chicken or the egg?\",\"description\":\"Chronic kidney disease (CKD) is definitely a cause of hypertension, and malignant hypertension a cause of CKD, but whether mild to moderate hypertension canÂ ...Missing:  consequence | Show results with:consequence\",\"url\":\"https://www.kidney-international.org/article/S0085-2538%2816%2930177-6/fulltext\",\"favicon\":\"\"},{\"id\":\"179\",\"title\":\"Blood pressure and kidney disease: chicken or egg (or both)?\",\"description\":\"A recent study supports the concept that reduced kidney function causes higher blood pressure, but it found no evidence of causality in the oppositeÂ ...\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/32828236/\",\"favicon\":\"\"},{\"id\":\"180\",\"title\":\"Determining the Relationship Between Blood Pressure, Kidney ...\",\"description\":\"Sep 9, 2022 Â· It is well established that decreased kidney function can increase blood pressure (BP), but it is unproven whether moderately elevated BPÂ ...\",\"url\":\"https://www.ahajournals.org/doi/10.1161/HYPERTENSIONAHA.122.19354\",\"favicon\":\"\"},{\"id\":\"181\",\"title\":\"APOL1 Variants Associate with Increased Risk of CKD among ... - NIH\",\"description\":\"We hypothesized that African Americans carrying two APOL1 risk alleles would have an increased risk of CKD and ESRD progression compared with those individualsÂ ...Missing:  debate | Show results with:debate\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC3752955/\",\"favicon\":\"\"},{\"id\":\"182\",\"title\":\"APOL1 Bi- and Monoallelic Variants and Chronic Kidney Disease in ...\",\"description\":\"Oct 26, 2024 Â· The evidence to date points to APOL1 CKD risk variants acting as a genetic risk factor for rapid deterioration in kidney function among WestÂ ...Missing:  debate | Show results with:debate\",\"url\":\"https://www.nejm.org/doi/full/10.1056/NEJMoa2404211\",\"favicon\":\"\"},{\"id\":\"183\",\"title\":\"What's behind racial disparities in kidney disease? - Harvard Health\",\"description\":\"Feb 3, 2021 Â· Kidney disease requiring dialysis or transplant is far more common among African Americans than among white Americans, but genetics andÂ ...\",\"url\":\"https://www.health.harvard.edu/blog/whats-behind-racial-disparities-in-kidney-disease-2021020321842\",\"favicon\":\"\"},{\"id\":\"184\",\"title\":\"Social Determinants of Health and Chronic Kidney Disease\",\"description\":\"Jan 2, 2023 Â· Social factors like income, education, and access to care affect CKD risk. Racial disparities in CKD stem from historical inequities, not race itself.\",\"url\":\"https://www.kidney.org/kidney-topics/social-determinants-health-and-chronic-kidney-disease\",\"favicon\":\"\"},{\"id\":\"185\",\"title\":\"Non-traditional risk factors of progression of chronic kidney disease ...\",\"description\":\"Jun 2, 2023 Â· According to the scientific community the most remarkable risk factors for CKD are diabetes and hypertension. However, some other risk factorsÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC10272583/\",\"favicon\":\"\"},{\"id\":\"186\",\"title\":\"5 Breakthroughs in Kidney Disease Treatment - Cromos Pharma\",\"description\":\"Mar 13, 2025 Â· On January 28, 2025, the FDA granted approval for Ozempic (semaglutide) as the first GLP-1 receptor agonist indicated for reducing the risk ofÂ ...\",\"url\":\"https://cromospharma.com/world-kidney-day-top-5-breakthroughs-in-kidney-disease-treatment/\",\"favicon\":\"\"},{\"id\":\"187\",\"title\":\"Interconnected pathways and emerging therapies in chronic kidney ...\",\"description\":\"Jun 18, 2025 Â· For the management of CKD, current treatment guidelines recommend the use of RAS inhibitors, SGLT2 inhibitors, the nonsteroidal MR antagonistÂ ...3 Diagnosis Of Hf In... Â· 6.2 Sglt2is Â· 6.3 Mras\u003c|separator|\u003e\",\"url\":\"https://onlinelibrary.wiley.com/doi/10.1002/ehf2.15345\",\"favicon\":\"\"},{\"id\":\"188\",\"title\":\"New gene therapy research offers hope for people with chronic ...\",\"description\":\"Dec 30, 2024 Â· Researchers are making strides in improving gene therapies for genetic diseases, particularly chronic kidney disease, using adeno-associated virus, or AAV,Â ...\",\"url\":\"https://news.ohsu.edu/2024/12/30/new-gene-therapy-research-offers-hope-for-people-with-chronic-kidney-disease\",\"favicon\":\"\"},{\"id\":\"189\",\"title\":\"UC Davis Health launches new cell therapy trial for chronic kidney ...\",\"description\":\"Apr 3, 2025 Â· This first-in-class cell therapy for CKD could potentially preserve kidney function in people whose kidneys have become damaged because of type 2 diabetes.\",\"url\":\"https://health.ucdavis.edu/news/headlines/uc-davis-health-launches-new-cell-therapy-trial-for-chronic-kidney-disease-patients/2025/04\",\"favicon\":\"\"},{\"id\":\"190\",\"title\":\"Top kidney disease research advancements from 2024\",\"description\":\"Jan 13, 2025 Â· From awake kidney transplants to gene-edited pig kidney transplants to a possible new treatment for lupus, here are the headlines in kidney disease researchÂ ...\",\"url\":\"https://www.kidneyfund.org/article/top-kidney-disease-research-advancements-2024\",\"favicon\":\"\"},{\"id\":\"191\",\"title\":\"Continuous Kidney Replacement Therapies: Core Curriculum 2025\",\"description\":\"Mar 9, 2025 Â· Continuous KRT (CKRT) is used across many ICUs as the therapy of choice for hemodynamically unstable patients with kidney failure. ThoughÂ ...\",\"url\":\"https://www.ajkd.org/article/S0272-63862401120-X/fulltext\",\"favicon\":\"\"},{\"id\":\"192\",\"title\":\"Representation of Patients With Chronic Kidney Disease in Clinical ...\",\"description\":\"Mar 7, 2024 Â· We identified significant evidence gaps in CVRM medications for all patients with CKD. Evidence gaps were most notable for patients with CKDÂ ...\",\"url\":\"https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2815795\",\"favicon\":\"\"},{\"id\":\"193\",\"title\":\"Closing CKD Treatment Gaps: Why Practice Guidelines and Better ...\",\"description\":\"Feb 13, 2025 Â· The analysis included 4,976 US participants with CKD not treated with dialysis and without apparent cardiovascular disease between 2001 and 2020Â ...\",\"url\":\"https://www.ajkd.org/article/S0272-6386%2825%2900054-X/fulltext\",\"favicon\":\"\"},{\"id\":\"194\",\"title\":\"Chronic Kidney Diseases at the Crossroads: From Failures to Future ...\",\"description\":\"Oct 10, 2025 Â· This infographic illustrates the diverse landscape of established and emerging drug classes for the management of chronic kidney disease (CKD).\",\"url\":\"https://www.sciencedirect.com/science/article/pii/S2468024925006254\",\"favicon\":\"\"},{\"id\":\"195\",\"title\":\"Closing Gaps in Chronic Kidney Disease Detection - NIH\",\"description\":\"Jul 28, 2025 Â· Inequities in CKD outcomes are common and well-documented, demanding interventions. Black and Hispanic individuals are less likely to receiveÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC12304639/\",\"favicon\":\"\"},{\"id\":\"196\",\"title\":\"Mind the Gap in Kidney Care: Translating What We Know Into What ...\",\"description\":\"These data illustrate gaps in both prescribing kidney protective medication and continuity of care over time, potentially related to cost, lack of patientÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC11102772/\",\"favicon\":\"\"}],\"images\":[{\"id\":\"01b91318b47d\",\"caption\":\"Kidney diseases world map - Deaths per million persons - WHO 2012\",\"url\":\"./_assets_/Kidney_diseases_world_map-Deaths_per_million_persons-WHO2012.svg.png\",\"position\":\"CENTER\",\"width\":0,\"height\":0},{\"id\":\"bfbcd1369cfc\",\"caption\":\"Kidney â€“ acute cortical necrosis\",\"url\":\"./_assets_/Kidney_%E2%80%93_acute_cortical_necrosis.jpg\",\"position\":\"CENTER\",\"width\":0,\"height\":0},{\"id\":\"bfbcd1369cfc\",\"caption\":\"Kidney â€“ acute cortical necrosis\",\"url\":\"./_assets_/Kidney_%E2%80%93_acute_cortical_necrosis.jpg\",\"position\":\"CENTER\",\"width\":0,\"height\":0},{\"id\":\"01b91318b47d\",\"caption\":\"Global map of kidney disease deaths per million persons (WHO 2012)\",\"url\":\"./_assets_/Kidney_diseases_world_map-Deaths_per_million_persons-WHO2012.svg.png\",\"position\":\"CENTER\",\"width\":0,\"height\":0},{\"id\":\"01b91318b47d\",\"caption\":\"Kidney diseases world map showing deaths per million persons (WHO 2012)\",\"url\":\"./_assets_/Kidney_diseases_world_map-Deaths_per_million_persons-WHO2012.svg.png\",\"position\":\"CENTER\",\"width\":0,\"height\":0}],\"fixedIssues\":[],\"slug\":\"Kidney_disease\",\"title\":\"Kidney disease\",\"content\":\"$1f\",\"description\":\"Kidney disease\\n\\nKidney disease comprises a range of disorders that impair the kidneys' capacity to filter blood, remove waste products, and regulate electrolytes and fluid balance, often resulting...\",\"metadata\":{\"categories\":[\"renal disease\",\"nephropathy\"],\"lastModified\":\"1761582918\",\"contentLength\":\"78872\",\"version\":\"1.0\",\"lastEditor\":\"system\",\"language\":\"en\",\"isRedirect\":false,\"redirectTarget\":\"\",\"isWithheld\":false},\"stats\":{\"totalViews\":\"134897\",\"recentViews\":\"134897\",\"dailyAvgViews\":4496.56689453125,\"qualityScore\":1,\"lastViewed\":\"1761887025\"},\"linkedPages\":null},\"found\":true},\"dataUpdateCount\":1,\"dataUpdatedAt\":1761887025699,\"error\":null,\"errorUpdateCount\":0,\"errorUpdatedAt\":0,\"fetchFailureCount\":0,\"fetchFailureReason\":null,\"fetchMeta\":null,\"isInvalidated\":false,\"status\":\"success\",\"fetchStatus\":\"idle\"},\"queryKey\":[\"page\",\"Kidney_disease\"],\"queryHash\":\"[\\\"page\\\",\\\"Kidney_disease\\\"]\"}]},\"children\":\"$L20\"}]\n"])</script><script nonce="YzBlMjE1NjMtYjg2MC00MmIzLWJmMzktNTk1ZDcyYjYzMzVi">self.__next_f.push([1,"c:{\"metadata\":[[\"$\",\"title\",\"0\",{\"children\":\"Kidney disease\"}],[\"$\",\"meta\",\"1\",{\"name\":\"description\",\"content\":\"Kidney disease comprises a range of disorders that impair the kidneys' capacity to filter blood, remove waste products, and regulate electrolytes and fluid balance, often resulting from damage to the nephrons, the functional units of the kidney. It includes acute kidney injury (AKI), characterized by a sudden decline in renal function that may be reversible if addressed promptly, and chronic kidney disease (CKD), defined as structural or functional abnormalities persisting for more than three...\"}],[\"$\",\"meta\",\"2\",{\"name\":\"author\",\"content\":\"system\"}],[\"$\",\"link\",\"3\",{\"rel\":\"manifest\",\"href\":\"/manifest.webmanifest\",\"crossOrigin\":\"$undefined\"}],[\"$\",\"meta\",\"4\",{\"name\":\"keywords\",\"content\":\"renal disease, nephropathy\"}],[\"$\",\"meta\",\"5\",{\"name\":\"robots\",\"content\":\"index, follow\"}],[\"$\",\"meta\",\"6\",{\"name\":\"googlebot\",\"content\":\"index, follow, max-snippet:-1\"}],[\"$\",\"link\",\"7\",{\"rel\":\"canonical\",\"href\":\"https://grokipedia.com/page/Kidney_disease\"}],[\"$\",\"meta\",\"8\",{\"property\":\"og:title\",\"content\":\"Kidney disease\"}],[\"$\",\"meta\",\"9\",{\"property\":\"og:description\",\"content\":\"Kidney disease comprises a range of disorders that impair the kidneys' capacity to filter blood, remove waste products, and regulate electrolytes and fluid balance, often resulting from damage to the nephrons, the functional units of the kidney. It includes acute kidney injury (AKI), characterized by a sudden decline in renal function that may be reversible if addressed promptly, and chronic kidney disease (CKD), defined as structural or functional abnormalities persisting for more than three...\"}],[\"$\",\"meta\",\"10\",{\"property\":\"og:url\",\"content\":\"https://grokipedia.com/page/Kidney_disease\"}],[\"$\",\"meta\",\"11\",{\"property\":\"og:site_name\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",\"12\",{\"property\":\"og:locale\",\"content\":\"en\"}],[\"$\",\"meta\",\"13\",{\"property\":\"og:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}],[\"$\",\"meta\",\"14\",{\"property\":\"og:image:width\",\"content\":\"512\"}],[\"$\",\"meta\",\"15\",{\"property\":\"og:image:height\",\"content\":\"512\"}],[\"$\",\"meta\",\"16\",{\"property\":\"og:image:alt\",\"content\":\"Kidney disease\"}],[\"$\",\"meta\",\"17\",{\"property\":\"og:type\",\"content\":\"article\"}],[\"$\",\"meta\",\"18\",{\"property\":\"article:modified_time\",\"content\":\"1970-01-21T09:19:42.918Z\"}],[\"$\",\"meta\",\"19\",{\"name\":\"twitter:card\",\"content\":\"summary\"}],[\"$\",\"meta\",\"20\",{\"name\":\"twitter:creator\",\"content\":\"@Grokipedia\"}],[\"$\",\"meta\",\"21\",{\"name\":\"twitter:title\",\"content\":\"Kidney disease\"}],[\"$\",\"meta\",\"22\",{\"name\":\"twitter:description\",\"content\":\"Kidney disease comprises a range of disorders that impair the kidneys' capacity to filter blood, remove waste products, and regulate electrolytes and fluid balance, often resulting from damage to the nephrons, the functional units of the kidney. It includes acute kidney injury (AKI), characterized by a sudden decline in renal function that may be reversible if addressed promptly, and chronic kidney disease (CKD), defined as structural or functional abnormalities persisting for more than three...\"}],[\"$\",\"meta\",\"23\",{\"name\":\"twitter:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}],[\"$\",\"link\",\"24\",{\"rel\":\"icon\",\"href\":\"/favicon.ico\",\"type\":\"image/x-icon\",\"sizes\":\"16x16\"}],[\"$\",\"$L21\",\"25\",{}]],\"error\":null,\"digest\":\"$undefined\"}\n"])</script><script nonce="YzBlMjE1NjMtYjg2MC00MmIzLWJmMzktNTk1ZDcyYjYzMzVi">self.__next_f.push([1,"11:\"$c:metadata\"\n"])</script><script nonce="YzBlMjE1NjMtYjg2MC00MmIzLWJmMzktNTk1ZDcyYjYzMzVi">self.__next_f.push([1,"22:I[61172,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"PageEditorProvider\"]\n"])</script><script nonce="YzBlMjE1NjMtYjg2MC00MmIzLWJmMzktNTk1ZDcyYjYzMzVi">self.__next_f.push([1,"23:I[63493,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"default\"]\n"])</script><script nonce="YzBlMjE1NjMtYjg2MC00MmIzLWJmMzktNTk1ZDcyYjYzMzVi">self.__next_f.push([1,"20:[\"$\",\"$L22\",null,{\"children\":[\"$\",\"$L23\",null,{\"slug\":\"Kidney_disease\"}]}]\n"])</script></body></html>